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Abstract 
Epilepsy is one of the most common chronic neurological disorders, and the 
symptomatic form is characterised by the occurrence of spontaneous recurrent 
seizures following a neurological insult.  One third of epilepsy patients are 
resistant to antiepileptic drugs (AEDs), therefore the development of novel 
treatments is required.  Glutamate is implicated in epilepsy however, only a few 
glutamate receptor antagonists have been successful in epilepsy trials. An indirect 
means of modifying glutamate-mediated excitation, such as targeting nitric oxide 
(NO), might be a reasonable alternative approach.  Selectively targeting NO 
signalling pathway by two drug interventions was investigated in this thesis.  Post-
synaptic density 95 blocking peptide (PSD95BP) is a protein that uncouples GluN2 
subunits of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor from 
neuronal NO synthase to prevent downstream neurotoxic signalling of NO. In 
contrast, 1400W is a highly specific inducible NO synthase inhibitor that binds to 
the guanidine recognition site of the enzyme, competing with L-arginine and 
preventing neurotoxic production of NO.  These compounds are effective in animal 
models of stroke and were tested here in a C57BL/6J mouse model of 
epileptogenesis. Kainic acid (KA) is widely used to induce status epilepticus (SE) in 
animals and the resulting neuropathology mimics that seen in humans with 
temporal lobe epilepsy.  Repeated low dose administration of KA via 
intraperitoneal injection every 30 minutes consistently induced generalised 
seizures but was associated with inter-animal variability in KA sensitivity, acute 
seizure severity and mortality rate. Extra-dural telemetry electrodes were 
implanted in mice for electroencephalography (EEG) recordings. Two algorithms, 
measuring spike frequency and EEG coastline respectively, were used to quantify 
epileptiform activity. Mice that received drug interventions following KA-induced 
SE had significantly lower mean spike frequency and fewer extended coastline 
epochs per day than the control group at both 7 and 14 days after the initial insult.  
Label-free proteomics quantification showed significant changes to the 
hippocampal protein profile as a result of both PSD95BP and 1400W 
administration following KA-induced seizures. Drug treatment, singly or in 
combination, also reversed the effects of KA on the expression of both 
transforming growth factor β1 and inwardly rectifying potassium channel 4.1 in 
the hippocampus. Surgical implantation of extra-dural electrodes significantly 
lowered the seizure threshold to KA and was associated with an increase in brain 
expression of pro-inflammatory cytokines, suggesting that careful consideration is 
required in studies involving intracranial surgery to assess epileptogenesis or AED 
effects. Current research investigating novel therapeutic agents is focusing on non-
NMDA glutamate receptors, such as α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid and kainate receptors, as potential AED targets. There are 
no compounds targeting the NO signalling pathway currently being investigated 
for the treatment of epilepsy.  The data reported in this thesis give cause for 
optimism but further studies are needed to fully investigate the antiepileptic and 
possible antiepileptogenic properties of PSD95BP and 1400W and true efficacy 
will ultimately require clinical evaluation. 
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1.1. Epilepsy 
 
1.1.1. Overview 
Epilepsy is one of the most common chronic neurological disorders worldwide 
and includes a number of conditions with the principal characteristics of 
spontaneous and recurrent seizures that arise as a result of prolonged and 
synchronised neuronal discharges (Chang and Lowenstein, 2003; Aroniadou-
Anderjaska et al., 2008; Vincent and Mulle, 2009).  The most current International 
League Against Epilepsy (ILAE) operational clinical definition of epilepsy is the 
occurrence of “at least two unprovoked (or reflex) seizures occurring more than 
24 hours apart” or “one unprovoked seizure and a probability of further seizures 
that are similar to the general recurrence risk (at least 60%) after two 
unprovoked seizures, occurring over the next 10 years” (ILAE, 2014).  Epilepsy 
usually presents in childhood or during adolescence but can occur for the first 
time at any age (Lindsay et al., 2010).   
 
1.1.2. Epidemiology and aetiology 
Approximately 5% of the world’s population will experience a single seizure 
during their lives but only 0.5% will develop spontaneous recurrent seizures 
(SRS) (Lindsay et al., 2010).  In developed countries, the incidence is 
approximately 1 in 2000 people annually and in poorer, developing countries, 
there are higher incidences affecting approximately 1 in 100 people per year 
(Sander, 2003).  The reasons for the increase in incidence in developing countries 
are attributed to the poorer health status of the patients and health care 
availability (Birbeck, 2010). 
 
Amongst epilepsy patients, the overall prognosis for seizure treatment is good, 
with 70% of patients well-controlled with antiepileptic drugs (AEDs) (Sander, 
2003; Lindsay et al., 2010).  However, the remaining 30% are resistant to drug 
treatment (Lindsay et al., 2010), and the new discovery of AEDs has thus far 
failed to significantly improve the prognosis of drug-resistant epilepsy (Herman, 
2010).  Non-pharmacological treatments of epilepsy, such as vagal nerve 
stimulation, ketogenic diet, transcranial magnetic stimulation are also considered 
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as alternatives to antiepileptic pharmacotherapy and have been shown to be as 
effective as pharmacotherapy in some patients (Wolf and Okujava, 1999; Saxena 
and Nadkami, 2011).  Despite being the most common neurological disorder, 
there is still a lack of understanding of the epidemiology of epilepsy due to 
heterogeneity of the syndrome (Sander, 2003).   
 
There are three aetiological classes of epilepsy, idiopathic, symptomatic and 
cryptogenic.  Idiopathic epilepsy cases are believed to be mainly genetically 
related and comprise of approximately 30% of all clinical cases and represent 
self-limited epilepsy syndromes with strictly defined clinical and 
electroencephalography (EEG) findings but with no other neurological findings 
(Sander, 2003; Berkovic et al., 2006; Shorvon, 2011).  Symptomatic epilepsy, 
which also constitutes approximately 30% of epilepsy cases, generally arises 
from an identifiable insult to the brain associated with gross pathological 
abnormalities, indicative of underlying disease or condition (Sander, 2003; 
Shorvon, 2011).  Seizures triggered by the insult are acute symptomatic seizures 
and do not constitute as epilepsy until SRS occur (Sander, 2003).  Some of the 
primary causes of symptomatic epilepsy include traumatic brain injury, stroke, 
tumours and central nervous system (CNS) infections (Sander, 2003; Dudek and 
Staley, 2011). Cryptogenic epilepsies are those that resemble symptomatic 
epilepsies in their phenomenology but in which the presumed lesion remains 
elusive on brain imaging (Shorvon, 2011). 
 
Epileptic seizures are classified into two broad groups – generalised and partial. 
Generalised seizures result from convulsive discharges that start from deeper 
midline structures, and arise in both cerebral hemispheres simultaneously, and 
can manifest as generalised tonic, clonic or tonic-clonic convulsions with the loss 
of consciousness (Sharma et al., 2007; Lindsay et al., 2010). Other generalised 
seizure types, such as absence and myoclonic, do not possess a major convulsive 
component. Generalised seizures generally exhibit no evidence of local onset 
(Dingledine et al., 1990).  In contrast, partial seizures are caused by attacks 
stemming from focal neurological lesions but can spread across the entire brain 
(Chang and Lowenstein, 2003) and may gradually develop into secondary 
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generalised seizures (Sharma et al., 2007).  Complex partial seizures are the most 
frequent single seizure type; they occur when a partial seizure is accompanied by 
impaired consciousness and they most commonly develop from the mesial 
temporal lobe (Samuel, 2000; Lindsay et al., 2010).  The mechanisms underlying 
partial seizures are not very well understood, despite being the most common 
seizure disorder in adults and accounting for up to 50% of incident and 60% of 
prevalent epilepsy cases (Samuel, 2000; Chang and Lowenstein, 2003).     
 
1.1.3. Temporal lobe epilepsy 
Temporal lobe epilepsy (TLE) is the most common and arguably most important 
type of symptomatic partial epilepsy and is often characterised by mesial 
temporal sclerosis with complex recurrent partial seizures (Samuel, 2000; 
Williams et al., 2009).  TLE is a progressive disease with silent intervals and 
progressive elaboration of seizures (French et al., 1993).  In some cases, 
epileptiform activity spreads to other limbic structures including the amygdala 
complex and the medial entorhinal cortex, causing secondary generalised tonic-
clonic seizures (Vincent and Mulle, 2009). 
 
TLE is invariably treated with AEDs, which provide only symptomatic 
intervention rather than disease-modifying treatment (Herman, 2002; Sharma et 
al., 2007).  TLE is often resistant to AED therapy (Samuel, 2000; Aroniadou-
Anderjaska et al., 2008) and symptomatic partial epilepsy in general is more 
likely to be drug-resistant than idiopathic epilepsy (Kwan and Brodie 2004; 
Gilioli et al, 2012).  The current alternative therapeutic approach for drug-
resistant TLE is surgical resection of specific structural lesions in the 
hippocampus, which is located in the mesial temporal lobe of the brain, with the 
elimination of seizures in up to 80% of patients (Schmidt and Löscher, 2003; 
Buckmaster, 2004).  Nevertheless, there can be risks of causing immediate and 
permanent loss of a patient’s ability to make new memories, as the hippocampus 
is responsible for memory formation (Buckmaster, 2004).  The potential adverse 
outcome of surgery makes surgical resection treatment for TLE less than ideal, 
meaning that it remains useful to develop novel drug treatments that can prevent 
“epileptogenesis” or the development of epilepsy (see below).  Studying the 
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molecular mechanisms of epileptogenesis would facilitate the identification of a 
mechanistic target or biomarker involved in the epileptogenic process, which can 
then be targeted for drug development.  Currently, clinical studies on the process 
of epileptogenesis rely on self-reporting of seizures from patients that may have 
post-seizure amnesia or unnoticed attacks that may have occurred during the 
night (Sridharan, 2002).  Unreported attacks, together with the lack of continuous 
EEG monitoring and the use of therapy to suppress seizures has prevented the 
collection of quantitative clinical data on the development and progression of 
epilepsy (Williams et al., 2009).  As an alternative, animal models can be used to 
provide insights into the temporal features of acquired epilepsy (Williams et al., 
2009). 
 
1.2. Epileptogenesis 
 
1.2.1. Overview 
The initial brain insult in symptomatic epilepsy that ultimately causes partial 
seizures is commonly followed by a latent period or “silent interval”, during 
which there is no seizure activity until the first appearance of SRS (Walker et al., 
2002; Chang and Lowenstein, 2003; Williams et al., 2009). Partial seizures can 
induce molecular and cellular changes to the brain, and the alterations in the 
surviving neurons that eventually lead to SRS is a measure of epileptogenesis 
(Walker et al., 2002; Aroniadou-Anderjaska et al., 2008).  Epileptogenesis occurs 
during the latent period and is the process by which surviving injured neurons 
progressively form hyperexcitable, epileptic neuronal networks (Aroniadou-
Anderjaska et al., 2008).  The latent period does not, however, define the duration 
of epileptogenesis (Williams et al., 2009), as epileptogenesis can continue after 
the onset of SRS (Williams et al., 2007; 2009).  The latent period is known to be 
highly variable in rat models of epileptogenesis and the unpredictability of the 
onset of SRS originally suggested that epileptogenesis occurred only during the 
latent period (Williams et al., 2009).  However, there is now strong evidence to 
support the suggestion that development of symptomatic epilepsy is continuous 
and/or progressive and persists after the onset of clinical seizures (Williams et 
al., 2009). 
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The understanding of epileptogenesis fundamentally comes from animal models 
investigating brain trauma, stroke or status epilepticus (SE)-induced 
epileptogenesis, and most models produce alterations in the brain similar to 
those found in resected temporal lobe tissue of patients with drug-resistant 
epilepsy (Pitkänen and Lukasiuk, 2009).  The understanding of cellular and 
molecular mechanisms of epileptogenesis is still incomplete and requires further 
investigation to help target the development of preventive therapeutic 
approaches (Herman, 2002; Friedman et al., 2009).  The latent period in 
particular is considered to be a window of opportunity for intervention designed 
to retard or prevent the subsequent development of epilepsy.  Animal models 
have been widely used in the past to study cellular and molecular mechanisms of 
TLE and can also be used to test potential novel anticonvulsant or 
antiepileptogenic therapies (Löscher, 2002; Buckmaster, 2004; Löscher, 2011; 
Bauer and Norwood, 2013).  Currently, administration of AEDs following acute 
brain insults has failed to prevent chronic epilepsy, indicating that present AEDs 
are antiepileptic but not antiepileptogenic, most likely because they were not 
designed for that purpose (Herman, 2002; Walker et al., 2002).   
 
Present AEDs are used to treat the acute symptoms of seizures and do not affect 
the development of chronic epilepsy (Smith et al, 2007).  Traditional AEDs were 
mostly discovered by chance, rather than designed (Baker and Jacoby, 2013; 
Brodie, 2010).  Phenobarbital was given to epilepsy patients for sedative 
purposes; the accompanying anticonvulsant effect was purely fortuitous (Brodie, 
2010).  Carbamazepine was synthesised as an atypical antipsychotic and only 
later recognised to have anticonvulsant properties (Brodie, 2010).  Valproic acid 
was initially used as a solvent to dissolve drugs of interest in an epilepsy drug 
screening study; its antiepileptic effects were realised when all animals in the 
screening study, including vehicle-treated controls, were protected against 
seizures (Brodie, 2010).  Subsequently identified AEDs were identified and 
screened as part of the Anticonvulsant Drug Development Programme (Smith et 
al, 2007) using  target-orientated design, modification of existing molecules and 
systematic screening against a range of animal seizure models (Brodie, 2010). 
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Using this discovery process, the identified AEDs share similar mechanistic 
characteristics in decreasing neuronal excitation or increasing neuronal 
inhibition (Smith et al, 2007) but they do not modify the course of epilepsy or 
prevent the development of epilepsy (Smith et al, 2007).   
 
1.2.2. Animal models of epileptogenesis 
Countless animal models have been used in epilepsy research, most of which are 
acute models of single seizures rather than chronic models of epileptogenesis 
(Löscher, 2011).  Chronic models of epileptogenesis, where animals develop SRS, 
can be spontaneous, as in the case of using mutant or transgenic animals with 
inherent epilepsy, or can be acquired, in which an initial brain insult is induced 
either chemically or electrically or by direct brain trauma (Löscher, 2011).  
Chronic epilepsy models with induced SE are considered to have the greatest 
resemblance to human TLE (Löscher, 2011).  Currently, the most widely used 
chemicals to induce SE in animals are pilocarpine and kainic acid (KA) (Löscher, 
2002).  Pilocarpine, a cholinergic muscarinic agonist, and KA, an excitotoxic 
glutamate analogue, can be administered systemically, intracerebrally or 
intracerebroventricularly.  Both chemicals, when administered systemically, 
target the hippocampus as the seizure onset zone (Lévesque and Avoli, 2013).  
The neuropathology arising from pilocarpine or KA-induced epilepsy includes 
mossy fibre sprouting in the dentate gyrus (DG), neuronal loss in thalamus, 
substantia nigra, amygdala, hippocampal formation, olfactory cortices and 
neocortex, marked atrophy and dendritic sprouting in the sensorimotor cortex, 
and reorganisation and neuroplasticity of neocortical networks (Curia et al., 
2008; Lévesque and Avoli, 2013).  These effects are similar to the neuropathology 
of patients with TLE, which is characterised by neuronal loss in the hippocampal 
formation, aberrant mossy fibre sprouting in the molecular layer of DG and 
granule cell dispersion (Berkovic et al, 1991; Buckmaster, 2012; Lévesque and 
Avoli, 2013).There are also differences between chemical-induced epilepsy 
models and TLE patients.  Seizure propagation is faster in animal models than in 
humans and TLE patients generally have lateraliesd foci and lesions, whereas 
seizure onsets and lesions are equal in both hemispheres in rodents (Jefferys, 
2014).   
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Despite showing similarities in seizure onset region and in their 
neuropathological characteristics, there are differences between pilocarpine and 
KA in their blood-brain-barrier (BBB) penetration and the duration of the latent 
period that follows the initial SE.  The opening of the BBB has been suggested to 
be a major precipitating factor in the induction of acute seizures (Marchi et al., 
2011; Lévesque and Avoli, 2013).  Pilocarpine is generally co-administered with 
compounds, such as lithium, bradykinin or histamine, that enhance BBB 
permeability in order to induce epileptiform activity at lower doses (Müller et al., 
2009; Lévesque and Avoli, 2013).  KA, on the other hand, is able to temporarily 
increase BBB permeability independently during acute seizures (Zucker et al., 
1983; Williams et al., 2009).  Pilocarpine-induced SE is reported to be far more 
intense than that induced by KA and therefore the onset of SRS is likely to occur 
earlier (Williams et al., 2009).  Pilocarpine-treated rats show presence of 
spontaneous seizures during the first week following SE (Jung et al, 2007), 
whereas KA-treated rats show first spontaneous motor seizures beyond 7 days 
after SE (Hellier et al, 1999).  Although lower doses can extend the latent period 
to SRS and lower the mortality rate, the average latency is still shorter for 
pilocarpine than for KA-treated rats (Curia et al, 2008; Glien et al, 2001; Hellier et 
al, 1998).  Evidence of a shortened latent period in the pilocarpine model could 
potentially mean a limited window of opportunity to investigate potential 
antiepileptogenic agents, where the intervention is administered after the initial 
acute neurological insult.  Nevertheless, both pilocarpine and KA have short 
latent period compared to human TLE, which can in some cases take 20+ years to 
develop following a complex febrile seizure (Williams et al, 2007).  Shorter latent 
period is even less characteristic of human TLE (White, 2002), therefore, the KA 
model of epileptogenesis may be considered to be more suitable for investigating 
antiepileptogenic properties of drug interventions and more consistent with the 
human disorder it is intended to model. 
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1.3. Neurotransmission in epilepsy 
 
Epilepsy can develop from an imbalance of excitatory and inhibitory 
neurotransmission.  Epilepsy occurs when there is an increase in neuronal 
activity caused by either an abnormally high level of excitatory 
neurotransmission or a decrease in inhibitory neurotransmission (Bradford, 
1995).  The abnormal amplification and synchronisation of neuronal firing that 
causes seizures, and also changes in amino acid content in brain tissues following 
the onset of epileptic seizures, involves the interaction of inhibitory 
neurotransmitter, -aminobutyric acid (GABA), and excitatory neurotransmitter, 
glutamate (Bradford, 1995).  Almost all excitatory CNS neurotransmission is 
controlled by glutamate. It is acknowledged as the most important transmitter for 
normal brain function (Purves et al., 2001) and is one of the most important 
factors in regulating the physiological balance of CNS function.  Glutamate is 
implicated in several neurological disorders, including epilepsy (Danysz et al., 
1995).  Excessive release of glutamate and prolonged excitatory synaptic 
transmission is toxic to neurons due to the resulting influx of calcium (Cao et al., 
2005).  The accumulation of calcium causes destruction of transporter proteins 
on pre-synaptic glial cells that are responsible for the uptake of glutamate from 
the synaptic cleft, hence causing a “feed-forward” excitotoxic mechanism of 
excessive stimulation of glutamate receptors (Nelson et al., 2003). 
 
A transient increase in extracellular glutamate levels in the brain has been 
observed in epileptic patients during spontaneous seizures (Chapman, 2000).  
Excitatory glutamatergic mechanisms play a key role in the pathophysiology of 
epileptogenesis (Chapman, 2000) and may be involved at 3 different levels – 
chronic sub-convulsive hyperactivity in the epileptic focus; amplified excitatory 
activity leading to initiation of seizures and recruitment of excitatory neurons 
adjacent to the focus; and propagation of the hyperactivity to precipitate a 
generalised seizure (Bradford, 1995).  Increased extracellular glutamate at the 
epileptic focus occurs at the onset of epileptic hyperactivity in animal models of 
epilepsy, and may precipitate further glutamate release (Bradford, 1995).  
Altering glutamate levels by manipulating glutamate transporter expression can 
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induce or suppress epileptic seizures in genetic models of epilepsy (Chapman, 
2000).   
 
Glutamate activates 3 major types of ionotropic receptors, N-methyl-D-aspartate 
(NMDA), -amino-2-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and KA 
(Danysz et al., 1995) and these receptors are expressed mainly in the CNS (Figure 
1.1).   
 
 
Figure 1.1.  A schematic diagram illustrating synaptic neurotransmission.  
Neurons release glutamate from the pre-synaptic termimal and glutamate 
transporters are responsible for the uptake of glutamate back into the pre-
synaptic terminal.  Extracellular glutamate binds to glutamate receptors, N-
methyl-D-aspartate (NMDA), -amino-2-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) or kainate (KA) on the post-synaptic neuron.  At physiological 
conditions, neuronal nitric oxide synthase (nNOS) that is closely associated with 
NMDA receptors, produces endogenous low levels of nitric oxide (NO•) which 
exerts neuroprotective effects by activating soluble guanylyl cyclase.  This 
activation can block glial cell activation, causing anti-inflammatory effects.  In the 
event of a neurological insult, glial cells up-regulate inducible nitric oxide 
synthase (iNOS) activity that results in higher concentrations of NO• that can 
cause acute glutamate release from neurons, which leads to neurotoxicity.  Image 
adapted from Araque et al (1999). 
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NMDA receptors (NMDAR) are involved in synaptic plasticity and long-term 
potentiation (Cull-Candy et al, 2001), and theiractivation largely mediates 
glutamate excitotoxicity and neuronal damage, and is involved in a variety of 
neurological disorders, including epilepsy (Danysz et al., 1995; Dingledine et al., 
1999; Zhou and Zhu, 2009).  
 
Glutamate receptors are an obvious therapeutic target in the search for new 
epilepsy drugs.  However, until the recent advent of perampanel, which is an 
antagonist at AMPA receptors, few glutamate receptor agents had been successful 
in epilepsy trials (Dingledine et al., 1999).  Competitive and uncompetitve NMDA 
receptor antagonists did not show convincing anticonvulsant activity but did 
cause severe neuropsychological adverse effects in healthy volunteers (Loscher, 
1998).  This prompted researchers to look at alternative, indirect means of 
modifying glutamate neurotoxicity. One such approach was to focus on nitric 
oxide, which is known to be a mediator of downstream signalling following 
glutamate activation (Dawson et al., 1991). 
 
1.4. Nitric oxide 
 
1.4.1. Overview 
Nitric oxide (NO) is a gaseous chemical messenger molecule with many roles in 
the CNS and is typically produced endogenously at low levels (Nelson et al., 2003; 
Cherian et al., 2006; Benarroch, 2011).  At physiological concentrations, NO 
exerts neuroprotective effects by inducing a structural change to NMDAR, and 
down-regulating its activity (Nelson et al., 2003).  When produced in excess, NO 
can cause acute glutamate release from neurons and astrocytes, which leads to 
neurotoxicity (Dawson and Dawson, 1996) (Figure 1.1).  NO induces cell death in 
a manner that is very similar to glutamate-induced cell death (Cao et al., 2005).  
Deficiency of NO is also associated with vasoconstriction of cerebral vessels, 
which can result in decreased cerebral blood flow and ischemia (Cherian et al., 
2006).  Developing novel drugs that target NO signalling has the potential to 
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benefit on its neuroprotective properties and prevent glutamate-induced 
neurotoxicity but also creates a risk of NO deficiency that can be equally 
detrimental.  This balance between efficacy and toxicity may only allow a small 
therapeutic window, which can make this a risky target for drug development.  
However, by identifying the therapeutic range, given the appropriate therapeutic 
dose levels and the use of appropriate biomarkers for the treatment, it may be 
possible achieve efficacious levels and minimise toxicity. 
 
1.4.2. Nitric oxide synthase 
NO is not stored in synaptic vesicles and does not undergo exocytosis or act on 
membrane-bound receptors (Dawson et al., 1992; Dawson and Dawson, 1996).  
Rather, NO is synthesised on demand (Dawson and Dawson, 1996) and is rapidly 
neutralised by haemoglobin, methylene blue and superoxide anion, with a half-
life of 3 to 5 seconds (Dawson et al., 1992; Rodeberg et al., 1995).  NO is 
membrane permeable and diffuses from one neuron to another and acts on 
intracellular components (Dawson and Dawson, 1996).  NO activity is regulated 
by its synthesis from the terminal guanidine group of L-arginine to a -hydroxyl-
L-arginine intermediate compound, a reaction that is catalysed by the enzyme NO 
synthase (NOS). This reaction uses molecular oxygen and nicotinamide adenine 
dinucleotide phosphate (NADPH) to oxidise the substrate to L-citrulline and NO 
(Rodeberg et al., 1995; Dawson and Dawson, 1996; Benarroch, 2011).  There are 
two types of NOS - constitutive and inducible. Constitutive forms include 
neuronal nitric oxide synthase (nNOS) and endothelial nitric oxide synthase 
(eNOS). Within the neurons, nNOS is mainly found in the cytoplasm but is 
concentrated at the post-synaptic membrane, closely associated with NMDAR 
(Cherian et al., 2006; Brown, 2010) (Figure 1.1).  In the endothelium, eNOS 
produces NO and causes increased vascular blood flow, as NO is a potent 
vasodilator (Cherian et al., 2006).  In contrast, inducible nitric oxide synthase 
(iNOS) is expressed predominantly in inflammatory cells, with NO production 
induced by pro-inflammatory cytokines or bacterial lipopolysaccharide (LPS) 
(Nomura and Kitamura, 1993; Kato et al., 2005; Benarroch, 2011).   
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1.4.3. Nitric oxide production under physiological conditions 
NO is produced by most tissues in the body, however NO concentrations are 
highest in the brain (Cherian et al., 2006).  All three isoforms of NOS can be 
expressed in the CNS, but under normal circumstances nNOS and eNOS 
predominate (Dawson and Dawson, 1996).  eNOS regulates cerebral blood flow 
and BBB permeability (Dawson and Dawson, 1996; Kato et al., 2005; Parathath et 
al., 2007).  Chemical signals in blood vessels activate eNOS by eliciting an increase 
in intracellular calcium (Benarroch, 2011).  In contrast, nNOS regulates synaptic 
potentiation and plasticity, and modifies release of glutamate in the brain 
(Dawson and Dawson, 1996; Kato et al., 2005; Parathath et al., 2007).  The 
mechanism of nNOS activation in neurons is through calcium influx via NMDAR 
(Dawson et al., 1992; Cherian et al., 2006; Benarroch, 2011).  NO production by 
nNOS is activated by the binding of calcium to calmodulin (Nelson et al., 2003; 
Cao et al., 2005) (Figure 1.2).   
 
The expression of nNOS is regulated by the activation of cyclic adenosine 
monophosphate response element-binding protein (CREB) by the calcium-
calmodulin complex following calcium influx (Benarroch, 2011).  At the post-
synaptic density synapse, nNOS and calmodulin form a macromolecular complex 
via post-synaptic density 95 protein (PSD95).  This complex promotes the 
calcium-calmodulin interaction with nNOS (Benarroch, 2011) (Figure 1.2).  NO 
can act as a negative feedback system by oxidising some redox sites within the 
NMDAR and inhibiting calcium influx (Lipton and Stamler, 1994; De Luca et al., 
2006).   
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Figure 1.2.  A schematic diagram illustrating the mechanism of neuronal nitric 
oxide synthase (nNOS) activation in postsynaptic neurons through calcium (Ca2+) 
influx via the N-methyl-D-aspartate receptor (NMDAR), converting L-arginine to 
L-citrulline and nitric oxide (NO).  NO production from nNOS is activated by 
binding of Ca2+ to calmodulin (CaM).  CaM and nNOS form a macromolecular 
complex via post-synaptic density 95 (PSD95), which promotes the Ca2+-CaM 
interaction with nNOS.  Image adapted from previous publications (Dawson et al., 
1992; Benarroch, 2011). 
 
 
1.4.4. Nitric oxide production in neurological disease states 
The activity of both constitutive forms of NOS can react rapidly to changes in 
physiological conditions, allowing transient increase in  low levels of NO.  In 
contrast,  iNOS, when induced, produces higher concentrations of NO but over 
longer periods of time (Benarroch, 2011).  iNOS expression in the brain is almost 
undetectable under normal physiological conditions but in several disease states, 
glial cells (specifically microglia and astrocytes) are triggered by pathogens, 
insult or hypoxia, and induce iNOS activity (Nelson et al., 2003; Cherian et al., 
2006; Benarroch, 2011) (Figure 1.1).  iNOS, once induced, is continuously 
activated without further induction (Nomura and Kitamura, 1993; Cherian et al., 
2006; Benarroch, 2011).  During an immune reaction, cytokines are produced to 
counteract pathogens and to coordinate a T-cell response.  The increase in pro-
inflammatory cytokines activates nuclear factor kB which induces iNOS 
   
15 
 
transcription in the nucleus (Nelson et al., 2003; Cherian et al., 2006; Benarroch, 
2011).  Hypoxia also induces iNOS via hypoxia-inducible factor-1 (Benarroch, 
2011).    
 
1.4.5. Neurotoxic properties of nitric oxide 
The mechanisms of action of NO are mediated by different pathways, hence NO 
can be neuroprotective or neurotoxic depending on its concentration and cellular 
production (Benarroch, 2011).  Low levels of NO are produced within seconds by 
nNOS and eNOS under normal physiological conditions.  This transient increase 
in NO exerts neuroprotective and anti-apoptotic effects via a rapid and short-
lasting activation of soluble guanylyl cyclase (Benarroch, 2011) (Figures 1.1 and 
1.3).   
 
This leads to the formation of cyclic guanosine monophosphate (cGMP) and 
activation of protein kinase G, which causes the inhibition of  intracellular 
calcium release and regulates downstream transcription factors such as CREB, 
through phosphorylation by cGMP-dependent protein kinases (Dawson et al., 
1992; Benarroch, 2011; Pilz and Casteel, 2003) (Figure 1.3).  In the CNS, NO is the 
major activator of cGMP formation (Dawson and Dawson, 1996).  This pathway 
modulates its effects on synaptic activity and vascular relaxation and its 
neuroprotective effects (Benarroch, 2011).  Soluble guanylyl cyclase activation 
can also block astrocyte and microglial activation, causing anti-inflammatory 
effects (Brown, 2010) (Figure 1.1).   
 
The neurotoxic effects of NO have been implicated in the pathogenesis of cerebral 
ischemia, neuroinflammation, brain tumours, neurodegenerative diseases and 
neurological disorders i.e. epilepsy (Kato et al., 2005; Brown, 2010).  In the 
disease state, an excess production of NO can be both beneficial and detrimental 
due to the complex roles of NO under normal physiological conditions.  NO itself 
is mildly toxic with limited number of potential cellular targets (Dawson and 
Dawson, 1996), but at high intracellular levels, NO may lead to nitrosative stress 
that is potentiated by the concomitant excessive production of reactive oxygen 
species (Dawson and Dawson, 1996; Benarroch, 2011).  
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Figure 1.3. A schematic diagram illustrating the neuroprotective and neurotoxic 
properties of nitric oxide (NO) depending on its level of synthesis from neuronal 
nitric oxide synthase (nNOS), endothelial nitric oxide synthase (eNOS) and 
inducible nitric oxide synthase (iNOS).  nNOS is activated through calcium influx 
via glutamate receptor activation and binding of calcium to calmodulin.  eNOS is 
activated by an increase in intracellular calcium.  iNOS expression is triggered by 
a neurological insult and the resulting increase in inflammatory cytokines 
induces iNOS transcription.  The transient increase in NO by nNOS and eNOS 
leads to cyclic guanosine monophosphate and protein kinase G complex 
activation (cGMP-PKG).  This pathway regulates the production of NO and its 
effects on synaptic plasticity, vasodilation and neuromodulation.  S-nitrosylation 
occurs when NO combines with oxygen (O2), which reversibly interacts with 
thiols to form S-nitrosothiol.  The S-nitrosylation process causes neuroprotection 
at low levels of NO, while excess S-nitrosylation causes neurotoxicity.  
Nitrotyrosylation occurs when NO reacts with superoxide anion (O2•) to produce 
peroxynitrite (ONOO-) that causes multiple neurotoxic effects via oxidative and 
nitrosative stress.  Image adapted from (Benarroch, 2011)). 
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A chronic increase in NO causes neurotoxic and apoptotic effects via S-
nitrosylation and nitrotyrosylation (Benarroch, 2011) (Figure 1.3).  S-
nitrosylation occurs when NO combines with oxygen to produce nitrosonium ion, 
which reversibly interacts with thiols to form S-nitrosothiol (Benarroch, 2011) 
(Figure 1.3).  It is this S-nitrosylation process that causes a structural change to 
the transmembrane calcium channel proteins of the NMDAR and down-regulates 
receptor activity, which reduces calcium influx and exerts neuroprotection at low 
levels of NO (Nelson et al., 2003; Benarroch, 2011).  Excess S-nitrosylation, 
however, causes neurotoxicity (Brown, 2010) (Figure 1.3).  Nitrotyrosylation 
occurs when NO reacts with superoxide anion to produce peroxynitrite, a potent 
oxidant involved in neurotoxicity that spontaneously isomerises to nitrate 
tyrosine residues of proteins forming 3-nitrotyrosine.  This causes multiple 
neurotoxic effects via oxidative and nitrosative stress (Benarroch, 2011) (Figure 
1.3).  Nitrosative stress contributes to the development of neurodegenerative 
disorders (Brown, 2010).   
 
NO toxicity mediated by the induction of iNOS by pro-inflammatory cytokines is 
exacerbated by concurrent excessive production of NO from the calcium-sensitive 
activation of nNOS through the overstimulation of NMDARs, leading to calcium 
overload in the cell (Zhou and Zhu, 2009; Benarroch, 2011).  Following a 
neurological insult, the homeostatic balance between endogenous antioxidants 
and reactive oxygen species (ROS) becomes unequal.  iNOS is expressed as a 
result of increased ROS production and a decreased antioxidant defence.  This 
results in oxidative stress that causes molecular damage and cell death (Nelson et 
al., 2003). 
 
NO can also cause mitochondrial inhibition, glutamate release and subsequent 
excitotoxic neuronal death via glutamate receptor activation (Brown, 2010).  
High levels of NO causes acute glutamate release from neurons, resulting from 
either the inhibition of mitochondrial respiration followed by reversal of 
glutamate uptake, or by direct activation of vesicular exocytosis by modifying 
protein thiols (Brown, 2010).  High NO levels can also induce acute glutamate 
release from astrocytes by causing intracellular calcium release followed by 
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calcium activation of vesicular exocytosis (Brown, 2010).  Under normal 
physiological conditions, glutamate is localised mainly in presynaptic vesicles.  
Following its release during depolarising events it is efficiently removed from the 
synapse by glutamate transporters and re-packaged back into presynaptic 
vesicles (Figure 1.1).  However, excessive release of glutamate leads to 
accumulation in the extracellular space, mediating cell death via NMDAR 
activation and the consequent increase in intracellular calcium levels in a process 
termed “excitotoxicity” (Dawson and Dawson, 1996; Brown, 2010).   
 
BBB disruptions are associated with excitotoxicity following neurotrauma or 
inflammatory reactions (Wong et al., 2004). Following neurological insult, 
astrocytes and microglia become activated around the insult sites in the brain 
leading to elevated iNOS expression in glia (Nomura and Kitamura, 1993).  The 
high concentrations of NO produced elicit neuronal death by causing inhibition of 
mitochondrial respiration in neurons, which in turn leads to neuronal 
depolarisation and glutamate release, therefore causing further excitotoxicity 
(Nomura and Kitamura, 1993; Brown, 2010).  Excess NO can also compromise 
BBB integrity, which further compounds the cellular damage following glutamate 
release but the mechanism involved is poorly understood (Wong et al., 2004; 
Parathath et al., 2007). 
 
1.4.6. Nitric oxide levels following acute neurological insult 
NOS expression has been shown to increase in the cerebral cortex of patients 
with  epilepsy (González-Hernández et al., 2000).  NO produced by nNOS and 
eNOS is shown to peak immediately after a neurological insult, with a later peak 
of NO produced by iNOS following an interval of relative NO deficiency (Cherian 
et al., 2006). This low level in the intervening period is associated with low 
cerebral blood flow (Cherian et al., 2006).  Following an insult, eNOS activity is 
believed to be beneficial, since genetically-modified rodents deficient in eNOS 
show more extensive neuronal damage than wild-type rodents following both 
experimental cerebral ischemia and traumatic brain injury (Huang et al., 1996; 
Parmentier et al., 1999; Jafarian-Tehrani et al., 2005).  On the other hand, nNOS 
contributes to neurotoxicity within minutes following an insult (Cherian et al., 
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2006).  An increase in NO levels in the hippocampus of mice has been observed 
after KA administration (Kato et al., 2005).  NO formation has also been shown to 
increase during KA-induced seizures in rat brain, but is not believed to be 
involved in the regulation of seizure generation and propagation (Milatovic et al., 
2002).  Pre-treatment with NOS inhibitors has been reported to reverse the 
increase in NO levels seen after KA administration in vivo, however, these 
inhibitors did not show any anti-seizure properties (Kato et al., 2005).  The effect 
of NOS inhibitors is controversial in the literature, with reports suggesting both 
pro- and anti-convulsant activity, depending on dosage, time of administration 
and the animal species used (Przegaliński et al., 1994; Dawson and Dawson, 
1996; Przegaliński et al., 1996; Kato et al., 2005).  This can be explained by the 
fact that non-specific NOS inhibitors have effects on cerebral blood flow mediated 
via inhibition of eNOS, resulting in greater neuronal damage than is observed 
with convulsant agents such as KA alone (Dawson and Dawson, 1996; Kato et al., 
2005).  This finding emphasises the importance of specificity amongst NOS 
inhibitors. Targeting NO synthesis via highly specific inhibition of either nNOS or 
iNOS may be able to prevent excitotoxicity mediated via NMDAR or inflammation, 
respectively.  These inhibitors can then be evaluated for potential antiepileptic or 
antiepileptogenic properties. 
 
1.5. Pharmacological neuroprotection by disrupting nitric 
oxide synthesis 
 
1.5.1. Post-synaptic density 95 blocking peptide 
Post-synaptic density (PSD) is a cytoskeletal adapter specialisation, involved in 
anchoring neurotransmitter receptors and regulating the response of post-
synaptic neurons to synaptic stimulation (Chen et al., 2006).  PSD is composed of 
4 major types of molecules – membrane-bound, cytoskeletal, scaffolding proteins 
and modulatory enzymes (Forder and Tymianski, 2009).  Of all PSD proteins, 
PSD95 plays an important organisational role by coupling NMDAR to intracellular 
proteins and signalling enzymes (Forder and Tymianski, 2009).  PSD95 is an 
essential synaptic adapter protein that binds to NMDAR subunits and activates 
the NMDAR-mediated cascade of downstream events, and thus has roles in 
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synaptic plasticity, neuronal ionic excitability and seizure susceptibility (Chen et 
al., 2006). Proteins from the same family as PSD95 are called channel-associated 
proteins of synapses (chapsyns), and it consists of four proteins: SAP90/PSD95, 
SAP97, PSD93/chapsyn-110 and SAP102 (Dingledine et al., 1999).  These 
proteins can bind to the C termini of NMDAR subunits (Dingledine et al., 1999).  
PSD95 is an abundant cytoskeletal protein found mainly in the postsynaptic 
fraction of synaptosomes, although it can also be found presynaptically 
(Dingledine et al., 1999).  PSD95 is also a multidomain protein that serves as a 
central mediator of assembly of the PSD complex (Cao et al., 2005).  PSD95 
contains 3 PDZ domains – PDZ1, PDZ2 and PDZ3.  The PDZ domain is a structural 
domain shared by 3 proteins, PSD95, Drosophilia disc large tumor suppressor, 
Dlg1, and zonula occludens-1 protein, zo-1, and its name is derived from the first 
letter of each protein in that order (Kennedy, 1995).   
 
PSD95 is central to the activation of nNOS. NO cannot be stored in the cells and 
must be generated on demand; this requires that nNOS is either bound to 
membranes directly or is anchored by adapter proteins to the membrane (Zhou 
and Zhu, 2009).  PSD95 assembles in a tight ternary complex with nNOS and 
NMDAR subunit 2B (NR2B) fusion protein, by interacting with the C-terminal of 
the NMDAR subunit 2 (NR2) via the PDZ1 and PDZ2 domains, and interacting 
with nNOS via the PDZ2 domain (Christopherson et al., 1999; Dingledine and 
McBain, 1999; Cao et al., 2005).  The NMDAR is therefore able to activate nNOS by 
coupling with PSD95 (Forder and Tymianski, 2009).  The PDZ3 domain of PSD95 
is not known to have any importance in glutamate-induced neuronal cell death 
(Cao et al., 2005).     
 
NMDAR antagonists have been studied as potential antiepileptic agents in rodent 
models of epilepsy (Dingledine et al., 1990; Danysz et al., 1995; Brandt et al., 
2003) and are shown to be weak AEDs when administered after SE (Brandt et al., 
2003; Aroniadou-Anderjaska et al., 2008).  Excitotoxic brain damage and 
epileptogenesis are likely to be controlled by different molecular pathways, 
therefore neuroprotective compounds may not necessarily be efficacious as AEDs 
in the treatment of epilepsy (Vincent and Mulle, 2009).  NMDAR antagonists may 
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potentially be more effective as antiepileptogenic agents for the prevention of 
epilepsy.  However, the development of a treatment that competitively blocks the 
NMDAR is unlikely to progress beyond clinical trials because of its neurotoxic 
side effects and the profound disturbances on normal brain function that would 
outweigh its therapeutic value (Dingledine and McBain, 1999; Löscher, 2002; 
Vincent and Mulle, 2009).  Different NMDAR antagonists exert different 
impairment of NMDA receptor function.  One of the variations depends on the off-
rate of the compound (Sleigh et al, 2014).  Ketamine, an open channel blocker, 
selectively influences the action of NMDAR by blocking the receptor when opened 
for prolonged period of time in pathological states, and has minimal effects when 
opened transiently at physiological states (Sleigh et al, 2014).  However, 
ketamine also has a slow off-rate, which means ketamine remains trapped in the 
closed ion channel and causes a prolonged tonic blockade that disrupts 
physiological and pathological function (Sleigh et al, 2014).  Antagonists with fast 
off-rate are able to escape from the ion channel before it closes, therefore 
preserving some physiological NMDA function with fewer adverse effects (Sleigh 
et al, 2014).  Memantine, a low affinity open-channel blocker with a fast off-rate 
only blocks NMDA receptors when open for a pathologically prolonged time and 
has minimal effect when NMDA receptor is only transiently open in physiological 
states (Lipton, 2007).  This mechanism is comparable to the effects of persistent 
sodium channel blockers (Devor, 2006), hence some NMDA antagonists maybe 
expected to have more adverse effects than sodium channel blockers.  Therefore,  
selectively blocking the downstream signalling of NMDAR, by suppressing the 
expression of nNOS or PSD95, without affecting NMDAR itself might also reduce 
the vulnerability of neurons to NMDA-mediated toxicity and thus avoid the 
profound consequences of glutamatergic inhibition (Sun et al., 2008; Vincent and 
Mulle, 2009).   
 
The NMDAR-PSD95-nNOS complex has been shown to be important in mediating 
excitotoxic damage (Cui et al., 2007).  Peptides that selectively disrupt the 
interaction of the NMDAR with PSD95 protein have shown to reduce excitotoxic 
neuronal loss after ischaemia, without blocking excitatory neurotransmission 
(Sun et al., 2008; Forder and Tymianski, 2009; Vincent and Mulle, 2009).  The 
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inhibition of nNOS has also been shown to have antiepileptic properties in the 
early phases of epileptogenesis in a mouse KA model (Beamer et al., 2012).  
However, inhibiting nNOS directly may also cause disturbance in physiological 
functions with undesirable long-term side effects, such as affecting learning and 
memory (Hopper and Garthwaite, 2006; Taqatqeh et al, 2009; Forstermann and 
Sessa, 2011).  Interfering with nNOS-PSD95 interaction may be preferable and 
has been shown to reduce NO production without affecting nNOS function (Cui et 
al., 2007; Zhou and Zhu, 2009). 
 
Disruption of the interaction between NR2B and PSD95 can be achieved by 
introducing a peptide that mimics the NMDAR subunit 2 (NR2) C-terminal 
interaction of NMDAR with the PDZ domain of PSD95.  This peptide is termed 
NR2B9c as it comprises nine C-terminal (9c) residues of the NR2B subunit but is 
often referred to as PSD95 blocking peptide (PSD95BP) (Cui et al., 2007; Forder 
and Tymianski, 2009). To achieve BBB permeability, NR2B9c was fused to the cell 
membrane protein transduction domain of a human immunodeficiency virus type 
1 Tat protein (Schwarze et al., 1999; Cui et al., 2007; Sun et al., 2008), hence 
PSD95BP is also named Tat-NR2B9c in some literature (Aarts et al., 2002; Cui et 
al., 2007; Forder and Tymianski, 2009; Cook et al., 2012).  PSD95BP given 
intravenously at a dose of 7.6 mg/kg to rodents has been shown to exclusively 
block the PDZ domain of PSD95 and nNOS only, and uncouple NMDAR and nNOS 
without blocking other cellular interactions (Cui et al., 2007).   
 
PSD95BP is the first pharmacological compound that has shown efficacy when 
administered after the ischemic insult in a primate model of stroke (Forder and 
Tymianski, 2009; Cook et al., 2012).  PSD95BP has also been tested during the 
early phases of epileptogenesis in a KA mouse model of epilepsy, using EEG as a 
surrogate marker of outcome (Beamer, 2013).  The administration of PSD95BP 
one hour after KA-induced SE significantly reduced epileptiform spike frequency 
during the subsequent 3-12 hours (Beamer, 2013).  To my knowledge, PSD95BP 
has not been tested in any other animal model of epilepsy or against any other 
aspect of epileptogenesis. 
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1.5.2. 1400W dihydrochloride 
N-(3-(aminomethyl)benzyl)acetamidine, also known as 1400W, is a highly 
selective, cell and tissue permeable iNOS inhibitor (Parmentier et al., 1999; 
Alderton et al., 2001).  1400W is currently the most selective known iNOS 
inhibitor and is at least 100-fold more selective in reducing vascular injury from 
LPS-induced iNOS in rats than previous iNOS inhibitors, such as aminoguanidine 
which also had inhibitory effects on nNOS and eNOS (Laszlo et al., 1995; Garvey 
et al., 1997).  1400W is 5000-fold more selective for iNOS than for eNOS, and 200-
fold more selective for iNOS than for nNOS (Garvey et al., 1997). The inhibition of 
iNOS by 1400W has a slow onset and is NADPH-dependent (Garvey et al., 1997).  
Its mechanism of inhibition involves competition with L-arginine and is 
considered to be either irreversible or only very slowly reversible (Garvey et al., 
1997; Alderton et al., 2001).  Irreversible or very slowly reversible inhibitors can 
have prolonged effects, which may be therapeutically advantageous in some 
circumstances.  However they may also cause more undesirable side effects as 
they permanently abolish the function of the respective enzyme and make the 
treatment of overdose problematic.  The amidine moiety of 1400W is a structural 
analogue of guanidine, which is the functional group on the side chain of arginine 
(Garvey et al., 1997). 1400W binds to the guanidine recognition site of the 
enzyme, preventing the production of NO from L-arginine (Garvey et al., 1997).  It 
shows biological activity with selectivity for iNOS in rat tissues and prevents 
microvasculature injury in an in vivo rat model (Garvey et al., 1997).   
 
An inflammatory response is one of the events that is activated following a 
neurological insult and NO is known to play a crucial role in neuroinflammation.  
The induction of iNOS during epileptogenesis has been reported in various 
rodent models of epilepsy (Park et al., 2001; Rehni et al., 2009).  The production 
of NO by iNOS can be detrimental to the brain, depending on the time of 
production (Jafarian-Tehrani et al., 2005).  In in vitro models, induction of iNOS in 
glial cells following LPS challenge has an onset at around 4 hours and peaks at 24 
hours, while NO levels increase linearly from 4 to 72 hours after LPS insult in the 
presence of L-arginine (Nomura and Kitamura, 1993).  The induction of iNOS has 
been shown to cause neuronal cell death up to 72 hours after LPS insult in 
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primary rat mixed glial-neuronal cultures (Dawson and Dawson, 1996).  
Following acute ischemia, when the first dose of 1400W was administered at 20 
mg/kg immediately or 1 hour after the insult and then subsequent doses 
administered between 24 – 72 hours after the insult, studies have shown 
improved pathological outcome in a rat model of stroke (Armengou et al., 2003; 
Pérez-Asensio et al., 2005; O'Neill et al., 2011).  iNOS inhibition is shown to be 
neuroprotective when an initial dose of 20 mg/kg 1400W was given immediately 
following traumatic brain injury in rats, and subsequent doses were administered 
between 18 – 72 hours after the injury (Jafarian-Tehrani et al., 2005).  However, 
when iNOS inhibition occurred beyond 72 hours after the injury, no 
neuroprotective role against traumatic brain injury in rodents was observed 
(Jafarian-Tehrani et al., 2005).  Based on the results from in vitro and in vivo 
studies, it would appear that inhibition of iNOS at any point up to 72 hours after 
an insult is likely to protect against neuronal damage.    
 
1400W has been tested during the early phases of epileptogenesis in a KA mouse 
model of epilepsy, using EEG as a surrogate marker of outcome (Beamer, 2013). 
No change in EEG spike frequency was observed for up to 7 days after KA-
induced SE (Beamer, 2013).  To my knowledge, the effect of 1400W in other 
models of epilepsy or beyond the initial 7 days in models of epileptogenesis has 
not been investigated. 
 
1.6. Aim of thesis 
 
The potential for NO to cause neurotoxicity can be potentiated by: (1) transient, 
low concentration production of NO from nNOS following activation of NMDAR, 
and (2) sustained, high concentration production of NO from iNOS following its 
induction by pro-inflammatory cytokines. As such, it is possible that selective 
inhibition of nNOS or iNOS (or both simultaneously) will have therapeutic benefit 
in neurological disorders, including epilepsy, that are known to be associated 
with a change in expression of brain NO (Alderton et al., 2001).  To date, selective 
inhibition of NO synthesis has not been systemically investigated for the 
treatment of epilepsy. Furthermore, many studies have explored 
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antiepileptogenic properties of novel therapeutic agents but most have 
administered those agents prior to the initial brain insult (i.e. the initial SE), 
thereby failing to distinguish between direct effects modifying the disease course 
and indirect effects which simply modified the severity of the precipitating injury 
(Löscher, 2002). Administration of antiepileptogenic agents after the initial insult 
is not commonly performed and to my knowledge, there is currently no potential 
antiepileptogenic agent that targets NO signalling pathway.  
 
The aim of my PhD was to explore the effects of PSD95BP and 1400W in a mouse 
model of epileptogenesis and to identify the protein pathways involved. The 
overall objective was to determine whether PSD95, and its coupling of NMDAR 
and nNOS, or iNOS, whose expression is induced following brain insults, might 
represent novel targets for the treatment of TLE. Administering PSD95BP and 
1400W after the initial neurological insult in this project was designed to 
improve the clinical relevance and to avoid any confounding effects of insult 
modification. 
  
   
26 
 
 
 
 
 
 
 
 
 
Chapter 2 
Methodology 
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2.1. Kainic acid model of epileptogenesis 
 
2.1.1. Animals 
Adult male C57BL/6J mice (weight range between 25-30g) were purchased from 
Charles River Laboratories, Margate, UK.  All animals were habituated in their 
housing environment in groups of five per cage for at least 7 days before any 
experimental procedures were performed.  All animals used were housed under 
standard conditions in the Biomedical Services Unit, University of Liverpool, with 
12h light/dark cycle and access to food and water ad libitum. 
 
2.1.2. Reagents 
KA (Abcam, Cambridge, UK) was formulated to 2.5mg/ml with distilled water and 
sonicated for approximately 15 minutes until the powder was dissolved.  KA was 
prepared and used on the day of a study.  Diazepam ampoules (Hameln 
Pharmaceuticals, Gloucester, UK) and sodium pentobarbitone (Pentoject®; 
Animalcare Limited, York, UK), were purchased by the Named Veterinary 
Surgeon, Biomedical Services Unit, University of Liverpool. 
 
2.1.3. Seizure induction protocol 
All in vivo experimental procedures were carried out in accordance with the 
Animals (Scientific Procedures) Act, 1986.  Where possible, experiments were 
designed and have been reported in accordance with the principles of the ARRIVE 
guidelines (Kilkenny et al, 2010).  Prior to the induction of seizures, all animals 
were weighed and separated into individual cages, with access to food and water 
ad libitum.  All animals were single-housed for the duration of seizure induction 
until the end of the experiment when sacrificed.  The first dose of KA 
administration started from between 8:30am-9:00am for all animals.  KA was 
administered by the same experimenter for all experiments.  KA-treated mice 
received 5mg/kg KA via intraperitoneal (i.p.) injection every 30 minutes until the 
onset of generalised seizures.  Behavioural indicators of seizure severity were 
scored using the modified Racine scale (Racine, 2002) characterised as follows: 
Stage 1, animals displayed mouth and facial twitching; Stage 2, animals displayed 
head nodding with myoclonic twitching and tremor; Stage 3, animals displayed 
   
28 
 
forelimb clonus with a lordotic posture; Stage 4, animals reared with concomitant 
forelimb clonus; Stage 5, generalised clonic convulsion when animals displayed 
exaggerated activity (i.e. exaggerated running or jumping) (Hellier et al., 1998; 
Williams et al., 2009; Macias et al., 2013).  All behavioural assessments were 
conducted by the same experimenter.  The dosing of KA in individual animals was 
discontinued after each had experienced a generalised seizure consistent with 
Stage 5 of the modified Racine scale.  Two hours after the onset of the first Stage 5 
seizure, all mice (KA-treated animals and their vehicle-treated counterparts) 
were administered 10mg/kg diazepam intramuscularly (i.m.) in order to 
standardise the duration of acute KA-induced seizures.  The use of diazepam at 
this dose and at this time-point does not interfere with subsequent 
epileptogenesis or the development of associated neuropathology (Ben-Ari et al., 
1980; Halonen et al., 2001; Aroniadou-Anderjaska et al., 2008).   
 
2.1.4. Euthanasia 
Mice were euthanised according to The Humane Killing of Animals under 
Schedule 1 to the Animals (Scientific Procedures) Act, 1986.  On the day of 
euthanasia, mice were administered an overdose of sodium pentobarbitone 
(60mg/kg, i.p.) and death was confirmed with exsanguination.  There is no 
evidence that sodium pentobarbitone used at this dose and at this time-point had 
any effect on subsequent analysis of blood or tissue samples obtained from the 
animals. 
 
2.2. Electroencephalography 
 
2.2.1. Surgery 
C57BL/6J mice were implanted with a telemetry device (Physiotel® transmitter, 
TA10ETA-F20, Data Science International (DSI), Amsterdam, The Netherlands) to 
allow freely-moving remote EEG recording.  Animals were placed individually in a 
clear induction chamber and anaesthesia was induced with 3% isoflurane in 
100% oxygen with a delivery rate of 2 litre per minute until the loss of the pinch 
reflex.  The animals were then transferred to an anaesthetic mask and 
anaesthesia was maintained with 2% isoflurane in 100% oxygen with a flow rate 
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of 2 litre per minute for the duration of the pre-operative procedures.  The head 
of the animal was shaved and iodine (Videne®, Adams Healthcare, UK) used to 
disinfect the scalp.  Animals were then administered a prophylactic antibiotic, 
enrofloxacin (5mg/kg, subcutaneously (s.c.); Baytril®, Bayer Health group, 
Germany), and an analgesic, buprenorphine (0.3mg/kg, i.m.; Vetergesic®, Reckitt 
Benckiser Healthcare, UK), prior to surgery.   
 
After the pre-operative preparation, animals were transferred to the operating 
theatre and anaesthesia was maintained with 2% isoflurane in 100% oxygen with 
a flow rate of 2 litre per minute via the anaesthetic mask throughout surgery.  An 
incision was made through the skin, muscle and connective tissue over the skull.  
A pocket was also created in the flank of the animal, by s.c. tunnelling, where the 
transmitter unit was placed.  One ml of sterile 0.9% saline solution was added to 
the pocket for lubrication and local hydration.  Burr holes, each of 2mm diameter, 
were drilled using a high-speed drill with a rose-head nail bilaterally over the 
hippocampal region, approximately 5mm cranial to lambda and 2mm lateral to 
the midline over each hemisphere.  No stereotactic apparatus was used but drill 
sites were pre-marked using a permanent pen and the head of the animal was 
held securely during drilling.  The rubber insulation covering the electrode 
terminals of the transmitter was removed, and the exposed terminals were 
placed directly onto the surface of the dura mater.  Electrodes were secured and 
terminals insulated using dental cement made from Alphracryl Rapid Repair 
mixed with methylacrylate (National Dental Supplies, Southport, U.K.).   
 
After the electrode terminals were fixed and the transmitter inserted into the s.c. 
pocket, the scalp incision was sutured using Polysorb 4.0 absorbable sutures and 
reinforced with Vetbond™ Tissue adhesive (3M Animal Care Products, USA).  
Animals were then given saline (0.5ml s.c.) for rehydration and placed in an 
incubator set at 30-35oC for warmth during recovery from anaesthesia.  Animals 
were given soft food and housed individually during recovery from surgery.  
Post-operative care consisted of daily monitoring of food/water intake and of 
body weight and continued until individual body weight, excluding the weight of 
the transmitter unit, returned to its pre-operative level.   
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2.2.2. Data Scientific International system and micro1401 set-up 
DSI PhysioTel® Implantable Telemetry devices were used for remote EEG 
monitoring from conscious laboratory animals.  The transmitters (ETA-F20) are 
designed to measure bi-potential parameters, including EEG, in small to medium 
sized laboratory animals.  Each transmitter unit is flat-shaped, 3.9g in weight, 
1.9cc in volume, has 1 bi-potential channel, and has a battery life of 4 months.  
The transmitter unit has an outer material of silicon elastomer and its on-off 
mechanism is magnetically actuated.  The transmitter signal was sensed by RMC-
1 DSI receiver pads, processed via signal analog adapters to the DSI Data 
Exchange Matrix system and the micro1401 data acquisition hardware 
(Cambridge Electronic Design, Cambridge, UK).  Six receiver pads were connected 
to the hardware to allow six animals to be monitored simultaneously.  The 
micro1401 hardware was connected to a laptop equipped with Spike2 version 3 
software (Cambridge Electronic Design) via a USB cable for recording.  Spike2 
software was set to record waveforms at 250Hz continuously for all 6 channels 
with data files automatically saved after every hour of recording. 
 
2.2.3. Video recording for behavioural analysis 
Four dome CCD cameras (Sony, UK) with built-in infra-red were placed next to 
each cage, filming across to allow the behaviour of up to 4 mice to be monitored 
concurrently with EEG recordings continuously over a 28 day period (Figure 2.1).  
The cameras were connected to a H.264 network digital video surveillance 
recorder that allowed video files to be exported and played back on the 
computer. 
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Figure 2.1.  Representative images of a C57BL/6J mouse per cage in one channel 
under video monitoring with the CCD camera filming across the cage (A) during 
the day and (B) at night using built-in infra-red light.   
 
2.2.4. EEG analysis 
 
Data sorting and filtering using Spike2 and MATLAB software 
Raw EEG data were saved in SMR format compatible with Spike2 software.  Each 
data file was then exported as a plain text file at an output sample rate of 100Hz 
using Spike2 version 5.  These files were imported into MATLAB (The 
MathWorks, Massachusetts, USA) and sorted into individual channels according 
to the respective receiver pad.  Data for each channel were then individually 
sampled at 100Hz into EEGLAB (Delorme and Makeig, 2004), a MATLAB toolbox 
for processing continuous electrophysiological data, for 1Hz high pass filtering 
before re-imported back into MATLAB for spike counting.  Artefacts were 
detected by manually scrolling through the data for each channel.  Any sections of 
the waveforms with exceedingly high amplitudes that were beyond the range 
limit of the EEGLAB toolbox were removed.  The data sorting and filtering 
processes were eventually automated using programming to increase efficiency.  
Raw EEG data files were sorted into individual channels using Python (See 
Appendix for full script).  The data filtering process was also automated using 
programming in MATLAB (See Appendix for full script). 
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Spike frequency analysis using MATLAB 
The spike counting was performed in a semi-automated manner using MATLAB.  
A spike in extradural EEG represents a combination of extensive simultaneous 
recordings from all surrounding neurons at the dura mater in contact with the 
electrode terminals (Telenczuk et al, 2015).  Each spike was counted using the 
‘findpeaks’ toolbox in MATLAB to count local maxima or peaks by comparing each 
element of data to its neighbouring values.  When an element of data is larger 
than both of its neighbouring elements, that element of data is classified as a local 
peak.  Within the toolbox, a name-value pair argument was added to set a 
threshold, which was determined by the data collected before KA was 
administered (baseline data).  The standard deviation (SD) of the baseline data 
was multiplied and used as the name-value pair argument to determine the 
number of spikes present in the baseline data that were beyond the set threshold.  
The cut off spike frequency for the threshold was set to be 5spikes/minute for 
all channels as this was the average number of spikes in every minute of all the 
baseline data.  This threshold was used to standardise the spike frequency after 
KA was administered for all animals.  For spike counting, a ‘minimum peak height’ 
threshold was specified as a real-valued scalar.  In other words, ‘findpeaks’ would 
only return local maxima that exceeded the ‘minimum peak height’ threshold 
value.  This method was subsequently automated using programming in MATLAB 
(See Appendix for full script). 
 
Coastline analysis using EEG Analyser (Java) 
The EEG Analyser version 1.0 program (See Appendix for the coastline analysis 
script) calculates coastline metrics based on the following equation (White et al., 
2006). 
 
 
x represents the voltage of the filtered EEG data, i indicates the data point of each 
epoch, ABS means all values are made absolute to account for and eliminate any 
negative values the program may generate, since coastline value should always 
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be a positive number.  Coastline values are calculated between each consecutive 
data point in each epoch with a total of 3000 data points, which is equivalent to 
30 seconds of EEG data collected at 100Hz; thus 120 coastlines were generated 
per hour of EEG and these were exported to text file.  A program to automatically 
sort all exported text files onto Microsoft Excel was created using Python to 
increase efficiency due to the large amount of data generated (See Appendix for 
the Python script).  
 
2.3. Bradford protein assay 
 
2.3.1.  Reagents 
Bovine serum albumin (BSA) standards were prepared using a stock solution 
containing 4000µg/ml BSA (Sigma Aldrich, UK).  Bradford reagent was also 
purchased from Sigma Aldrich, UK. 
 
2.3.2.  Protein quantification 
BSA standards were diluted with distilled water to concentrations ranging from 
100 – 1400µg/ml.  A 10µl volume of each sample and BSA standards were added 
in duplicate to individual wells of a 96-well plate.  A 200µl volume of Bradford 
reagent was added to each well and the 96-well plate left to incubate at room 
temperature for 5 minutes.  The maximum absorbance frequency for each sample 
was measured at 595nm using a multimode plate reader (DTX 880; Beckman 
Coulter, USA) and protein content of samples was determined by comparison to a 
standard curve generated using a serial dilution of BSA. 
 
2.4.  Proteomics 
 
2.4.1.  Reagents 
Ammonium bicarbonate (Sigma Aldrich, UK) was formulated to 25mM with 
distilled water.  Rapigest SF (Waters MS Technologies, Manchester, UK) was 
formulated to 1% w/v with 25mM ammonium bicarbonate.  Dithiothreitol 
(Melford Laboratories, UK) was formulated to 9.2mg/ml with 25mM ammonium 
bicarbonate.  Iodoacetamide (Sigma Aldrich, UK) was formulated to 33mg/ml 
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with 25mM ammonium bicarbonate.  Trypsin (Sigma Aldrich, UK) was 
formulated to 0.2µg/µl in 50mM acetic acid (Sigma Aldrich, UK).  Trifluoroacetic 
acid (TFA), high performance liquid chromatography (HPLC) grade acetonitrile 
and formic acid were all purchased from Sigma Aldrich, UK.  Bradford assay 
reagent (Pierce Coomassie Plus) was purchased from Thermo Scientific, UK. 
 
2.4.2.  Tissue homogenisation and digestion  
Hippocampi were dissected out from the extracted brains and homogenised in 
500µl of ice-cold 25mM ammonium bicarbonate for 30s using a TissueRuptor 
(Qiagen, UK).  A 10µl aliquot of the resulting homogenate representing a pre-
acidification digest, was analysed by sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) to compare the presence of proteins with the post-
acidification digest.  For digestion, 15µl of homogenate was diluted to 160µl with 
25mM ammonium bicarbonate in an Eppendorf® LoBind tube (Sigma Aldrich, 
UK) and 10µl of 1% (w/v) Rapigest SF was added.  Digested samples were then 
heated to 80oC for 10 min.  A 10µl volume of 9.2mg/ml dithiothreitol was added 
to each tube and samples held at 60oC for 10 min.  Thereafter, 10µl of 33mg/ml 
iodoacetamide was added and samples were incubated at room temperature in 
the dark for a further 30 min.  A 10ml aliquot of 0.2µg/µl trypsin was then added 
to each tube and the samples incubated at 37oC overnight.  All samples were 
diluted 300-fold with distilled water for protein quantification using Bradford 
protein assay.  The 96-well plate was measured using a spectrophotometer 
(Multiskan™ FC Microplate Photometer; Thermo Scientific, UK) and the protein 
content of each sample was determined as previously described. 
 
After overnight incubation, 2µl of 99% (v/v) TFA was added to each digest for 
acidification and the samples incubated at 37oC for 45 min.  Samples were then 
centrifuged at 17,000 x g for 45 min and the resulting supernatant was 
transferred to an Eppendorf® LoBind 0.5mL tube.  The centrifugation step was 
repeated and 10l of resulting supernatant was transferred to a total recovery 
vial for liquid chromatography-mass spectrometry (LC-MS) analysis.  In addition, 
10µl of the post-acidification resulting supernatant was then analysed by SDS-
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PAGE to confirm complete digestion and absence of protein in comparison to the 
pre-acidification digest.   
 
2.4.3.  Liquid chromatography separation 
All peptide separations were carried out using a nanoAcquity UPLC™ system 
(Waters MS Technologies, Manchester, UK).  For each analysis, 1µl of sample 
digest was loaded onto a trapping column (C18, 180mm x 20mm, Waters), using 
partial loop injections for 3 minutes at 5µl/min with an aqueous solution 
containing 0.1% (v/v) TFA and 2% (v/v) HPLC grade acetonitrile.  The sample 
was resolved on an analytical column (nanoAcquity UPLC™ HSS T3 column, C18 
150mm x 75mm inner diameter, 1.8µm, Waters) using a gradient mobile phase 
which comprised a mixture of aqueous (A) and organic (B) solvents.  Solvent A 
was HPLC grade water with 0.1% (v/v) formic acid (Sigma Aldrich, UK), and 
solvent B was HPLC grade acetonitrile with 0.1% (v/v) formic acid.  Separations 
were performed by applying a linear gradient of 3% to 40% solvent B over 30 
min followed by a washing step (5 min at 99% solvent(B) and an equilibration 
step (15 min at 3.8% solvent(B), and using a flow rate of 300nl/min.  The 
equivalent of 1µg of protein for each sample was injected. 
 
2.4.4. Mass spectrometry 
 
Orbitrap Velos™ mass spectrometry 
The Orbitrap Velos™ instrument (Thermo Fisher, UK) was operated in the data 
dependent mode to automatically switch between full scan mass spectrometry 
(MS) and tandem MS (MS/MS) acquisition. Survey full scan MS spectra (m/z 350-
2000) were acquired in the Orbitrap with 30,000 resolution (m/z 400) after 
accumulation of ions to 1x106 target value based on predictive automatic gain 
control (AGC) values from the previous full scan.  The 20 most intense multiply 
charged ions (z ≥ 2) were sequentially isolated and fragmented in the linear ion 
trap by collisional-induced dissociation (CID) with a fixed injection time of 100 
ms. Dynamic exclusion was set to 20s.  Typical mass spectrometric conditions 
were as follows: spray voltage, 1.5kV, no sheath and auxillary gas flow; heated 
capillary temperature, 200oC; normalised CID collision energy 35%. The MS/MS 
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ion selection threshold was set to 500 counts and 1.2Da isolation width was set.  
A metal-coated picotip (New Objective, Aquilant Scientific, UK) was used in the 
nanospray assembly and was maintained at a voltage of 1500V. 
 
Q Exactive™ mass spectrometry 
The Q Exactive™ instrument (Thermo Fisher, UK) was operated in the data 
dependent mode to automatically switch between full scan MS and MS/MS 
acquisition.  Survey full scan MS spectra (m/z 300-2000) were acquired in the 
Orbitrap with 70,000 resolution (m/z 200) after accumulation of ions to 1x106 
target value based on predictive AGC values from the previous full scan.  Dynamic 
exclusion was set to 20s.  The 10 most intense multiply charged ions (z ≥ 2) were 
sequentially isolated and fragmented in the octopole collision cell by higher 
energy collisional dissociation (HCD) with a fixed injection time of 100 ms and 
35,000 resolution.  Typical mass spectrometric conditions were as follows: spray 
voltage, 1.9kV, no sheath and auxillary gas flow; heated capillary temperature, 
275C; normalised HCD collision energy 30%.  The MS/MS ion selection 
threshold was set to 1 x 104 counts.  A 2Da isolation width was set. 
 
2.5. Western blot 
 
2.5.1. Reagents 
Homogenisation buffer consisted of 25mM ammonium bicarbonate (Sigma 
Aldrich, UK) supplemented with 10% (v/v) protease inhibitor cocktail (Sigma 
Aldrich, UK).  The cocktail contains 4-benzenesulfonyl fluoride hydrochloride at 
2mM, aprotinin at 0.3µM, bestatin at 130mM, E-64 at 14mM, leupeptin at 1mM 
and ethylenediaminetetraacetic acid (EDTA) at 1mM.  Reducing buffer consisted 
of 30:70 (v/v) NuPAGE® Sample Reducing Agent (10X)/NuPAGE® LDS Sample 
Buffer (4X).  Running buffer was prepared by 1:20 dilution of NuPAGE® MOPS 
SDS Running Buffer (20X) in distilled water, with NuPAGE® antioxidant (1:400) 
added, as necessary.  Transfer buffer was prepared by 1:20 dilution of NuPAGE® 
Transfer Buffer (20X) in 80:20 (v/v) distilled water/methanol, supplemented 
with 1:1000 NuPAGE® antioxidant to enhance transfer of proteins to 
membranes.  A 10X stock of Tris buffered saline (TBS 10X) was prepared with 8% 
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sodium chloride (Sigma Aldrich, UK), 0.2% potassium chloride (Fisher Scientific, 
UK), 3.03% Trizma Base (Sigma Aldrich, UK) and pH adjusted to 7.4 using 0.1M 
hydrochloric acid.  TBS with Tween 20 (TBST) comprised 10% of TBS 10X and 
0.1% Tween 20 (Sigma Aldrich, UK) prepared in distilled water.  Stripping buffer 
consisted of 2% SDS (Fisher Scientific, UK), 12.5% Tris HCl (1M, pH 6.8, Sigma 
Aldrich, UK) and 0.7% -mercaptoethanol (Sigma Aldrich, UK) in distilled water.  
Chemiluminescence substrate solution consisted of 50:50 (v/v) mix of Reagent A 
(luminol) and Reagent (enhancer) from the Novex® ECL horse-radish peroxidase 
(HRP) Chemiluminescent Substrate Reagent Kit.  All reagents, unless stated 
otherwise, were purchased from Life Technologies, UK. 
 
2.5.2. Tissue homogenisation  
Brain tissue samples for western blot analysis were thawed on ice and 
homogenised in 500µl of homogenisation buffer using a TissueRuptor, as 
described previously.  Homogenates were then centrifuged at 14,000 x g for 10 
minutes at 4oC and the supernatants isolated.  Bradford protein assay was 
performed on each supernatant to determine the amount of protein present, as 
described in section 2.3.  Thereafter, supernatants were aliquoted into 
microcentrifuge tubes and stored at -20oC. 
 
2.5.3. Western blot protocol 
 
Sample loading, gel electrophoresis, protein transfer to membrane 
Supernatants were thawed on ice and the volume required from each sample to 
achieve the requisite amount of protein for each assay was aliquoted into 
individual microcentrifuge tubes.  A 5l volume of reducing buffer mix was added 
to each sample and heated at 85oC for 5 minutes to denature the proteins.  
Reduced and denatured samples were then cooled on ice for 10 minutes and 
vortex with a whirlmixer.   
 
Reduced and denatured samples were loaded onto the gel (NuPAGE® Novex® 4-
12% Bis-Tris gel, Invitrogen, UK) with a prism protein ladder, which contains 11 
proteins that resolve into bands in the range of 10 to 175kDa (Abcam, UK) for 
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comparative purposes added on the first lane.  After all samples were loaded, 
running buffer (1X) supplemented with antioxidant was first added to the 
running tank from the upper cathode buffer chamber of the gel electrophoresis 
running tank (XCell SureLockTM Mini-Cell, Invitrogen, UK) until completely filled.  
The external anode chamber was then filled with running buffer (1X) without 
antioxidant, until the buffer reached the level of wells of the gel.  The power lead 
was connected to a PowerPac™ 300 (Bio-Rad, UK) set at 90V and the gel run for 
10 minutes until the lanes had run straight.  Thereafter, the voltage was increased 
to 170V and the gel run for an additional 45 minutes.   
 
After gel electrophoresis, the gel was placed in the transfer gel sandwich within 
the gel holder cassette and inserted into the module of the transfer tank (Mini 
Trans-Blot® Cell, Bio-Rad, UK), filled with 1X transfer buffer.  The tank was 
connected to a PowerPac™ set at 80V and run for 1.5 hours.       
 
Blocking procedures and antibody incubations 
Ponceau S dye (Sigma Aldrich, UK) was added to the membrane in a plastic tray 
until the whole membrane was fully stained to check the uniformity and 
effectiveness of the transfer of proteins to the membrane.  The dye was 
subsequently washed off using TBST before blocking the membrane with 5% 
skim milk powder prepared in TBST (Sigma Aldrich, UK) at 4oC overnight under 
gentle shaking to prevent non-specific binding of the primary antibodies to be 
added later.  After blocking, the milk powder solution was discarded and diluted 
primary antibodies prepared in 5% skim milk in TBST were added to the 
membrane and incubated at room temperature for 1 hour under gentle shaking.  
After incubation with primary antibodies, the membrane was rinsed with TBST 
for 20 minutes (with TBST replaced every 5 minutes) to remove any unbound 
primary antibodies.  After rinsing, TBST was discarded and diluted secondary 
antibodies prepared in 5% skim milk in TBST were added and incubated at room 
temperature for 1 hour under gentle shaking.  The secondary antibodies were 
chosen based on the species-specific portion of the primary antibody and were all 
horseradish peroxidase-linked in order to cleave a chemiluminescent agent.  
After the incubation of secondary antibodies, the membrane was rinsed with 
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TBST for 20 minutes, as previously described, to remove any unbound secondary 
antibodies.   
 
Chemiluminescence detection of proteins, film exposure and development 
After rinsing, the membrane was incubated for 1 minute in 1ml of pre-mixed 
chemiluminescence substrate solution.  Excess substrate solution was then 
drained from the membrane using paper towels.  The membrane was then placed 
between 2 sheets of acetate in a development folder, with photographic film 
(Carestream® Kodak® BioMax® light film, Sigma Aldrich, UK) placed on top of 
the acetate sandwich and exposed by closing the development folder for the 
optimum exposure time of each assay.  After exposure, the film was placed in a 
tray with developer (Carestream® Kodak® autoradiography GBX 
developer/replenisher, Sigma Aldrich, UK) diluted to 1:4.5 with water, until blots 
appeared on the film.  The film was then immediately rinsed in a tray filled with 
water before being placed into another tray with fixative (Carestream® Kodak® 
autoradiography GBX fixer/replenisher, Sigma Aldrich, UK), also diluted to 1:4.5 
with water.  The film was left immersed in the fixative tray for 5-10 minutes. 
 
Membrane stripping and reprobing with loading control 
After the exposure of blots for the protein of interest, the membrane was stripped 
to remove any detection antibodies and chemiluminescence substrates.  The 
membrane was then blotted for the loading control, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), which was used as a housekeeping protein against 
which the levels of the proteins of interest were normalised.  Stripping was 
carried out by placing the membrane in a plastic tray with stripping buffer and 
washing for 45 minutes at 60oC under gentle shaking.  After stripping, the buffer 
was discarded and the membrane rinsed using TBST for 20 minutes, as 
previously described.  The membrane was then blocked with 5% skim milk 
powder solution in TBST for 1 hour at room temperature under gentle shaking.  
The milk solution used for blocking was then discarded and anti-GAPDH mouse 
monoclonal antibody (Abcam, UK) diluted to 1:5000 using 5% skim milk in TBST 
was added.  The primary antibody was incubated for 1 hour at room temperature 
under gentle shaking and was then washed for 20 minutes using TBST, as 
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described previously.  After rinsing, goat anti-mouse secondary HRP antibody 
(Abcam, UK) diluted to 1:5000 in 5% skim milk in TBST was added and the 
membrane incubated for 1 hour at room temperature under gentle shaking.  
Thereafter, the membrane was once again rinsed with TBST for 20 minutes, with 
the TBST solution replaced every 5 minutes.  Chemiluminescence detection of 
GAPDH, film exposure and development was as previously described.  The 
optimum film exposure for GAPDH was 5 minutes.  All antibody dilutions were 
kept in 4oC and re-used within 1 week of dilution in order to minimise the effect 
of degradation. 
 
2.5.4. Analysis 
All developed films were scanned using a GS-800TM Calibrated Densitometer (Bio-
Rad, UK) and captured using Quantity One® 1-D Analysis Software (Bio-Rad, UK).  
Images were quantified using the ‘1D electrophoresis gel and western blot 
analysis’ within TotalLab Quant tools applications (TotalLab Ltd, UK), with 
densitometric quantitation of band volumes exported into Microsoft Excel.   
 
2.6. Meso Scale Discovery Proinflammatory Panel 1 mouse V-
PLEX kit 
 
2.6.1. Reagents 
Tris lysis buffer consisted of 150mM sodium chloride (Fisher Scientific, UK), 
20mM Tris (Fisher Scientific, UK) adjusted to pH 7.5, 1mM EDTA, 1mM 
ethyleneglycoltetraacetic acid and 1% Triton-X-100.  One PBS tablet was 
dissolved in 200mL of distilled water to yield 0.01M phosphate buffer.  Wash 
buffer consisted of PBS with 0.05% Tween 20.  All reagents were purchased from 
Sigma Aldrich, UK, unless stated otherwise. 
 
2.6.2. Tissue homogenisation and sample preparation 
Brain tissue samples were thawed on ice and weighed. Tris lysis buffer 
containing 1:50 protease inhibitor was added to each sample at a volume of 10µl 
per mg of tissue.  Samples were then homogenised using a TissueRuptor, 
sonicated to remove bubbles and then centrifuged at 10,000 x g for 20 minutes at 
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4oC.  The resulting supernatants were aliquoted and the protein content in one 
aliquot from each sample were determined using a Bradford assay, as described 
in section 2.3.  All brain supernatants were diluted to 1:50 with distilled water 
prior to protein assay.  Plasma samples for MSD V-PLEX assay were prepared by 
thawing on ice, vortexing and centrifuging at 13,000 x g for 10 minutes at 4oC.   
 
2.6.3. Meso Scale Discovery reagents preparation 
Preparation of standards solution, detection antibody solution and read buffer 
was performed in accordance with the manufacturer’s instructions (Meso Scale 
Discovery (MSD) kit reference K15048D-1).  All reagents from the kit were 
allowed to warm at room temperature prior to preparation.  The “multi-analyte 
lyophilised calibrator” supplied by MSD is the standards stock that contains the 
highest concentration of all the cytokines in the assay.  The calibrator was 
reconstituted in 1000µl of Diluent 41 (MSD, USA), mixed by vortexing and left for 
5 minutes before serial dilution.  A series of standards was prepared by serial 
dilution of the calibrator by adding 100ml of the calibrator to 300ml of Diluent 
41, vortex-mixing, and repeating the process 5 times to generate a total of 7 
standards.  Diluent 41 alone was used as the blank.  The kit provided 10 separate 
detection antibodies, 60µl of each at 50X stock solution.  All detection antibody 
solutions were combined together (600µl) and added to 2400ml of Diluent 45 
(MSD, USA) for a 1:50 dilution.  Reader buffer T 4X stock solution (MSD, USA) was 
diluted to 1:2 with distilled water prior to use.   
 
2.6.4. Protocol 
The assay was performed in accordance with the manufacturer’s instructions 
(MSD kit reference K15048D-1).  The standards, blank and samples solution were 
measured in duplicates, with 50µl of each solution added to an allocated well 
within the customised 96-well plate before sealing the plate with an adhesive 
plate seal and incubating at room temperature with shaking for 2 hours.  After 
incubation, the plate was washed for 3 times by adding 150µl wash buffer per 
well and emptying after each wash.  Thereafter, 25µl of the diluted detection 
antibody was added to each well, the plate resealed with an adhesive plate seal, 
and incubated at room temperature with shaking for a further 2 hours.  After 
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antibody incubation, the plate was washed 3 times, as previously described, and 
then 150µl of 2X read buffer T was added to each well.  The plate was then placed 
on the MSD instrument and read immediately. 
 
2.6.5. Meso Scale Discovery instrument 
The reading of the V-Plex plate was performed using the MSD SECTOR Imager 
2400 according to the manufacturer’s manual (MSD, USA).  The plate possessed a 
MSD barcode label that allowed the SECTOR Imager to detect the type of plate 
being run.  The data generated were automatically analysed with a template 
using the Discovery Workbench version 4.0 software. 
 
2.7. Immunohistochemistry 
 
2.7.1. Reagents  
PBS used for immunohistochemistry (IHC) consisted of stock A/stock B/distilled 
water (140:360:500 v/v), adjusted to pH 7.2 with 0.9% sodium chloride (Fisher 
Scientific, UK).  Stock A consisted of 2.76% (w/v) of sodium dihydrogen 
orthophosphate monohydrate (VWR International Ltd, UK) in distilled water.  
Stock B consisted of 7.164% (w/v) of di-sodium hydrogen orthophosphate 
dodecahydrate (Fisher Scientific, UK) in distilled water.  Paraformaldehyde (PFA; 
Sigma Aldrich, UK) was dissolved in PBS to a concentration of 4% at 60oC while 
stirring, and adjusted to pH 7 with 1M sodium hydroxide.  Gelatin solution 
comprised 15% sucrose (Fisher Scientific, UK), 0.1% sodium azide (Fisher 
Scientific, UK) and 7.5% gelatin from porcine skin (Sigma Aldrich, UK) prepared 
in PBS, heated at 45-50oC with stirring.  Chrom Alum Gelatin (CAG) solution was 
prepared by dissolving gelatin from porcine skin to a concentration of 3% in 
distilled water at 60oC, adding chromium potassium sulphate (0.5%, Sigma 
Aldrich, UK) to a final concentration of 0.5% and stirring until dissolved, and then 
adding a few crystals of thymol (Sigma Aldrich, UK) as a preservative.  Donkey 
serum (Santa Cruz Biotechnology, UK) was diluted to a concentration of 0.5% in 
PBS to make the blocking solution.  Antibody diluting fluid was prepared with 
0.25% donkey serum, 0.25% sodium azide (Fisher Scientific, UK), and 0.2% 
Triton-X-100 (Sigma Aldrich, UK) prepared in PBS. 
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2.7.2. Brain perfusion, gelatin embedding and cryostat sectioning 
 
Brain perfusion 
Animals were anaesthetised with 5 mg/kg sodium pentobarbitone (i.p.), with 
anaesthesia confirmed by loss of the pinching reflex.  Animals were 
exsanguinated by cardiac perfusion with PBS, followed by perfusion-fixation with 
4% PFA.  Brains were then removed and further fixed by immersion in 4% PFA 
solution for 4 hours, before then immersing in 20% sucrose.   
 
Gelatin embedding 
After sucrose had diffused throughout the tissue, brains were immersed in warm 
gelatin solution and placed in an incubator at 40oC for 3 hours.  The gelatin 
solution containing the intact brain was then allowed to cool at room 
temperature before being chilled at 4oC overnight.  The resulting solidified gelatin 
with embedded brains was trimmed into a block and attached to a ‘Disc cork for 
Cryostat’ (20mm diameter x 3mm depth, Fisher Scientific, UK) using Tissue-Tek® 
O.C.T.™ Compound (Sakura, The Netherlands) before being snap-frozen with 
isopentane cooled in liquid nitrogen. 
 
Cryostat sectioning 
Superfrost™ microscope slides (Fisher Scientific, UK) were dipped in warm CAG 
solution (40-50oC), drained onto paper towels and left to air dry overnight before 
being used for mounting sections.  Serial cryostat sections of whole brains were 
cut coronally from rostral to caudal at -20oC and at 12µm thickness per section 
throughout the septal and temporal extension of the hippocampus using a Leica 
CM1950 cryostat (Leica Biosystems, UK).  Each frozen section was mounted on a 
warm CAG-coated Superfrost™ slide kept in room temperature, which allowed 
the section to instantaneously melt and adhere to the slide.  The first 10 sections 
were mounted on 10 separate slides, as the first specimen on each slide.  The 
subsequent 10 sections were then mounted sequentially as the second specimen 
on each of the 10 slides.  This method of mounting continued until there were at 
least 4 sections on each slide to ensure that each slide had an equivalent cross-
   
44 
 
section of the brain.  After mounting, the slides and remaining uncut tissue were 
stored in -20oC.  
 
2.7.3. Protocol 
Frozen sections mounted on slides were thawed for 20 minutes at room 
temperature.  Slides were aligned with Shandon® Sequenza coverplates (Thermo 
Scientific, UK) and attached to the Shandon® Sequenza slide rack (Thermo 
Scientific, UK).  Brain sections on the slides were then washed with PBS to 
remove any fixatives or excess PFA from the earlier perfusion by filling the cover-
plates with PBS and allowing them to drain.  This was repeated five times.  A 
70ml volume of blocking solution was then added and the slide rack was 
incubated at 4oC for 1.5 hours.  Thereafter, 70ml of diluted primary antibody of 
interest (prepared in antibody diluting fluid) was added to the slides and left 
overnight at 4oC.  Slides were then washed with PBS continuously for 1 hour to 
remove any unbound primary antibodies before adding 70ml of diluted 
secondary antibody conjugated with a fluorophore, again prepared in antibody 
diluting fluid.  The secondary antibody was selected according to the species of 
the host animal in which the primary antibody was raised.  The slides were then 
incubated at 4oC for 1.5 hour before being washed with PBS continuously for 1 
hour to remove any unbound secondary antibodies.  After washing, slides were 
mounted using one drop of Vectashield® Mounting Medium containing 4’,6-
diamidino-2-phenylindole (DAPI; Vector Laboratories, UK) per microscope slide 
and a coverslip was placed over the stained sections.  Slides were stored in 4oC 
until examined under a microscope. 
 
2.7.4. Fluorescence microscope 
A Zeiss Axioimager microscope was connected to an X-Cite 120 Fluorescence 
Illumination System for fluorescence imaging and a camera connected to a 
computer pre-installed with Axiovision 4.8.2 Release software was used to 
capture the images.  Microscope slides were placed onto the mechanical stage 
and secured with the slide holder.  The objective lens was selected to 20× 
magnification with a theoretical resolution limit of 0.50mm.  The appropriate 
filter position was chosen to visualise the fluorophore of interest using the 
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eyepiece.  Two fluorophores, fluorescein isothiocyanate (FITC; Jackson 
ImmunoResearch Laboratories, USA) and cyanine 3 (CY3; Jackson 
ImmunoResearch Laboratories, USA), conjugated with the secondary antibodies 
raised against different animal species were used for double-staining.  FITC is a 
green fluorescent dye with excitation and emission spectrum peak wavelengths 
of approximately 492nm and 520nm, respectively (Imhof et al., 1999).  CY3 is a 
red fluorescent dye with excitation and emission spectrum wavelengths of 
approximately 550nm and 570nm, respectively (Mujumdar et al., 1993).  DAPI, 
present in the mounting medium, is a blue fluorescent stain that binds to DNA, 
with excitation and emission spectrum peak wavelengths of 360nm and 460nm, 
respectively.  When capturing an image on the microscope, the light path was 
switched from the eyepiece to the camera in order for the image to be captured 
and exported to TIFF images using the Axiovision software. 
 
2.7.5. Analysis 
All TIFF images were imported to Image Processing and Analysis in Java (ImageJ) 
version 1.48 and the images were analysed according to the area and the 
percentage of the stained cells.  The “quantify gray value” function was used to 
quantify the area of the gray levels at the pixel intensity adjusted to a set value to 
standardise the intensity level for the images.  A different threshold intensity was 
set for each protein of interest.  The number of cells stained with the protein of 
interest was manually counted using the cell counter plugin on ImageJ and 
quantified in relation to the number of DAPI-positive cells.  
 
2.7.6. Determination of optimum antibodies dilutions for 
immunohistochemistry 
The primary antibody for albumin was detectable at the dilution range of 1:200 
to 1:1000, with the secondary antibody dilution of 1:150 to 1:500 (Figure 2.2).  
The primary antibody dilution at 1:200 and secondary antibody dilution at 1:500 
were chosen as they gave the least background staining.  The detection of 
transforming growth factor β1 (TGFβ1) increased with rising dilutions of the 
primary antibody from 1:20 to 1:5.  The primary antibody dilution at 1:10 and 
secondary antibody dilution at 1:150 were chosen as they gave minimal 
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background staining with clear visualisation of TGFβ1 (Figure 2.2).  Similarly, for 
transforming growth factor β receptor I (TGFβRI), the primary antibody dilution 
at 1:10 and secondary antibody dilution at 1:150 were chosen as they gave 
minimal background staining with clearer visualisation of TGFβRI (Figure 2.2).  
For Kir4.1, the highest primary antibody dilution tested at 1:150 and the highest 
secondary antibody dilution tested at 1:150 were chosen as they gave the 
brightest visualisation of the Kir4.1 stained cells (Figure 2.2). 
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Figure 2.2.  Paraformaldehyde-fixed gelatin-embedded mouse brain tissue were 
cut coronally and stained with albumin, transforming growth factor β1 (TGFβ1), 
transforming growth factor β receptor 1 (TGFβRI) and inwardly-rectifying 
potassium channel (Kir4.1).  Albumin was stained using mouse-raised primary 
antibody and anti-mouse secondary antibody conjugated with cyanine 
fluorophore.  (A) Primary 1:1000, secondary 1:500. (B) Primary 1:500, secondary 
1:250. (C) Primary 1:200, secondary 1:150.  TGFβ1 was stained using rabbit-
raised primary antibody and anti-rabbit secondary antibody conjugated with 
cyanine fluorophore.  (D) Primary 1:20, secondary 1:300. (E) Primary 1:10, 
secondary 1:150. (F) Primary 1:5, secondary 1:150.  TGFβRI was stained using 
rabbit-raised primary antibody and anti-rabbit secondary antibody cyanine 
fluorophore.  (G) Primary 1:20, secondary 1:300. (H) Primary 1:10, secondary 
1:150. (I) Primary 1:5, secondary 1:150.  Kir4.1 was stained using guinea pig-
raised primary antibody and anti-guinea pig secondary antibody conjugated with 
cyanine fluorophore.  (J) Primary 1:300, secondary 1:300. (K) Primary 1:150, 
secondary 1:300. (L) Primary 1:150, secondary 1:150. 
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Chapter 3 
Acute behavioural seizures in a 
kainic acid model of 
epileptogenesis 
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3.1. Introduction 
 
3.1.1. Kainic acid 
KA has been used extensively as a chemoconvulsant in rodent models of 
epileptogenesis (Sperk et al., 1983; Sperk, 1994) to study the mechanisms of 
neurodegeneration (Wang et al., 2005) and specifically TLE (Nadler, 1981).  It is a 
selective KA receptor agonist and a cyclic analogue of L-glutamate, which mimics 
the excitatory effects of glutamate (Nadler, 1981; Sharma et al., 2007) and causes 
sustained neuronal depolarisation that leads to acute seizure generation in 
animals following systemic or central administration (Sharma et al., 2007).  
Excessive glutamatergic activity induces neuronal pathology and can lead to 
hyperexcitability and epilepsy.  Neuronal damage with KA is exacerbated due to 
excessive glutamate release associated with epileptic seizures (Aroniadou-
Anderjaska et al., 2008).  KA is 30- to 50-fold more potent than glutamate 
(London and Coyle, 2005; Wang et al., 2005) and can cause a cascade of cellular 
events leading to neuronal cell death (Wang et al., 2005) (Figure 3.1). 
 
The KA model is based upon SE as the precipitating neurological insult, 
associated with prolonged and repetitive seizure activity within the limbic 
system (Hellier et al., 1998).  When administered to experimental animals, KA has 
been shown to elicit a pattern of post-SE neuronal cell loss and astrogliosis 
similar to the neuropathology observed in human TLE (Nadler, 1981; Vincent and 
Mulle, 2009).  Most animal models are focused on reproducing hippocampal 
sclerosis to study the pathogenesis of TLE in patients.  Hippocampal lesions that 
develop in animals following acute seizures induced by KA are similar to the 
hippocampal sclerosis observed in patients with TLE (Sharma et al., 2007).  
Hippocampal sclerosis involves extensive loss of neurons in Cornu Ammonis 1 
(CA1) and Cornu Ammonis 3 (CA3) regions, together with pyramidal cells and 
interneurons in the hilus of the DG (Berkovic et al., 1991; Buckmaster, 2004; 
Vincent and Mulle, 2009). 
  
   
50 
 
 
Figure 3.1. Schematic diagram showing the pathway of kainic acid (KA)-induced 
neuronal cell death.  KA stimulates AMPA and KA receptors (Ca-A/K receptors) 
that are permeable to calcium (Ca2+), leading to rapid Ca2+ entry.  This activates 
Ca2+-dependent enzymes that generate reactive oxygen species (ROS).  Excessive 
Ca2+ and ROS lead to the breakdown of the mitochondrial membrane potential 
and open the mitochondrial permeability transition pores to release cytochrome-
c.  This release forms the apoptosome complex and activates the caspase-3 
pathway, leading to apoptosis and neuronal cell death.  Ca2+ overload could also 
cause mitochondrial damage and decrease in adenosine triphosphate (ATP).  This 
causes the increase in ROS which leads to oxidative stress, necrosis and neuronal 
cell death.  Image adapted from (Wang et al., 2005).  
 
 
The hippocampus, particularly CA3 pyramidal cells, is susceptible to the 
epileptogenic effect of KA (Vincent and Mulle, 2009).  KA has also been shown to 
cause necrosis, demyelination, astrogliosis, perivenous haemorrhages and 
vascular sprouting in the pyriform cortex, amygdala, olfactory bulb and olfactory 
tubercle (Sperk et al, 1983).  KA induces epileptiform seizures that originate in 
the CA3 region of the hippocampus and extend to other limbic structures and 
cause excitotoxic cell death in CA3 and CA1 hippocampal subfields and within the 
   
51 
 
hilus of the DG (Nadler et al., 1978; Ben-Ari et al., 1980; Schwob et al., 1980; 
Nadler, 1981; Vincent and Mulle, 2009).  CA3 acts as the pacemaker for the 
generation of synchronised activities that propagate to CA1 and other limbic 
regions (Ben-Ari and Cossart, 2000).   
 
KA receptors are highly expressed in the hippocampus and are assembled from 
combinations of 5 receptor subunits, GluK1-5, also referred to as GluR5, GluR6, 
GluR7, KA1 and KA2 (Carta et al., 2014).  The GluK1 subunit is expressed in 
GABA-ergic interneurons throughout the hippocampus (Carta et al., 2014).  The 
GluK2 subunit is highly expressed in the principal cell layers of CA1-CA3 
pyramidal cells, the DG and in interneurons (Carta et al., 2014).  The GluK3 
subunit is predominantly expressed in the DG (Carta et al., 2014).  The GluK4 
subunit is highly expressed in CA3 pyramidal cells but only weakly expressed in 
CA1 and the DG (Rattka et al., 2013; Carta et al., 2014), and the GluK5 subunit is 
the most abundantly expressed subunit, present in all subregions and highly 
expressed in both CA1 and CA3 pyramidal cells (Rattka et al., 2013; Carta et al., 
2014).  The high expressions of GluK2, GluK4- and GluK5-containing receptors 
render the CA3 region highly susceptible to the excitotoxic effects of KA and make 
the hippocampus the principal target for seizure onset of KA agonists (Rattka et 
al., 2013; Carta et al., 2014).   
 
In addition to the loss of pyramidal cells and interneurons, mossy fibre sprouting 
occurs in both humans with TLE and in animal models of TLE.  Mossy fibres 
originating from dentate granule cells form an aberrant glutamatergic network 
within the DG, with increased KA receptor subunit expression leading to the 
formation of a functional recurrent excitatory circuit.  This facilitates the 
generation of epileptiform activity in the hippocampus by reducing the threshold 
for granule cell synchronisation (Sharma et al., 2007; Vincent and Mulle, 2009; 
Carta et al., 2014).  The clinical manifestation of TLE in patients is usually an 
acute neurological insult followed by a latent period of a few months to several 
years before the development of SRS (French et al., 1993; Sharma et al., 2007).  
Administration of KA closely mimics this clinical scenario, albeit over a much 
shorter timescale by causing repetitive seizures or SE in rodents that represents 
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the initial insult, followed by a latent period of several weeks preceding the 
development of epilepsy (Sperk, 1994; Hellier et al., 1998; Brandt et al., 2003; 
McCord et al., 2008).  SE is a relatively rare cause of epilepsy in patients and may 
not be a condition that best represents human epileptogenesis.  However, these 
models have contributed to the understanding of the molecular and cellular 
changes in TLE that can be used to test hypotheses for developing therapeutic 
prevention of epilepsy (Pitkänen and Lukasiuk, 2009). 
 
3.1.2. Route of kainic acid administration 
Various routes of KA administration have been reported to induce acute seizures 
in rodents, including intracerebral (Schwob et al., 1980) (both hippocampal 
(Cavalheiro et al., 1982; Rattka et al., 2013) or amygdaloid (Ben-Ari et al., 1980)), 
intranasal (Chen et al., 2002; 2004) and systemic (Schwob et al., 1980; Hellier et 
al., 1998).  The morphological, behavioural and epileptogenic features of KA 
administered intracerebrally or systemically are similar, except for the extent of 
neuropathological damage (Ben-Ari et al., 1980; Pitkänen and Lukasiuk, 2009; 
Lévesque and Avoli, 2013).  The pattern of neuropathological lesions induced by 
systemic administration of KA is similar to that seen after intrahippocampal 
administration, but with more symmetrical bilateral damage and with damage 
extending to extrahippocampal regions (Ben-Ari et al., 1980; Schwob et al., 1980; 
Sperk et al., 1983).  The extent of damage to these regions depends on the 
severity of seizure activity (Sperk et al., 1983).  Systemic administration of KA 
produces neuronal damage in limbic structures with hippocampal pyramidal 
neurons being the most vulnerable (Vincent and Mulle, 2009).  The extent of 
neuronal damage in the brain of an animal treated systemically with KA is more 
widespread and more severe than that observed in humans with TLE (Rattka et 
al., 2013), but the semiology of the acute seizures and the chronic nature of the 
resulting epilepsy appears to be similar (Hellier et al., 1998).  Intracerebral 
administration of KA has also been shown to be a useful model of epileptogenesis 
that produces less extensive damage in the brain and which might be a better 
representation of human TLE (Rattka et al., 2013).  However, substantial 
variability in the pattern of neuronal degeneration has been reported (Schwob et 
al., 1980).  Although the systemic KA model produces more severe acute seizure 
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activity and greater pathological damage in the limbic system than is seen in 
humans, it is a more convenient way to administer KA than the intracerebral 
route, allowing multiple animals to be injected at the same time and without the 
need for surgical intervention (Sperk, 1994; Lévesque and Avoli, 2013).  Due to 
the possibility of post-surgical complications and the technical difficulty involved 
in intracerebral administration of KA to a large number of animals, the systemic 
route was preferred for this project. 
 
3.1.3. C57BL/6J mice 
The C57BL/6 mouse is the most commonly used inbred strain across scientific 
disciplines and the substrain, C57BL/6J, has been used widely in several seizure 
models (Ferraro et al., 1995; Schauwecker and Steward, 1997; Benkovic et al., 
2004; Wang et al., 2005; Mekada et al., 2009).  C57BL/6J is known as a seizure-
resistant strain compared to other inbred mouse strains because C57BL/6J mice 
are more resistant to seizure-induced neuronal excitotoxicity than some inbred 
strains, such as FVB/N, despite experiencing a similar seizure severity (Seyfried 
et al., 1980; Green and Seyfried, 1991; McKhann et al., 2003; McLin and Steward, 
2006; Vincent and Mulle, 2009).  However, it has been shown that the limited 
seizure activity induced by KA in C57BL/6J mice can cause significant excitotoxic 
neuronal damage, suggesting that the damage occurs as a result of the direct 
neurotoxic effect of KA, and not as a result of the severity of the acute seizures 
that are elicited (Benkovic et al., 2004).  It has also been suggested that C57BL/6J 
mice show similar neurodegeneration following KA-induced seizures as other 
strains, but that they recover more rapidly and to a greater degree than other 
mouse strains (Benkovic et al., 2004).  Genetic factors may be relevant in 
determining the extent of hippocampal damage following acute seizures in 
resistant strains like C57BL/6J (Vincent and Mulle, 2009).  On occasion, strains 
that are more sensitive to KA-induced seizures show no pyramidal cell loss or 
mossy fibre reorganisation, whilst more resistant strains can exhibit extensive 
pyramidal cell loss and mossy fibre sprouting (Vincent and Mulle, 2009).  
Differences in excitotoxic cell death following KA administration may result from 
genetically determined differences in intracellular cascades, together with 
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differential levels of glutamate receptor expression between strains of mice, 
underlying the variation in their seizure susceptibility (Vincent and Mulle, 2009).   
 
3.1.4. Repeated low doses of kainic acid 
Systemic administration of KA has been given as a single bolus injection or in 
multiple injections to induce acute seizures in rodents.  Single injection of KA in 
rats is associated with a higher mortality rate of up to 30% compared to 15% 
seen with multiple doses (Hellier et al., 1998; Sharma et al., 2007; Lévesque and 
Avoli, 2013).  Single dose KA also results in a smaller proportion of animals 
subsequently developing epilepsy.  Most epilepsy models involving systemic 
administration of KA use a 60 to 120 minute period of SE as the initial insult and 
employ compounds such as diazepam to terminate the SE and thereby 
standardise the duration of SE amongst animals.  Diazepam may also help reduce 
the mortality associated with chemically induced SE (Löscher and Brandt, 2010).  
Unlike the single bolus dose approach, the repeated low-dose method of KA 
administration is tailored to the behaviour of the animal, decreasing the 
probability of an overdose while ensuring animals have a sufficiently long 
duration of acute seizures to maximise the likelihood of them later developing 
epilepsy (Hellier et al., 1998).  This method of administration allows a slower 
diffusion of KA into the brain and extends overall exposure to KA (Hellier et al., 
1998).   
 
Another disadvantage of the single bolus dose of KA is that not all animals 
develop acute seizures upon administration of KA, possibly due to the variable 
absorption of KA or its penetration into the brain (Pitkänen et al., 2005; Lévesque 
and Avoli, 2013).  Multiple dose models are more reliable at maximising seizure 
activity by titrating the KA dose based on observed acute seizure severity in 
individual animals and by ensuring that all animals have a similar severity of 
seizures.  This results in a higher survival rate, which is important from both 
experimental and animal husbandry perspectives, and the resulting 
histopathological changes more closely resemble those seen in human mesial 
temporal sclerosis (Hellier et al., 1998; McKhann et al., 2003).  However, the 
multiple dosing approach introduces a different variability, with animals 
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potentially exposed to quite different total doses of KA (Lévesque and Avoli, 
2013) and this requires careful consideration in experimental design and data 
interpretation. 
 
The multiple dosing regimen of KA not only improves the survival rate of animals 
but can also determine the severity of the resulting epilepsy.  Post-SE models of 
TLE are considered to be good models for studying epileptogenesis, as they 
produce short latent periods and high incidences of SRS after the initial 
neurological insults (Löscher and Brandt, 2010).  This can shorten the study 
duration whilst achieving higher success rate of animals developing epilepsy.   
 
In summary, systemic KA administration using a repeated low-dose regimen 
maximises survival, enhances the proportion of animals experiencing acute 
seizures, standardises seizure severity during the SE period, and ultimately the 
resulting epilepsy mimics human TLE and shares important neuropathological 
features.  As such, this model was chosen for the investigations of epileptogenesis 
reported in this thesis.  The C57BL/6J mouse was specifically chosen as a result of 
the large volume of published data available regarding behavioural and 
neuropathological changes in response to KA and the molecular mechanisms 
involved in epileptogenesis in this strain. 
 
3.1.5. Overview 
An animal model of disease should be designed carefully to mimic the human 
condition as closely as possible in order to address specific questions regarding 
the disease state.  No animal model of epileptogenesis can completely match the 
complex aetiology of human epilepsy, but it can contribute to the understanding 
of the mechanisms of epileptogenesis (Herman, 2002; Löscher, 2011).  There are 
differences between humans and experimental animal models in terms of the 
manifestation of epilepsy, duration and mechanisms of epileptogenesis, and the 
relative contribution of individual neurobiological pathways to the development 
of epilepsy (Aroniadou-Anderjaska et al., 2008).  These differences may also be 
dependent on the brain region and type of neurological insult involved.  It is vital 
to understand the molecular and cellular alterations that arise from a 
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neurological insult and that specifically lead to the development of epilepsy in 
some cases and brain repair in others (Löscher and Brandt, 2010).  The use of 
experimental models to replicate the behavioural, electroencephalographic and 
histopathological features of human epilepsy is necessary to understand the 
anatomical region of the seizure onset and molecular mechanisms underlying 
epileptogenesis (Lévesque and Avoli, 2013).   
 
3.2. Materials and methods 
 
3.2.1. Animals 
All experimental procedures were performed in accordance with the Animal 
(Scientific Procedures) Act, 1986 (UK).  All methodological details regarding the 
source of animals, their housing conditions and KA-induced seizures are provided 
in section 2.1.  The C57BL/6J strain was introduced to Charles River in 2004 and 
breeding was conducted in accordance with The Jackson Laboratory genetic 
management system (Charles River Laboratories, UK).   
 
3.2.2. Behavioural assessment for acute seizures 
The preparation of KA and the induction of seizures are described in sections 
2.1.1 and 2.1.2.  For this project, a 2-hour period of acute seizures was used for all 
mice.  After the onset of the first Stage 5 generalised seizures (see 
below/described in section 2.2.3), the dosing of KA was discontinued and 
animals’ behaviour was assessed continuously for 2 hours.  The most severe 
seizure severity during every 5-minute epoch was recorded based on the 
modified Racine scale, with the following criteria: stage 1 (non-convulsive) – 
mouth and facial twitching; stage 2 (non-convulsive) – head nodding with 
myoclonic twitching and tremor; stage 3 (convulsive) – forelimb clonus with a 
lordotic posture; stage 4 (convulsive) – rearing with concomitant forelimb 
clonus; stage 5 (convulsive) - generalised clonic convulsion with exaggerated 
activity.     
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3.2.3. Seizure severity quantification 
Seizure severity was quantified using the modified Racine scores recorded during 
each 5-minute epoch and summing the total score for the 2-hour acute seizure 
period between onset of the first generalised seizure and diazepam 
administration.  The lowest score of 0 would indicate no abnormal behaviour 
observed during the SE period.  The highest score of 120 would indicate at least 
one Stage 5 seizure every 5 minutes for the whole 2-hour SE period.  Thus, 
seizure severity for each individual animal is indicated by the total cumulative 
modified Racine score over the 2-hour SE period.  Since only the highest scoring 
seizure in each epoch was recorded, the maximum score in any given 5-minute 
period was 5 irrespective of how many acute seizures occurred in that period or 
their individual severity.  This quantification was used to investigate the variation 
of behavioural seizures with respect to the difference in total KA doses 
administered to individual animals.   
 
3.3. Results 
 
During this project, KA was administered (i.p.) to a total of 187 C57BL/6J mice 
using the repeated low dose regimen described in section 2.2.3.  These mice were 
delivered in 19 separate batches from Charles River (UK), according to 
experimental need.  All mice experienced Stage 5 generalised convulsive seizures 
after receiving KA.   
 
3.3.1. Mortality 
A total of 11 mice died following KA administration, with a variable mortality rate 
between batches of animals.  The overall mean mortality rate of animals after 
receiving KA was 5.9%.  The highest mortality rate of 22.2% was seen in batch 7 
with 2 mice from a total of 9 that died after receiving KA (Figure 3.2).  In all cases, 
mortality occurred after the onset of Stage 5 generalised seizures and prior to the 
administration of diazepam, and was associated with convulsive seizures. 
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3.3.2. KA sensitivity variation 
When administered i.p. at 5mg/kg every 30 minutes, the cumulative KA dose 
required to reach the first Stage 5 generalised seizure in C57BL/6J mice ranged 
from 15 to 55mg/kg (Figure 3.3).  More than 90% of animals required ≤35mg/kg 
of total KA dose (Figure 3.4).  The KA sensitivity also varied between batches of 
animals, even when ordered at the same age and weight range from the same 
supplier (Figure 3.5).   
 
Figure 3.2.  The mortality rate, expressed as a percentage of all kainic acid-treated 
animals, presented by batch number. 
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Figure 3.3.  Total kainic acid (KA) dose (mg/kg) required to induce generalised 
convulsive seizures in all C57BL/6J mice (n=187) following repeated 
intraperitoneal administration of KA at 5mg/kg every 30 minutes.  Data are 
expressed as the percentage of animals that reached Stage 5 seizures, with dose 
reported as a categorical variable. 
 
 
Figure 3.4.  Dose-response relationship between total kainic acid (KA) dose 
(mg/kg) and proportion of all C57BL/6J mice (n=187) experiencing Stage 5 
generalised convulsive seizures following repeated intraperitoneal 
administration of KA at 5mg/kg every 30 minutes.  Data are expressed as the 
proportion of animals that reached Stage 5 seizures, with dose reported as a 
continuous variable. 
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Figure 3.5.  Comparative kainic acid (KA) sensitivity in different batches of 
C57BL/6J mice purchased from Charles River, UK.  Data are expressed as mean 
total KA dose (± SEM) required to induce generalised convulsive seizures 
following repeated intraperitoneal injection of KA at 5mg/kg every 30 minutes.  
Batch size ranged n=4 to n=17. 
 
3.3.3. Seizure severity variation 
During the 2-hour seizure assessment period, all animals had at least one 
occurrence of a generalised seizure hence the lowest possible seizure severity 
score is 5.  A cumulative behaviour score (calculated from 24 separate 5-minute 
epochs over the 2-hour assessment period) of less than 50 was indicative of mice 
that either had occasional episodes of convulsive seizures (scores 3-5) with 
behaviour returning to normal in-between (score 0) or that remained in non-
convulsive states (scores 1-2) for the majority of the period.  A behavioural score 
of between 50 and 100 was typically indicative of animals experiencing multiple 
episodes of generalised seizures and spending the majority of the time in 
convulsive seizure states.  A behavioural score of above 100 was recorded in 
animals with the most severe seizures; these animals generally had one or more 
Stage 4 or 5 seizures every 5 minutes throughout the assessment period (Figure 
3.6).  Comparison of seizure severity score and total dose of KA showed no strong 
correlation (R2 = 0.0128; Figure 3.6).  Higher doses of KA were not associated 
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with increased seizure severity, and seizure severities at a given dose varied 
widely (Figure 3.6). 
 
3.4. Discussion 
 
KA is a chemoconvulsant that consistently induces generalised convulsive 
seizures in mice when administered systemically.  However, there was 
considerable inter-animal variation in the sensitivity to KA and in the severity of 
acute seizures caused by KA in the C57BL/6J mice used in this study.  Rates of 
mortality also differed between different batches of animals.  This variation 
appears to be consistent with published literature on the variability of response 
to KA (Schwob et al., 1980; Hellier et al., 1998; McKhann et al., 2003).  The overall 
mortality rate of C57BL/6J mice in this study is lower than the 15% mortality 
rate reported in rats following repeated doses of KA (Hellier et al., 1998).  Mice 
require a range of doses of KA to induce generalised seizures (Figure 3.3).  Those 
that had onset of generalised seizures at the same dose of KA also had different 
seizure severities over the 2-hour period thereafter (Figure 3.6).   
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Figure 3.6. Correlation between seizure severity score and total dose of kainic 
acid (KA) required to induce generalised convulsive seizures following 
intraperitoneal administration of KA at 5mg/kg every 30 minutes.  Each 
datapoint represents a single animal (n=187).  Pearson’s product-moment 
correlation is illustrated by the solid line, with the corresponding correlation co-
efficient reported. 
 
There was no correlation between the total dose of KA and the cumulative 
seizure severity during the 2-hour assessment period after the onset of the first 
generalised seizure (Figure 3.6). The cause of this variability in seizure severity is 
unknown.  It could simply be due to variability of KA concentration in the brain 
but this has not been investigated.  There is some evidence that low 
concentrations of KA can generate acute seizures whilst higher concentrations 
can lead to overall conduction block (Ben-Ari and Cossart, 2000).  This may partly 
explain the lack of association between the dose of KA and seizure severity.  
Systemic KA administration has been shown to induce dose-dependent 
behavioural effects in other rodents (Giorgi et al., 2005) but this was not 
observed in this model using C57BL/6J mice and a repeated low-dose treatment 
regimen.  The variation in the seizure response to KA was not only observed 
between individual animals given the same doses but also the mean dose 
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required to induce generalised seizures was significantly different between 
batches of animals from the same breeding facility.  All mice were outsourced 
from the same supplier rather than bred in-house, and always ordered at a 
specific body weight range.  Given the extensive use of C57BL/6J mice in 
biomedical research and the high demand on their supply, it is unlikely that 
batches of animals were always derived from exactly the same breeding stock.  
On that basis, subtle genetic variations between breeding lines may explain at 
least some of the intra-strain differences observed (Watkins-Chow et al., 2008). 
 
Although the repeated low dose KA regimen was used in an attempt to ensure 
that all mice consistently achieved generalised seizures, this introduced 
variability in terms of the total KA dose to which each animal was exposed.  It has 
been reported that different doses of KA can trigger different degrees of brain 
damage and different forms of neuronal death (Vincent and Mulle, 2009).  A 
moderate KA dose of 12 mg/kg when given i.p. to rats induced necrosis whereas a 
low KA dose of 9 mg/kg induced programmed cell death without apoptotic 
morphology (Tokuhara et al., 2007).  However, without measuring serum and/or 
brain concentrations of KA it is impossible to know the extent to which variability 
in absorption and distribution may have contributed to within-dose or inter-
animal variability in response.  The duration and/or the severity of seizures in 
response to KA is also not predictive of the subsequent hippocampal cell death or 
synaptic reorganisation (Vincent and Mulle, 2009).  Differences in the duration 
and/or the severity of seizures can cause variation in the degree of neuronal 
damage. 
 
Limiting the duration of SE with diazepam standardises the insult and is a 
common approach in such models.  There is no evidence that it has any effect on 
the subsequent epileptogenesis (Halonen et al., 2001; Aroniadou-Anderjaska et 
al., 2008).  It has been shown that diazepam given after 2 hours of generalised 
seizure does not reduce brain damage despite blocking seizure discharges 
induced by KA in the hippocampus induced by KA (Ben-Ari et al., 1980).  Most 
investigators allow 90 to 120 minutes of acute seizure activity prior to 
pharmacological termination with drugs such as diazepam as this allows 
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sufficient duration of the initial insult to induce the later development of epilepsy, 
standardises the duration of insult, and limits mortality (Löscher, 2002). 
 
The reason for using this model was to ensure that all animals experienced a 
generalised seizure and to minimise the mortality associated with KA 
administration.  SE is characterised by prolonged seizure activity and some 
published papers have established criteria to assess when animals are in SE and 
when they are simply experiencing repeated single acute seizures (Hellier et al., 
1998; Hellier and Dudek, 1999; Buckmaster, 2004; Hellier and Dudek, 2005).  
Different laboratories use different criteria to define SE, but generally it is 
reported to be consistent with convulsive motor seizures at a Racine score of ≥3 
for more than 2 hours (Hellier et al., 1998; Buckmaster, 2004; Hellier and Dudek, 
2005).  As such, not all mice used in this study can be considered to have achieved 
SE.  There were many variations in the response to KA in this model, but there is 
strength in the fact that all animals were allowed 2 hours of seizure activity after 
the onset of the first generalised convulsive seizure prior to termination with 
diazepam.  This standardised the initial seizure duration and eliminated the 
major confounding effects of differing seizure durations on the long-term 
outcome (Löscher and Brandt, 2010).  Variations between animals in terms of 
seizure induction, duration and severity are difficult to avoid despite refinement 
of protocols.  Reduced variability between batches of animals might be achievable 
using animals bred in-house to minimise genetic variation.  However, producing a 
homogeneous, reproducible model that behaves in the same way every time is 
unrealistic and arguably not representative of the clinical condition.  
Nevertheless, experimental design needs to be carefully considered to control the 
inherent variability associated with the KA model of epileptogenesis. 
  
   
65 
 
 
 
 
 
 
 
 
Chapter 4 
Spike frequency and coastline: 
algorithms for electrographic 
spikes in intracranial EEG 
recordings 
 
  
   
66 
 
4.1. Introduction 
 
EEG is the recording of spontaneous electrical activity of the brain over a period 
of time (Niedermeyer and de Silva, 2005).  EEG is often used in encephalopathies 
to indicate a CNS disorder, a focal process or ongoing seizure activity without 
motor manifestations (Brenner, 2009).  Clinically, EEG can be used to confirm an 
established diagnosis or rule out a diagnosis (Brenner, 2009), and is the most 
useful diagnostic tool for epilepsy (Noachtar and Rémi, 2009).  EEG is also used in 
animal models to study the development of epilepsy (Lehmkuhle et al., 2009).   
 
There are two types of EEG electrode placement for animals, epicranial and 
intracranial (Galanopoulou et al., 2013).  Epicranial surface recording of the brain 
involves placing electrodes on the skull surface and does not require opening the 
skull, hence minimising the risk of brain damage.  It is easier to implant the 
electrodes for epicranial than intracranial recordings (Galanopoulou et al., 2013).  
Intracranial (subdural or extra-dural) and depth electrode implantation require 
opening the skull and inserting the EEG electrode through a burr hole to record 
electrical activity from the brain.  Intracranial or depth electrode implantation 
can detect recordings from focal seizures arising from deeper structures within 
the brain, and in general provides a better signal-to-noise ratio and is more 
reliable than epicranial electrode implantation (Galanopoulou et al., 2013).  
Extra-dural electrode implantation involves placing the electrodes on the surface 
of the dura mater without penetrating through it (Galanopoulou et al., 2013).  On 
the other hand, intracranial subdural or depth electrode implantation involves 
inserting the electrodes into the brain by penetrating the dura mater and can 
directly record activity precisely from the seizure onset zone, but the placement 
of the electrode is difficult to confirm and can cause additional injury within the 
brain (Galanopoulou et al., 2013).  Methods of receiving data from the electrodes 
can be either tethered or remote.  Tethered systems tend to cause some distress 
to the animals and cause more movement artefacts than remote systems.  Remote 
systems are overall better systems with all the electrodes and the transmitter 
implanted within an animal’s body so that the animal can move freely within its 
cage, providing more comfort for long-term monitoring (Chang et al., 2011). 
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The measurement of EEG has the benefits of applying an objective measure to 
support the subjective behavioural observations that could differ between 
experimenters.  Behavioural observation of animals to assess seizure severity is 
an easy method to set up with minimal equipment needed.  However, the 
behavioural method is not standardised between experimenters and can cause 
inconsistent reports of seizure severity (Benkovic et al., 2004).  Additionally, EEG 
monitoring enables experimenters to quantitatively measure brain activity and to 
define what pattern of electrographic activity is indicative of a seizure in 
experimental animals (Galanopoulou et al., 2013).  Seizures are transient 
symptoms with a complex manifestation of underlying aberrant synchronous 
electrical activity in the brain but the correlation between seizure severity and 
neuropathology is unclear, hence the use of electrical recording of neuronal 
activity may give a better representation of seizure severity (Benkovic et al., 
2004; Chang et al., 2011).   
 
Furthermore, there is evidence that electrographic brain activity can precede the 
first observable behavioural seizure (Williams et al., 2007; 2009; Dudek and 
Staley, 2011).  Studies have used KA to induce acute seizures and showed that 
EEG spikes occurred a few days before the first spontaneous convulsive motor 
seizure was observed (Bertram and Cornett, 1993; Williams et al., 2009; White et 
al., 2010).  It was accordingly proposed that EEG spikes may be used as a 
predictive experimental biomarker for the development of chronic epilepsy 
(White et al., 2010).  The duration of epileptogenesis has been shown to be 
variable and differed substantially between animals that were video-monitored 
and those with EEG recordings (Lévesque and Avoli, 2013), demonstrating 
discrepancies between behavioural and electrographic seizure assessments.  By 
measuring electrical activity in the hippocampus of experimental animals, EEG 
patterns indicative of SE are observed without any significant behavioural seizure 
activity suggesting that electrographic activity may not be reflected in behaviour 
(Benkovic et al., 2004).  This may partly explain the discrepancies between 
behavioural and electrographic seizure reports from the literature.  Given these 
examples, using EEG to monitor seizure activity would be more reliable than 
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behavioural assessment alone.  Using EEG to continuously monitor electrographic 
signals is now a common method in experimental epilepsy research 
(Galanopoulou et al., 2013) and can be used to explore the efficacy of potential 
antiepileptogenic drugs, with EEG generally recorded immediately after a brain 
insult and before SRS occur (Löscher, 2011).   
 
Two types of method to identify seizure-like events have been used for EEG 
analysis.   This can be achieved by visual pattern recognition or computer-based 
algorithms (Galanopoulou et al., 2013).  Computer-based algorithms are generally 
more efficient and objective than visually reviewing EEG traces (Galanopoulou et 
al., 2013).  Several different algorithms for detecting seizures have been 
investigated, including spike frequency (White et al., 2010), coastline (White et 
al., 2010), power spectral density (White et al., 2010; Tsuchiya and Kogure, 
2011), range autocorrelation (White et al., 2006), wave area/spike amplitude 
ratio (Huneau et al., 2013), wavelet transformation (Bergstrom et al., 2013), 
logistic regression (Subasi and Erçelebi, 2005) and spike sorting (Lewicki, 1998).  
Their accuracies in seizure detection from EEG in experimental animals vary and 
the algorithms relying on spike frequency, coastline or power spectral density 
have been shown to have lower sensitivity to detect subtle non-convulsive 
seizures than range autocorrelation due to the impact of noise and artefact on 
these algorithms (White et al., 2006).  Nevertheless, there is currently no 
reported study demonstrating the correlation between any seizure-detecting 
algorithms with behavioural seizure severity in experimental animals. 
 
The objective of the work described in this chapter is to investigate the use of 
spike frequency and coastline algorithms to analyse the EEG data recorded from 
C57BL/6J mice with electrodes implanted extra-durally prior to KA 
administration.  The correlation of the two algorithms with behavioural seizure 
severity (as described in section 3.2.3) after the first onset of generalised seizures 
was also investigated.  Additionally, the effects on EEG activity of the potential 
anti-epileptogenic drug interventions, PSD95BP and PSD95BP plus 1400W, as 
described in section 1.5, were also investigated when administered after KA-
induced seizures.     
   
69 
 
 
4.2. Materials and methods 
 
4.2.1. Animals 
All experimental procedures were completed in accordance with the Animal 
(Scientific Procedures) Act, 1986 (UK).  All methodological details regarding the 
source of animals, their housing conditions, surgical implantation of telemetry 
electrodes, KA-induced seizures, EEG equipment set-up, video monitoring for 
behavioural analysis and EEG data analyses are provided in sections 2.1 and 2.2.  
The method for the behavioural seizure severity quantification is provided in 
section 3.2.3.  Prior to the start of baseline recordings, all animals were housed 
individually and were therefore all treated the same way before the induction of 
acute seizures.  Each cage was placed on top of a DSI receiver pad with a 
maximum of 6 animals being recorded simultaneously.  Implanted transmitters 
were turned on by placing a magnet next to the animal until the ‘carrier’ light on 
the receiver pad was illuminated.  This light indicated the transmitter was 
detected.  Video recording also began from the start of baseline recordings until 
the end of the experiment. 
 
4.2.2. Study design 
All mice were given KA treatment with 5 mice allocated per treatment group.  As 
this was a pilot study, the expected effect size, power and standard deviation for 
each treatment group for each EEG algorithm were not known, therefore the 
sample size was not calculated.  A sample size of n=5 per treatment group was 
chosen based on the n numbers used in previous experiments demonstrating 
changes in epileptiform activity during the early phases of epileptogenesis 
following the administration of PSD95BP and 1400W (Beamer et al, 2013).  There 
were 3 treatment groups for the study in this chapter, one group served as 
control and received KA alone, another group was treated with PSD95BP alone 
and the remaining group was treated with a combination of PSD95BP and 
1400W.  PSD95BP (courtesy of Professors Tymianski and Salt, University of 
Toronto) was prepared in saline and administered as a single bolus dose of 
7.6mg/kg via intravenous injection to mice one hour after diazepam 
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administration.  1400W dihydrochloride (Tocris Bioscience, Bristol, UK) was 
formulated to 4mg/ml with distilled water and mice were given an initial dose of 
20mg/kg via i.p. injection one hour after diazepam administration, followed by a 
further two doses administered 1 and 3 days after the first onset of Stage 5 
seizures.  Seizure severity data from one control animal were lost, meaning that 
analysis was based on a total of 14 animals, with n=4 in the control group.   
  
4.2.3. Data analysis 
EEG analyses for spike frequency and coastline are described in section 2.2.5.  
Spike frequency is the number of spikes with amplitudes greater than the 
threshold determined from baseline EEG recordings (before KA was 
administered), per minute.  Coastline is the sum of distances between consecutive 
data points over a specified time interval.  Coastline was normalised to each 
animal’s mean baseline coastline value (before KA was administered) by 
determining the difference between the coastline of each mouse from the first 
dose of KA and their respective baseline values.  Another method to illustrate 
normalised coastline was by separating the coastline data into 30 second epochs.  
The coastline per epoch in normal baseline EEG recording remains generally 
constant, while an epileptiform spike would transiently increase the coastline.  
Therefore, the absolute number of post-KA epochs that were out-with 3 x SD of 
the mean baseline epoch.   
 
The correlation of spike frequency and normalised coastline against behavioural 
seizure severity in the KA model of epileptogenesis was performed using 
Pearson’s product-moment correlation approach.  The mean spike frequency and 
the mean normalised coastline during the 2-hour behavioural assessment period 
between first onset of generalised seizures and diazepam administration were 
correlated with the quantified behavioural seizure severity (as described in 
section 3.2.3).   
 
4.2.4. Video monitoring of animals’ behaviour 
Video recordings were carried out concurrently with EEG recordings in order to 
correlate behaviour with EEG activity.  The video set up is described in section 
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2.2.4.  The assessment of animals’ behaviour from the videos was carried out 
during the 24 hours after diazepam administration, and again for 24 hours on the 
7th day and on the 14th day after KA-induced seizures.  The raw EEG data from 
animals with observed behavioural seizures from the video recordings were 
traced back to the approximate time to when the seizure occurred.  Raw EEG data 
were then visually reviewed to identify any seizure-like events that may have 
occurred approximately when seizures may have occurred for confirmation. 
 
4.2.5. Statistical analysis 
Statistical comparisons of seizure severity, spike frequency and coastline 
between treatment groups (control vs. PSD95BP and control vs. combination 
treatment of PSD95BP and 1400W dihydrochloride) were performed by one-way 
Analysis of Variance (ANOVA) using SPSS version 21 (IBM).  Statistical 
comparisons of specific spike frequencies on days 7 and 14 after KA-induced 
seizures between treatment groups was also performed by two-sample t-test 
using SPSS.  Area under the curve (AUC) from the start of KA administration to 28 
days after KA-induced seizures for all treatment groups was calculated using the 
trapezium rule.  The AUC was most accurately determined by calculating the sum 
of the area between every consecutive data point within a 1-hour interval using 
the following equation. 
 
s indicates spike frequency or coastline value of the data point; n indicates the 
hour of the data point; t indicates the time interval which is 1-hour.  Statistical 
analysis comparing AUC between treatment groups was performed by two-
sample t-test using SPSS.  Raw p-values are reported throughout, without 
correction for occasional multiple testing. 
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4.3. Results 
 
4.3.1. Kainic acid sensitivity 
A total of 15 mice implanted with an EEG transmitter were dosed with KA.  The 
range of KA doses required to induce Stage 5 generalised seizures in these 
animals was between 5-30mg/kg i.p. (Figure 4.1).   
 
Figure 4.1.  Total dose of kainic acid (KA), when given in repeated doses of 5 
mg/kg per dose via intraperitoneal injection, required to reach Stage 5 seizures 
in C57BL/6J mice implanted with a Data Scientific International TA10ETA-F20 
Physiotel® transmitter.  Data are expressed as the percentage of all mice 
implanted with EEG transmitter (n=15). 
 
4.3.2. Seizure severity between treatment groups 
The seizure severity induced by KA after the first onset of generalised seizure for 
the control group had a cumulative score of 30 (± 6.99), which was significantly 
lower when compared to the group that received a combination of PSD95BP plus 
1400W that had a cumulative score of 100.6 (± 4.37) (p<0.01) (Figure 4.2).  The 
group that received PSD95BP alone had a cumulative score of 55.6 (± 14.18), 
which was also significantly lower than compared to the PSD95BP plus 1400W 
group (p<0.05) (Figure 4.2). 
 
4.3.3. Behavioural vs. electrographic seizure severity 
Correlation analyses were undertaken to explore the relationship, if any, between 
spike frequency and normalised coastline, as recorded by EEG, and behavioural 
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seizures, during the 2-hour behavioural assessment between the first onset of 
Stage 5 seizures induced by KA administration and the administration of 
diazepam.  There was a clear correlation between mean spike frequency during 
the 2-hour assessment period and the severity of behavioural seizures based on 
the modified Racine scale, which showed a correlation coefficient (R2) of 0.5857 
(Figure 4.3).  The correlation between normalised coastline and behavioural 
seizure severity was less robust, with an R2 of 0.1438 (Figure 4.4).   
 
 
 
Figure 4.2.  The behavioural seizure severity for C57BL/6J mice in each treatment 
group (n=4 for the control group, n=5 for the drug intervention treatment 
groups), determined using the cumulative Racine score from the first onset of 
generalised seizures induced by kainic acid (KA) administration to the 
administration of diazepam 2 hours after.  Repeated administration of KA was 
given via intraperitoneal injection every 30 minutes until the first onset of 
generalised seizures.  Behavioural assessment on the highest seizure score 
observed in each 5-minute epoch was recorded based on the Racine scale and 
summed over the 2-hour period.  Data are expressed as the cumulative Racine 
score (± SEM) and was compared statistically using one-way Analysis of Variance 
(*p<0.05; **p<0.01). 
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4.3.4. Effect of drug interventions on spike frequency 
Spike frequency increased for all animals when KA was administered and 
reached a maximum of 248.6 (± 53.5) spikes per minute when the first onset of 
Stage 5 generalised seizures occurred (Figures 4.5 and 4.6).  After diazepam was 
administered, the spike frequency for all animals decreased and reached 4.1 (± 
2.1) spikes per minute (Figures 4.5 and 4.6).  PSD95BP was given 1 hour after 
diazepam and 1400W was given over 3 days after diazepam.     
 
 
Figure 4.3.  Correlation between mean spike frequency recorded by extra-dural 
EEG and behavioural seizure severity quantification during the 2-hour period 
following onset of the first Stage 5 seizure induced by kainic acid in C57BL/6J 
mice.  Spike frequency data are expressed as the mean number of spikes per 
minute recorded in 5-minute epochs and averaged across the 2-hour period.  
Seizure severity quantification is reported as the Racine scale score observed in 
each 5-minute epoch and summed over the 2-hour period.  Each data point 
represents a single animal (n=14).  Pearson’s product-moment correlation is 
represented by the solid line, with the corresponding correlation co-efficient (R2) 
reported.   
 
 
There were no differences in spike frequencies from days 1 to 5 after KA-induced 
seizures between the control group and the drug intervention groups (Figures 
4.5, 4.6 and 4.7).  The control group had a mean spike frequency of 31.0 (± 23.1) 
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spikes per minute, the PSD95BP plus 1400W combined group had a mean of 29.5 
(± 13.8) spikes per minute, and PSD95BP group had a mean of 21.3 (± 14.5) 
spikes per minute (Figures 4.5, 4.6 and 4.7).  From days 6 to 10, the spike 
frequencies of the control group and the drug intervention groups started to 
diverge, with the spike frequency of the control group gradually increasing from 
42.6 (± 35.9) to 83.7 (± 78.4) spikes per minute whilst the PSD95BP plus 1400W 
combined treatment group had a mean spike frequency of 15.7 (± 6.1) spikes per 
minute, and the PSD95BP group had a mean of 16.6 (± 8.8) spikes per minute 
(Figures 4.5, 4.6 and 4.7).   
 
 
Figure 4.4. Correlation between mean normalised coastline recorded by extra-
dural EEG and behavioural seizure severity quantification during the 2-hour 
period following onset of the first Stage 5 seizure induced by kainic acid in 
C57BL/6J mice.  Coastline data are expressed as the mean sum of distances 
between consecutive data points in 5-minute epochs averaged across the 2-hour 
period.  The coastline data were normalised to the baseline coastline value of 
each mouse before KA was administered.  Seizure severity quantification is 
reported as the Racine scale score observed in each 5-minute epoch and summed 
over the 2-hour period.  Each data point represents a single animal (n=14).  
Pearson’s product-moment correlation is represented by the solid line, with the 
corresponding correlation co-efficient (R2) reported.   
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At day 10 after KA-induced seizures, the spike frequency for the control group 
levelled out at 96.8 (± 77.2) spikes per minute up to 28 days after KA-induced 
seizures (Figures 4.5, 4.6 and 4.7).  The PSD95BP plus 1400W combined 
treatment group had a mean spike frequency of 23.0 (± 11.8) spikes per minute 
from day 10 up to day 28 after KA-induced seizures (Figures 4.5 and 4.7).  The 
PSD95BP treatment group had a mean spike frequency of 10.2 (± 3.1) spikes per 
minute from day 10 up to day 28 after KA-induced seizures (Figures 4.6 and 4.7).  
There appears to be some regular oscillations in the spike frequency profiles 
from day 9 in all treatment groups (Figures 4.5 and 4.6) which correlates with a 
24h cycle, suggests that spike frequency may be able to detect the circadian 
rhythm using EEG. 
 
Assessing the statistical significance using ANOVA for spike frequency by day did 
not show significant differences between the control group and either of the 
drug-intervention groups (Figure 4.7).  A two-sample t-test was then used to 
compare the differences in spike frequency between the control group and the 
drug intervention groups on days 7, 14 and 26.  The spike frequency of the 
PSD95BP plus 1400W combined treatment group was significantly lower than 
that of the control group on days 7 and 14 (p<0.05) (Figures 4.8 and 4.9).  The 
spike frequency of the PSD95BP plus 1400W combined treatment group on day 7 
was 14.7 (± 6.2) spikes per minute and on day 14 was 14.6 (± 7.1) spikes per 
minute, compared to the spike frequency of the control group on day 7 with 58.3 
(± 53.3) spikes per minute, and on day 14 with 84.6 (± 77.3) spikes per minute 
(Figures 4.8 and 4.9).  There were no significant differences in spike frequency 
between control group and the combined treatment group on day 26, with 109.9 
(± 76.9) spikes per minute and 41.2 (± 18.9) spikes per minute, respectively 
(Figure 4.10).  For PSD95BP treatment alone, no significant difference was 
observed on day 7 after KA-induced seizures, with a spike frequency of 20.0 (± 
12.9) spikes per minute compared to the control group of 58.3 (± 53.3) spikes per 
minute (Figure 4.8).  The spike frequency of the PSD95BP treatment group on day 
14 was 9.2 (± 2.0) spikes per minute and on day 26 was 10.1 (± 3.5) spikes per 
minute, which were significantly lower than that of the control group, with 84.6 
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(± 77.3) spikes per minute on day 14 and 109.9 (± 76.9) spikes per minute on day 
26 (p<0.05) (Figures 4.9 and 4.10).  
 
AUC was used to measure the spike frequency over a 28-day profile for all 
animals and to compare the control group with drug-intervention groups using a 
two-sample t-test.  The overall AUC of the PSD95BP treatment group was 8962 (± 
3281) spikes.hour/min, which was significantly lower than the control group 
with the overall AUC of 54261 (± 43280) spikes.hour/min (p<0.05) (Figure 4.11).  
The overall AUC of the PSD95BP plus 1400W treatment group was 15414 (± 
4648) spikes.hour/min, which was also significantly lower than the control group 
(p<0.05) (Figure 4.11).   
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Figure 4.5. Spike frequency over 28 days post-kainic acid (KA), comparing animals from the control group (red data points) and those 
treated with a combination of post-synaptic density 95 blocking peptide (PSD95BP) and 1400W (blue data points).  KA was administered to 
groups of C57BL/6J mice until the first onset of generalised seizures and diazepam was administered 2 hours thereafter.  Intravenous 
injection of PSD95BP at 7.6 mg/kg and the first intraperitoneal dose of 1400W at 20mg/kg were administered 1 hour after diazepam 
administration.  Two further doses of 1400W at 20mg/kg were administered 1 and 3 days after generalised seizure.  Spike frequency is 
reported as the mean number of spikes per minute ( SEM) over one hour epochs (n=5). 
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Figure 4.6. Spike frequency over 28 days post-kainic acid (KA), comparing animals from the control group (red data points) and those 
treated with post-synaptic density 95 blocking peptide (PSD95BP) (green data points).  KA was administered to groups of C57BL/6J mice 
until the first onset of generalised seizures and diazepam was administered 2 hours thereafter.  Intravenous injection of PSD95BP at 
7.6mg/kg was administered 1 hour after diazepam administration.  Spike frequency is reported as the mean number of spikes per minute ( 
SEM) over one hour epochs (n=5). 
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Figure 4.7. Daily spike frequency over 28 days post-kainic acid (KA), comparing animals from the control group (red bars), those treated 
with a combination of post-synaptic density 95 blocking peptide (PSD95BP) and 1400W (blue bars), and those treated with PSD95BP alone 
(green bars).  KA was administered to groups of C57BL/6J mice until the first onset of generalised seizures and diazepam was administered 
2 hours thereafter.  Intravenous injection of PSD95BP at 7.6mg/kg and the first intraperitoneal dose of 1400W at 20mg/kg were 
administered 1 hour after diazepam administration.  Two further doses of 1400W at 20mg/kg were administered 1 and 3 days after 
generalised seizure.  Spike frequency is reported as the mean number of spikes per minute (± SEM) over 24 hour epochs (n=5).   
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Figure 4.8. Mean spike frequency recorded by extra-dural EEG on day 7 after 
acute seizures induced by kainic acid in C57BL/6J mice (n=5 per group) treated 
with post-synaptic density 95 blocking peptide (PSD95BP) and a combination of 
PSD95BP plus 1400W, in comparison to vehicle-treated animals (control).  Data 
are expressed as mean ( SEM) number of spikes per minute recorded in one-
hour epochs and averaged across the full day and was compared statistically 
using a two-sample t-test (*p<0.05). 
 
 
 
Figure 4.9. Mean spike frequency recorded by extra-dural EEG on day 14 after 
acute seizures induced by kainic acid in C57BL/6J mice (n=5 per group) treated 
with post-synaptic density 95 blocking peptide (PSD95BP), and a combination of 
PSD95BP plus 1400W, in comparison to vehicle-treated animals (control).  Data 
are expressed as the mean ( SEM) number of spikes per minute recorded in one-
hour epochs and averaged across the full day and was compared statistically 
using a two-sample t-test (*p<0.05). 
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Figure 4.10.  Mean spike frequency recorded by extra-dural EEG on day 26 after 
acute seizures induced by kainic acid in C57BL/6J mice (n=5 per group) treated 
with post-synaptic density 95 blocking peptide (PSD95BP) and a combination of 
PSD95BP plus 1400W, in comparison to vehicle-treated animals (control).  Data 
are expressed as the mean ( SEM) number of spikes per minute recorded in one-
hour epochs and averaged across the full day and was compared statistically 
using a two-sample t-test (*p<0.05). 
 
 
Figure 4.11.  Mean area under the curve recorded by extra-dural EEG over 28 
days after acute seizures induced by kainic acid in C57BL/6J mice (n=5 per 
group) treated with post-synaptic density 95 blocking peptide (PSD95BP) and a 
combination of PSD95BP plus 1400W, in comparison to vehicle-treated (control).  
Data are expressed as the mean ( SEM) area under the curve determined from 
the sum of the area between every consecutive data point within an-hour 
interval, averaged across the 28 days and compared statistically using a two-
sample t-test (*p<0.05). 
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4.3.5. Effect of drug interventions on coastline 
The change in normalised coastline profile over 28 days following KA-induced 
seizures did not show any significant differences between control and the drug 
intervention groups (Figures 4.11-4.13).  The coastline data were then analysed 
in 30-second epochs and reported as the absolute number of post-KA epochs 
each day that had lengths more than 3 SDs from the mean baseline (Figure 4.15).  
From the epoch calculation method, there were significantly fewer numbers of 
extended post-KA epochs on day 7 in the PSD95BP treatment group, with 92.2 (± 
42.23) epochs, compared to the control group, with 919.6 (± 581.64) epochs 
(p<0.01) (Figure 4.16).  On day 14, there were significantly fewer numbers of 
extended post-KA epochs in the PSD95BP plus 1400W combined group, with 
122.2 (± 105.3) epochs, compared to the control group, with 850.2 (± 552.93) 
epochs (p<0.05) (Figure 4.17).  Calculating AUC for the epoch calculated data 
over a 28-day profile did not show any significant differences between control 
and the drug intervention groups (Figure 4.18). 
 
4.3.6. Video monitoring of animals’ behaviour 
A maximum of four animals per treatment group could, in theory, be video-
monitored using the available hardware.  However, due to various technical 
difficulties, unexpected mortality, and animal housing issues, videos were only 
available for 4 control animals, 3 PSD95BP animals, and just 1 animal from the 
combined treatment group.     
 
In order to confirm that diazepam administration had terminated SE in all 
animals and that subsequent seizure onset was spontaneous, behavioural 
assessment was performed for a 24-hour period after diazepam administration.  
One out of four control mice recovered from the sedative effects of diazepam 
within 1 hour post-dose and the remaining three mice recovered 4 hours post-
diazepam with no abnormal behaviour thereafter.   
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Figure 4.12. Normalised coastline over 28 days post-kainic acid (KA), comparing animals from the control group (red data points) and 
those treated with a combination of post-synaptic density 95 blocking peptide (PSD95BP) and 1400W (blue data points).  KA was 
administered to groups of C57BL/6J mice until the first onset of generalised seizures and diazepam was administered 2 hours 
thereafter.  Intravenous injection of PSD95BP at 7.6mg/kg and the first intraperitoneal dose of 1400W at 20mg/kg were administered 1 
hour after diazepam administration.  Two further doses of 1400W at 20mg/kg were administered 1 and 3 days after generalised seizure.  
Normalised coastline is reported as the mean sum of distances ( SEM) between consecutive data points normalised to the baseline 
coastline value before KA insult over one hour epochs (n=5). 
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Figure 4.13. Normalised coastline over 28 days post-kainic acid (KA), comparing animals from the control group (red data points) and 
those treated with post-synaptic density 95 blocking peptide (PSD95BP) only (green data points).  KA was administered to groups of 
C57BL/6J mice until the first onset of generalised seizures and diazepam was administered 2 hours thereafter.  Intravenous injection of 
PSD95BP at 7.6mg/kg was administered 1 hour after diazepam administration.  Normalised coastline is reported as the mean sum of 
distances ( SEM) between consecutive data points normalised to the baseline coastline value before KA insult over one hour epochs 
(n=5). 
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Figure 4.14.  Daily normalised coastline over 28 days post-kainic acid (KA), comparing animals from the control group (red bars), those 
treated with a combination of post-synaptic density 95 blocking peptide (PSD95BP) and 1400W (blue bars), and those treated with 
PSD95BP alone (green bars).  KA was administered to groups of C57BL/6J mice until the first onset of generalised seizures and 
diazepam was administered 2 hours thereafter.  Intravenous injection of PSD95BP at 7.6mg/kg and the first intraperitoneal dose of 
1400W at 20mg/kg were administered 1 hour after diazepam administration.  Two further doses of 1400W at 20mg/kg were 
administered 1 and 3 days after generalised seizure.  Normalised coastline is reported as the mean sum of distances ( SEM) between 
consecutive data points normalised to the baseline coastline value before KA insult over one hour epochs (n=5). 
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Figure 4.15.  The absolute number of post-kainic acid (KA) epochs with coastline that was more than 3 standard deviations (SDs) from 
the mean baseline (pre-KA) epoch length per day.  The data compare animals from the control group (red bars), those treated with a 
combination of the post-synaptic density 95 blocking peptide (PSD95BP) and 1400W (blue bars), and those treated with PSD95BP alone 
(green bars).  The coastline data for all animals were separated into 30-second epochs and the SD in each 30-second epoch during 
baseline for each animal was determined.  The absolute number of post-KA epochs ( SEM) each day wth coastline lengths out-with 3 
SDs of the mean baseline (n=5). 
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Figure 4.16.  The absolute number of post-kainic acid (KA) epochs with coastline 
that was more than 3 standard deviations (SD) from the mean baseline (pre-KA) 
epoch length on day 7 after acute seizures induced by KA in C57BL/6J mice (n=5 
per group).  The data compare animals from the control group, those treated with 
post-synaptic density 95 blocking peptide (PSD95BP) alone, and those treated 
with a combination of the PSD95BP and 1400W.  The coastline data for all 
animals were separated into 30-second epoch and the SD in each 30-second 
epochs during baseline for each animal was determined.  Data are expressed as 
the absolute number of post-KA epochs each day (± SEM) that had lengths more 
than 3 SDs from the mean baseline length, and was compared statistically using 
two-sample t-test (**p<0.01). 
 
 
All three mice given PSD95BP returned to normal behaviour 3 hours post-
diazepam and the mouse given PSD95BP and 1400W combined treatment 
returned to normal behaviour 12 hours after diazepam administration. 
 
On day 7, one control mouse had one occurrence of Stage 4 seizures that lasted 
less than 1 minute.  Raw EEG traces for this mouse at the corresponding time 
revealed higher amplitude discharges than the baseline EEG trace that lasted 34 
seconds (Figure 4.19).  All mice treated with PSD95BP, and the mouse treated 
with PSD95BP and 1400W combined had normal behaviour throughout the 24-
hour monitoring, with no evident behavioural seizures.  On day 14, two other 
control mice had convulsive seizures, one experienced a single occurrence of a 
Stage 3 seizure that lasted less than 1 minute and another experienced a single 
occurrence of a Stage 5 seizure that also lasted less than 1 minute.   
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Figure 4.17.  The absolute number of post-kainic acid (KA) epochs with coastline 
that was more than 3 standard deviations (SDs) from the mean baseline (pre-KA) 
epoch length on day 14 after acute seizures induced by KA in C57BL/6J mice (n=5 
per group).  The data compare animals from the control group, those treated with 
post-synaptic density 95 blocking peptide (PSD95BP) alone, and those treated 
with a combination of the PSD95BP and 1400W.  The coastline data for all 
animals were separated into 30-second epoch and the SD in each 30-second 
epochs during baseline for each animal was determined.  Data are expressed as 
the absolute number of post-KA epochs each day (± SEM) that had lengths more 
than 3 SDs from the mean baseline length, and was compared statistically using 
two-sample t-test (*p<0.05). 
 
 
Raw EEG traces for the mouse that experienced the Stage 3 seizure at the 
corresponding time to the behavioural seizure also revealed higher amplitude 
discharges than the baseline EEG trace that lasted 28 seconds (Figure 4.30A & B).  
For the mouse that experienced the Stage 5 seizure, raw EEG traces at the 
corresponding time to the behavioural seizure also revealed higher amplitude 
discharges than baseline EEG trace that lasted 49 seconds (Figure 4.30C & D).  All 
mice treated with PSD95BP and the mouse treated with PSD95BP and 1400W 
combined had normal behaviour throughout the 24-hour monitoring, with no 
evident behavioural seizures.  All seizures observed in control animals only 
occurred in the light phase. 
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Figure 4.18.  Mean area under the curve recorded by extra-dural EEG over 28 
days after acute seizures induced by kainic acid in C57BL/6J mice (n=5 per 
group) treated with post-synaptic density 95 blocking peptide (PSD95BP) and a 
combination of PSD95BP plus 1400W, in comparison to vehicle-treated (control).  
Data are expressed as the mean (± SEM) area under the curve determined from 
the absolute number of post-KA epochs each day that had lengths more than 3 
SDs from the mean baseline length averaged across the 28 days and compared 
statistically using a two-sample t-test.  
 
4.4. Discussion 
 
The purpose of the study in this chapter was to investigate the use of spike 
frequency and coastline for analysing extra-dural EEG recordings from C57BL/6J 
mice in a KA model of epileptogenesis.  The effects of PSD95BP alone and the 
combination of PSD95BP plus 1400W, with potential anti-epileptogenic effects 
were also evaluated.  There was a variable range of KA doses required to induce 
Stage 5 generalised seizures in mice implanted with EEG transmitter (Figure 4.1).  
The inherent variation may be partly due to subtle genetic variations between 
breeding lines, as described in chapter 3, or due to the surgical implantation of 
EEG transmitter that may have affected the KA sensitivity of the mice, or possibly 
both.  Spike frequency and coastline analyses have been previously studied to 
detect seizures in rat EEG recordings in order to determine their sensitivity and 
specificity to subtle behavioural seizures (White et al., 2006).   
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Figure 4.19.  Electroencephalography (EEG) traces of one C57BL/6J mouse implanted with a DSI TA10ETA-F20 Physiotel® transmitter 
that experienced an isolated Stage 4 seizure 7 days after being subject to kainic acid (KA)-induced acute seizures.  Repeated 
intraperitoneal administration of KA at 5 mg/kg was given every 30 minutes until the first onset of generalised seizures.  Diazepam was 
administered intramuscularly 2 hours after the first onset of generalised seizures.  (A) A normal EEG trace over 30 seconds of the animal 
during baseline recording.  (B) An EEG trace over 40 seconds of the same animal on day 7 after KA-induced seizures.  The EEG trace 
showing epileptiform discharges that occurred at a similar timing to when Stage 4 seizures occurred, confirmed using video monitoring.  
EEG was recorded at an output sample rate of 100Hz using Spike2 version 5 and is expressed as volts.  
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Figure 4.20.  Electroencephalography (EEG) traces of one C57BL/6J mouse implanted with a DSI TA10ETA-F20 Physiotel® transmitter 
that experienced an isolated Stage 3 seizure 7 days after being subject to kainic acid (KA)-induced acute seizures.  Repeated 
intraperitoneal administration of KA at 5 mg/kg was given every 30 minutes until the first onset of generalised seizures.  Diazepam was 
administered intramuscularly 2 hours after the first onset of generalised seizures.  (A) A normal EEG trace over 30 seconds of the animal 
during baseline recording.  (B) An EEG trace over 40 seconds of the same animal on day 14 after KA-induced seizures.  The EEG trace 
showing epileptiform discharges that occurred at a similar timing to when Stage 3 seizures occurred, confirmed using video monitoring.  
EEG was recorded at an output sample rate of 100Hz using Spike2 version 5 and is expressed as volts.  
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Figure 4.21.  Electroencephalography (EEG) traces of one C57BL/6J mouse implanted with a DSI TA10ETA-F20 Physiotel® transmitter 
that experienced an isolated Stage 5 seizure 7 days after being subject to kainic acid (KA)-induced acute seizures.  Repeated 
intraperitoneal administration of KA at 5 mg/kg was given every 30 minutes until the first onset of generalised seizures.  Diazepam was 
administered intramuscularly 2 hours after the first onset of generalised seizures.  (A) A normal EEG trace over 30 seconds of the animal 
during baseline recording. (B) An EEG trace over 58 seconds of the same animal (number 4) on day 14 after KA-induced seizures.  The 
EEG trace showing epileptiform discharges that occurred at a similar timing to when Stage 5 seizures occurred, confirmed using video 
monitoring.  EEG was recorded at an output sample rate of 100Hz using Spike2 version 5 and is expressed as volts. 
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Both algorithms were shown to be insensitive to non-convulsive seizure activities 
(White et al., 2006).  In this study, the correlation between behavioural seizure 
severity using the cumulative Racine score in the 2-hour assessment period and 
the two algorithms were investigated.  Spike frequency (Figure 4.3) appeared to 
show a better correlation to behavioural seizure severity than normalised 
coastline (Figure 4.4), suggesting that spike frequency is the better algorithm of 
the two for analysing the EEG data recorded in this study.   
 
The spike frequency profiles of the control group, PSD95BP plus 1400W combined, 
and PSD95BP alone diverged from 6 days after the acute seizures (Figures 4.4, 4.5 
and 4.6).  On day 7, the spike frequency of PSD95BP plus 1400W combined 
treatment group is significantly lower than the control group (Figure 4.8), however 
PSD95BP treatment alone did not show any significant differences (Figure 4.8).  On 
day 14, the spike frequencies of both treatment groups, PSD95BP plus 1400W 
combined and PSD95BP alone, were significantly lower than the control group 
(Figure 4.9).  On day 26, the spike frequency of PSD95BP alone treatment was 
significantly lower than the control group, however the combined PSD95BP plus 
1400W treatment group did not show any significant differences (Figure 4.10).  
These results suggest that PSD95BP alone and PSD95BP plus 1400W combined 
treatments were both able to reduce the spike frequency after KA-induced 
seizures.  The significant reduction in spike frequency of the PSD95BP plus 1400W 
combined treatment group did not persist until 28 days after KA-induced seizures.  
On the other hand, the significant reduction seen with PSD95BP treatment alone 
continued up to 28 days after KA-induced seizures.  Using AUC, the spike frequency 
profiles in the PSD95BP group and in the combined treatment group were 
significantly lower than in the control group (Figure 4.11), with PSD95BP 
appearing to be more effective than the combined treatment of PSD95BP and 
1400W.  It is possible that 1400W limited the efficacy of PSD95BP in a combined 
treatment or the differences in initial severity of SE affected the efficacy of the 
combined treatment group (Figure 4.2).   
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No significant differences in normalised coastline profile were observed between 
the control and the drug-intervention groups, when data were plotted for every 
hour (Figures 4.11 and 4.12) or in mean normalised coastline per day (Figure 
4.14).  This was possibly due to the transient changes in coastline being swamped 
by overall EEG coastline in each one hour epoch.  Normal physiological relevant 
EEG frequency in a mouse brain band from 0-25Hz (Bergstrom et al, 2013), which 
is lower than the frequency signal of 100Hz used in this study. High frequency 
noise may have disguised the high amplitude discharges that were observed when 
animals experienced convulsive seizures.  This may explain why coastline has a 
poorer correlation with behavioural seizure severity than spike frequency.  The 
noise detected may also have suppressed the differences in normalised coastline 
between control and drug-intervention groups that could explain the non-
significant differences between treatment groups.  Apart from recording at a lower 
frequency, this could be resolved by applying more aggressive signal filtering to 
further reduce the high frequency noise.  Alternatively, splitting the coastline 
profile into smaller 30-second epochs and profiling the number of epochs with an 
extended coastline (more than 3 SDs from the mean baseline epoch length) may be 
another method to differentiate the coastline changes during high amplitude 
discharges and high frequency noise.  The number of extended epochs showed 
significant differences between the control and drug-treated groups (Figure 4.15).  
PSD95BP treated group had significantly fewer numbers of extended epochs than 
the control group on day 7 (Figure 4.16) and PSD95BP plus 1400W combined 
group had significantly fewer numbers of extended epochs than the control group 
on day 14 (Figure 4.17).  However, AUC for extended epochs per day over 28-day 
profile did not show any overall significant changes (Figure 4.18).   
 
The EEG profiles for all 3 treatment groups were continuously monitored from the 
time of KA-induced acute insult to the end of the experiment with no breaks in the 
period of recording, meaning that seizure clusters did not obscure the progressive 
nature of acquired epileptogenesis (Dudek and Staley, 2011; Galanopoulou et al., 
2013).  Based on the animals’ behaviour from video monitoring, no apparent 
seizure activity was observed in any animals within 24 hours after the 
administration of diazepam.  This suggests that the diazepam administered was 
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able to suppress SE induced by KA for up to 24 hours post-dose and therefore any 
subsequent seizure occurrence is likely to be spontaneous and not continued from 
the initial insult.  One control mouse had a spontaneous seizure on day 7 and two 
other control mice had spontaneous seizures on day 14.  None of the mice treated 
with PSD95BP or combined treatment of PSD95BP and 1400W showed any 
evidence of spontaneous seizures on days 7 and 14.  The changes in EEG traces for 
the control mice at a time corresponding to the behavioural seizures showed 
higher amplitude discharges than the baseline traces.  The duration of these higher 
amplitude traces appeared to correlate with the severity of the behavioural seizure 
observed, as the longest trace was observed for the Stage 5 seizure and the Stage 3 
seizure showed the shortest trace (Figures 4.19-4.21).  However, this would 
require confirmation with software that is able to record EEG traces and video 
monitoring simultaneously in real-time in order to accurately assess the 
relationship between the duration of epileptiform discharges and behavioural 
seizure severity.     
 
The mean seizure severity during the 2-hour behavioural assessment period was 
different between treatment groups.  The control group had the lowest seizure 
severity score and the combined PSD95BP plus 1400W group had the highest 
severity score (Figure 4.2).  Given that the control group had significantly higher 
spike frequency and higher number of extended coastline epochs than the drug-
treated groups during the 28 day follow-up period, this would suggest that a low 
seizure severity in the initial behavioural assessment period did not hinder the 
subsequent changes in spike frequency or coastline epochs. 
 
The spike frequency and coastline for the control group after KA-induced seizures 
were variable, with a greater degree of variability in the control group than in the 
drug-treated groups.  Variability in the latency to the first spontaneous motor 
seizure after the initial insult between rats was reported in an epilepsy model 
where KA was administered in a repeated low dose regimen (Hellier et al., 1998; 
Bauer and Norwood, 2013).  Greater degree of variability seen in the control group 
could be due to the different latency in the onset of spontaneous seizures between 
the mice.  Statistical significance was not achieved by comparing the spike 
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frequency and coastline between the control and the drug intervention groups 
during the 28 day follow-up period using ANOVA.  A post hoc power analysis 
(Cohen, 2013) for spike frequency showed that the sample size required to give 
sufficient statistical power to yield significant differences between control and 
drug intervention groups is n=35 to 40 per treatment group (Figure 4.22).  This 
suggests that the EEG algorithms investigated in this chapter are so variable that 
robust conclusions could not be drawn about the differences between treatment 
groups without resorting to a study with unreasonably large number of animals.     
 
Current spike detection techniques are known to have flaws due to disagreement 
amongst experts with regard to what constitutes an EEG spike (White et al., 2006).  
The criteria of a spike used in the spike frequency analysis of this study focused on 
those with amplitudes that were higher than baseline, before the induction of KA 
insult.  It is unknown whether all high amplitude spikes detected were directly 
related to seizures, although more high amplitude spikes appeared during seizure 
activity.  Although it is unsure whether spike frequency algorithm can be used to 
predict seizure activities, it has been reported that a significant increase in spike 
frequency is seen in rodents that developed chronic epilepsy compared to those 
that did not (White et al., 2010).   
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Figure 4.22. Post hoc power analysis for spike frequency on day 14 after KA-
induced seizures comparing control with post-synaptic density 95 blocking 
peptide (PSD95BP) and the combined treatment of PSD95BP and 1400W.  Power 
is (1- β error probability when the null hypothesis is false) a function of effect size 
and sample size.  One-tailed independent t-test was used to compare the difference 
between two independent means of the control and the combined group, or the 
control and the PSD95BP group.  The effect size d was 0.570477 for control vs. 
PSD95BP and 1400W combined treatment group and d was 0.616882 for control 
vs. PSD95BP.  The allocation ratio N2/N1 was 1 and the significance level ( error 
probability when the null hypothesis is true but rejected) was 0.05. 
 
In this study, spontaneous seizures were observed in some mice from the control 
group when there was a higher spike frequency.  Nevertheless, an increase in spike 
frequency would not be able to reliably predict the occurrence of subsequent 
spontaneous seizures due to the lack of sensitivity of this analysis.  Further 
investigation will be required to refine the spike frequency algorithm to improve 
on its specificity.    
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Chapter 5  
Proteomic profile of the 
hippocampus:  
acute insult vs. potential anti-
epileptogenic drug interventions 
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5.1. Introduction 
 
Proteins are the most multi-purpose macromolecules in the living system and are 
crucial to the various cellular events that govern the function of biological systems 
(Berg et al., 2002; Kumar and Mann, 2009).  Altered protein expressions are 
implicated in several disease states, therefore the understanding of proteins and 
their interactions is fundamental for biomedical research (Hondermarck, 2004; 
Kumar and Mann, 2009).  Proteomics is a large-scale study of proteins that 
determines the entire complement of proteins expressed in a particular cell or 
tissue at a single point in time.  Their interactions with other molecules are also 
determined in order to characterise their roles in biological processes, disease 
progression and therapeutic drug effects (Anderson and Anderson, 1998; Morrison 
et al., 2002; Hondermarck, 2004).   
 
5.1.1. Principles and instrumentation 
A proteomics assay is typically a two-stage process: large-scale protein separation, 
followed by characterisation of the separated proteins by MS analysis (Molloy and 
Witzmann, 2002; Morrison et al., 2002).  Multi-dimensional capillary liquid 
chromatography (LC) separation of protein digests is normally used to minimise 
the number of peptides being introduced to the mass spectrometer, thus 
increasing the overall dynamic range of the MS measurements and optimising the 
detection of low abundance peptides (Morrison et al., 2002).  The sensitivity of the 
proteomics assay required to identify low abundance proteins is ultimately 
dependent on the MS instrumentation (Morrison et al., 2002).  MS is a well-
established protein identification tool and has become a powerful technology for 
the large-scale study of proteins (Ong et al., 2003; Kumar and Mann, 2009).  It 
enables rapid identification and characterisation of proteins in a global study of 
cellular proteomes in tissues or cells (James, 1997; Molloy and Witzmann, 2002; 
Kumar and Mann, 2009).  Two commonly used forms of MS in proteomics are: 
matrix-assisted laser desorption ionisation time-of-flight (MALDI-TOF) 
spectrometry and MS/MS (Hondermarck, 2004).  MALDI-TOF makes use of a single 
mass analyser and is normally used to analyse simple peptide mixtures, whereas 
MS/MS integrated with LC is used for the analysis of more complex samples 
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(Aebersold and Mann, 2003).  MS/MS was the method of choice for the protein 
identification described in this chapter due to the level of information it can 
provide (Hondermarck, 2004).   
 
5.1.2. Protein identification and quantification 
Protein identification is based on peptide ion analysis, where the peptide ion data 
obtained for each sample is queried against a peptide database in an effort to 
correlate the measured peptide ions with known peptide ions derived from 
theoretical digests of unique proteins (Molloy and Witzmann, 2002).  A popular 
approach to identification with raw MS/MS data is to search databases of known 
genomes and proteomes with un-interpreted data using Mascot 
(http://www.matrixscience.com) (James, 1997; Perkins et al., 1999; Ma et al., 
2003).  Protein quantification mostly involves the use of isotope labelling to 
compare samples that were labelled via MS (Elrick et al., 2006).  However, for 
proteins that were not isotopically labelled, such as from animal tissues, samples 
are typically analysed by label-free quantification (Kumar and Mann, 2009).  Label-
free quantification measures and compares the MS signal intensity of the peptide 
ions to determine the relative amount of proteins in the biological samples of 
interest (Bantscheff et al., 2007). A variety of analytical methods have been applied 
to interpret quantified proteomics datasets, such as multivariate statistics 
(Tarroux, 1983; Anderson et al., 1984; Vilain et al., 2004), relative quantitation or 
expression (Blackstock and Weir, 1999; Ong et al., 2003; Bantscheff et al., 2007), 
quantitative trait loci mapping (Damerval et al., 1994; Picotti et al., 2013) and 
cluster correlation (Weinstein et al., 1997; Carlson et al., 2007).  Another approach 
for protein quantification is using PEAKS (Bioinformatics Solutions Inc.; 
http://www.bioinfor.com), which calculates the peptide ratios from raw MS/MS 
data based on peak areas of the top-3 unique peptides identified for the protein in 
order to visualise the quantification results in a 2D heat map (Ma et al., 2003; Bin 
Ma and Johnson, 2012).   
 
5.1.3. Protein profiling and interactions 
The most simple and common way to present large-scale proteomics data is to list 
the expression of proteins as a function of the tissue condition, to help identify any 
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changes in protein expressions associated with its biological function (Aebersold 
and Mann, 2003).  Relative quantitative analysis can provide a list of proteins that 
are different between each sample in order to compare the level of protein 
expression between different conditions or treatments (Bantscheff et al., 2007).  It 
has been suggested that listing the affected proteins based on magnitude of change 
does not necessarily facilitate the identification of biomarkers of disease because 
changes in protein expression of small magnitude may be just as likely to initiate 
the disease process as changes of large magnitude (Drabik et al., 2007).  The 
prediction of cellular processes from relative quantitative data alone is also known 
to be inadequate, especially when aiming to identify a biomarker for a specific 
disease (Aebersold and Mann, 2003; Drabik et al., 2007).  The study of protein 
function and its interactions within the organism is helpful in identifying disease-
associated protein markers (Drabik et al., 2007).  Cellular processes are typically 
carried out by stable or transiently assembled protein complexes and so 
identifying protein-protein interactions can allude to cellular function (Kumar and 
Mann, 2009).  Functional analysis of the quantitative expression mapping can 
emerge from proteomic comparisons between treatment groups (Kumar and 
Mann, 2009).  On a functional level, proteins can be mapped to network and 
pathway databases to visualise those proteins in their modular functional contexts, 
which may be important in the disease process or in the mechanism of action of 
drug interventions (Banks et al., 2000; Kumar and Mann, 2009).  Search Tool for 
the Retrieval of Interacting Genes/Proteins (STRING; http://string-db.org) is a 
database containing information from numerous sources about known and 
predicted protein interactions, including direct (physical) and indirect (functional) 
associations (Mering et al., 2003; 2005; Szklarczyk et al., 2011; Franceschini et al., 
2013).  These associations are derived from genomic context, high throughput 
experiments, co-expression and previous knowledge from published literature.  
Protein-protein interaction networks can also be used to predict interaction 
networks that can lead to hypotheses for follow up experimental research and 
interaction mapping (Schwartz et al., 2009).   
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5.1.4. Proteomics in neurosciences 
Proteomic technology provides the opportunity to integrate information about the 
expression of proteins and their cellular localisation (Jain, 2002). It has been used 
to study the mechanisms of several neurological and neurodegenerative disorders 
and has facilitated the development of diagnostic biomarkers and potential 
therapeutic targets (Jain, 2002; Morrison et al., 2002; Kim and Sheng, 2004).  These 
disorders include Alzheimer’s disease (Fountoulakis, 2001; Jain, 2002; Johnson et 
al., 2005; Drabik et al., 2007), Parkinson’s disease (Johnson et al., 2005; Drabik et 
al., 2007), Huntington’s disease (Drabik et al., 2007), Down’s syndrome 
(Fountoulakis, 2001; Jain, 2002; Johnson et al., 2005), schizophrenia (Jain, 2002), 
prion disease (Banks et al., 2000; Drabik et al., 2007), polyglutamine disease 
(Johnson et al., 2005), injury-induced neurodegeneration (Johnson et al., 2005), 
motor neuron disease (Johnson et al., 2005) and epilepsy (Krapfenbauer et al., 
2001a; 2001b; Liu et al., 2008; Li et al., 2010; Löscher and Brandt, 2010; Kan et al., 
2012; Persike et al., 2012).  A proteomic approach can help dissect the molecular 
pathways involved in both physiological and pathological neurological states.  In 
epilepsy, protein expression profiles in brains from patients (Kan et al., 2012; 
Persike et al., 2012) and mouse models have been investigated (Krapfenbauer et 
al., 2001a; 2001b; Liu et al., 2008; Li et al., 2010; Löscher and Brandt, 2010), in 
order to gain insight into the mechanisms of epileptogenesis and to identify 
potential targets for treatment.  The use of proteomic technology to characterise 
the cellular effects of potential anti-epileptogenic drugs has not been reported.  
The abundance or structure of proteins that are regulated by drugs can provide 
important insight into their mechanisms of action (Anderson and Anderson, 1998).   
The objective of the research described in this chapter was therefore to investigate 
the proteomic profile of the hippocampus of C57BL/6J mice following KA-induced 
seizures and the subsequent effect of pharmacological interventions that target NO 
signalling pathway. Details of the KA model and the respective drugs, PSD95BP and 
1400W, are provided in previous chapters. Changes in the proteomic profile were 
investigated using relative protein quantitation, heat map visualisation and 
predicted protein-protein interaction mapping. 
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5.2. Materials and methods 
 
5.2.1. Animals 
All experimental procedures were completed in accordance with the Animal 
(Scientific Procedures) Act, 1986 (UK).  All methodological details regarding the 
source of animals, their housing conditions, and administration of KA to induce 
seizures are provided in section 2.1.  There were six treatment groups in this study 
(n=4 per group), three of which received KA followed by either PSD95BP, 1400W 
or distilled water (as a treatment control)  and three that received distilled water 
(to control for KA administration) and then either PSD95BP, 1400W or additional 
distilled water (again as a treatment control). The preparation and dosing 
regimens of PSD95BP and 1400W are outlined in section 4.2.2. Seven days after 
KA-administration (or appropriate control), all mice were euthanised, as described 
in section 2.1.4.  This timepoint was chosen based on the spike frequency EEG 
algorithm that appeared to diverge between the control animals and the drug-
intervention groups from 7 days after KA-induced acute seizures in chapter 4.  The 
divergence may be indicative of the start of spontaneous seizures in the control 
animals.  The brains were removed and the hippocampi were dissected and stored 
in cryovials prior to being snap-frozen in liquid nitrogen.  All samples were stored 
in -80oC until required for proteomic analysis. 
 
5.2.2. Proteomics protocol 
All hippocampi were thawed on ice before homogenisation. Protocols for tissue 
homogenisation, digestion and LC-MS are outlined in section 2.4.  Tryptic digests of 
hippocampal homogenates were analysed by nanoflow reversed-phase LC-MS on 
the Q Exactive™ (Thermo Fisher, UK) at 2h LC gradients with an Orbitrap analyser. 
Each MS cycle had a full range scan at high resolution followed by sequential 
fragmentation of the 10 most abundant peptide ions. The fragments were then 
measured at high mass resolution in the Orbitrap.   
 
5.2.3. Data collection 
Raw data files were searched against the Universal Protein Resource (UniProt; 
http://www.uniprot.org) mouse database using Proteome Discoverer 3.1 and 
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between 1,650 and 1,800 proteins were identified with a false discovery rate of 
0.1-0.5%.  Label-free LC-MS analysis was performed using Progenesis LC-MS 
version 4.0 (Nonlinear Dynamics Ltd, UK) with protein identifications from the 
Mascot search engine based on the mouse UniProt database. 
   
5.2.4. Statistical analysis 
The MS peak list produced in Progenesis and searched in Mascot against the 
UniProt mouse database returned 2,426 protein hits.  Statistical analysis for the 
proteomics data was performed by one-way ANOVA using a built-in tool within the 
Progenesis software. All identified proteins were short-listed based on statistical 
significance with a cut off p-value of 0.0125, which incorporates a Bonferroni 
correction to account for multiple comparisons (n=4). 
 
5.2.5. Protein quantification and interaction analysis 
The outcome of comparisons between treatment groups was represented by the 
total number of proteins showing significant changes, separated into those that 
were down-regulated or up-regulated, and was also expressed as the percentage of 
the total number of proteins identified (n=2,426). Relative protein quantitative 
analysis was carried out by listing all proteins with significant changes between 
treatment groups in the order of statistical significance, from lowest p-value to 
highest.  The percentage change in relative abundance between the treatment 
groups was also shown. Heat maps were generated using PEAKS Studio 7.0 
(Bioinformatics Solutions Inc., Canada).  The raw MS/MS data were filtered to a 
retention time range of 0-270s for each sample and the cut-off value for statistical 
significance was p<0.01. Predicted protein-protein interactions were mapped for 
each of the three most significantly changed proteins between treatment groups 
using STRING version 9.1. The known or predicted functional partner(s) with the 
strongest evidence for association, indicated by the number of connectors in the 
network map, was selected for further scrutiny. 
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5.3. Results 
 
5.3.1. Overall changes in protein expression between treatment groups 
KA administration resulted in SE in all animals, which was followed by treatment 
with either PSD95BP, 1400W or vehicle alone. Interventions were applied after 
KA-induced seizures to ensure that they did not exert their effects by modulating 
the initial insult. In the 7 days between KA-induced SE and harvesting of tissue, 
there were no obvious signs of seizure activity in any of the animals and no notable 
behavioural sequelae of the interventions. The overall effects of KA-administration, 
and/or treatment with PSD95BP or 1400W, on protein expression in the 
hippocampus are outlined in Table 5.1.  
 
The administration of KA resulted in a significant change in the expression of 30 
proteins (1.2% of total; 27 up-regulated, 3 down-regulated) in the hippocampus 7 
days thereafter when compared to animals that had initially received vehicle alone. 
Treatment with either PSD95BP or 1400W alone was associated with modest 
numbers of affected proteins; the expression of 16 proteins (0.7% of total; 6 up-
regulated, 10 down-regulated) was altered by PSD95BP administration and just 8 
proteins (0.3% of total; 6 up-regulated, 2 down-regulated) were altered by 1400W.  
Animals that received KA followed by PSD95BP showed 38 affected proteins (1.6% 
of total; 26 up-regulated, 12 down-regulated) when compared to those that 
received PSD95BP alone, while those that were treated with KA plus 1400W 
showed a difference in expression of 41 proteins (1.7% of total; 22 up-regulated, 
19 down-regulated) in the hippocampus compared to mice that received 1400W 
alone. Finally, animals that received KA followed by PSD95BP showed 31 affected 
proteins (1.3% of total; 12 up-regulated, 19 down-regulated) when compared to 
those that received KA alone. In contrast, animals that were treated with KA plus 
1400W showed a difference in expression of 36 proteins (1.5% of total; 21 up-
regulated, 15 down-regulated) in the hippocampus compared to mice that received 
KA alone.  
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5.3.2. Relative quantitative analysis 
Proteins whose expression patterns were significantly changed in the treatment 
group comparisons described above were sorted by p-value and are listed in 
Tables 5.2-5.8. The three proteins with lowest p-values in each of the comparisons 
were shortlisted for further investigation of their protein-protein interactions 
mapping, as reported in section 5.3.4. 
 
 
Treatment group comparisons Up-
regulated 
(n) 
Down-
regulated 
(n) 
Total 
significant 
% significant of 
all proteins 
identified 
Vehicle alone vs  KA alone 27 3 30 1.2% 
Vehicle alone vs PSD95BP alone 6 10 16 0.7% 
Vehicle alone vs 1400W alone 6 2 8 0.3% 
PSD95BP alone vs KA+PSD95BP 26 12 38 1.6% 
1400W alone vs KA+1400W 22 19 41 1.7% 
KA alone vs KA+PSD95BP 12 19 31 1.3% 
KA alone vs KA+1400W 21 15 36 1.5% 
 
Table 5.1. The number of proteins significantly altered in the hippocampus of 
C57BL/6J mice at 7 days after kainic acid (KA) administration followed by 
treatment with either PSD95BP, 1400W or vehicle alone (n=4 per group). Results 
are expressed as the number of proteins up-regulated, the number down-
regulated, the total number of proteins changed, and also as percentage of the total 
protein identified (n=2,426). Statistical significance (p<0.05) was determined by 
one-way Analysis of Variance with Bonferroni correction for multiple comparisons.   
 
 
 
The effect of kainic acid alone 
A total of 30 proteins showed significantly altered expression in the hippocampus 
between mice that received KA and those that received vehicle alone. P-values for 
those proteins ranged from 9.56 × 10-6 to 3.35 × 10-2 (Table 5.2).  
 
The effect of drug interventions alone 
A total of 16 proteins showed significantly altered expression in the hippocampus 
when comparing mice that received PSD95BP and those that received vehicle 
alone. P-values for those proteins ranged from 3.31 × 10-3 to 3.99 ×10-2 (Table 5.3).  
A total of 8 proteins showed significantly altered expression in the hippocampus 
when comparing mice that received 1400W and those that received vehicle alone. 
P-values for those proteins ranged from 5.0 × 10-3 to 3.34 × 10-2 (Table 5.4).   
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Rank Protein P-value % change 
1 Complement C1q subcomponent subunit B 9.56×10-6 66% 
2 Galectin-1 3.57×10-4 93% 
3 Moesin 5.08×10-4 83% 
4 CD44 antigen 1.72×10-3 213% 
5 Cystatin C 2.33×10-3 30% 
6 Glial Fibrillary Acidic Protein 2.37×10-3 162% 
7 Complement C1q subcomponent subunit C 3.47×10-3 49% 
8 Protein kinase C and casein kinase substrate in neurons 2, isoform 
CRA_a 
3.68×10-3 22% 
9 Hspb1 protein 3.88×10-3 177% 
10 Vimentin 4.96×10-3 150% 
11 Protein-glutamine gamma-glutamyltransferase 2 7.20×10-3 73% 
12 Murinoglobulin-1 7.48×10-3 -46% 
13 Metallothionein-2 7.72×10-3 87% 
14 Complement C1q subcomponent subunit A 9.92×10-3 109% 
15 MCG142467 1.21×10-2 61% 
16 Cytosolic 10-formyltetrahydrofolate dehydrogenase 1.24×10-2 24% 
17 Translational activator of cytochrome c oxidase 1 1.32×10-2 31% 
18 MCG18019 1.36×10-2 56% 
19 Lysosomal membrane glycoprotein 1, isoform CRA_c 1.49×10-2 38% 
20 Rho-related GTP-binding protein RhoC 1.76×10-2 21% 
21 DNA topoisomerase 2-beta 2.01×10-2 69% 
22 Secretogranin-2 2.31×10-2 53% 
23 Heme oxygenase (Decycling) 2 2.46×10-2 11% 
24 Bleomycin hydrolase 2.57×10-2 -18% 
25 Annexin 2.62×10-2 82% 
26 Filamin, alpha 2.74×10-2 71% 
27 Calbindin 2.75×10-2 -36% 
28 Dehydrogenase/reductase SDR family member 1 2.82×10-2 90% 
29 Transgelin 3.02×10-2 84% 
30 Proenkephalin-A 3.35×10-2 53% 
 
Table 5.2. Proteins (n=30) whose expression was significantly changed in the 
hippocampus of C57BL/6J mice 7 days after kainic acid-induced seizures, when 
compared to hippocampi of mice that received vehicle (distilled water) alone (n=4 
per group). Homogenised hippocampal tissues were analysed using liquid 
chromatography mass spectrometry, and proteins identified based on the peptide 
sequences detected and queried through Mascot. Results are ranked in the order 
of p-value (lowest to highest), with percentage change in expression indicated (a 
negative percentage change represents a down-regulation). Statistical significance 
(p<0.05) was determined by one-way Analysis of Variance with Bonferroni 
correction for multiple comparisons. 
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Rank Protein P-value % change 
1 Rho guanine nucleotide exchange factor 2 3.31×10-3 -24% 
2 Protein farnesyltransferase subunit beta 5.72×10-3 -38% 
3 DNA topoisomerase 2-beta 1.68×10-2 72% 
4 Adenosine kinase 1.75×10-2 -10% 
5 ADP-ribosylation factor guanine nucleotide-exchange factor 
2 (Brefeldin A-inhibited) 
1.78×10-2 -16% 
6 Filamin, alpha 2.26×10-2 41% 
7 Signal transducing adaptor molecule (SH3 domain and ITAM 
motif) 1 
2.32×10-2 -12% 
8 Cacna2d1 protein 2.44×10-2 -19% 
9 Syntaxin-2 2.58×10-2 30% 
10 Microsomal glutathione S-transferase 3 2.80×10-2 -30% 
11 Ubiquitin-fold modifier-conjugating enzyme 1 2.93×10-2 -25% 
12 Huntingtin-associated protein 1 3.08×10-2 192% 
13 Calumenin, isoform CRA_a 3.09×10-2 8% 
14 Collagen, type IV, alpha 2 3.51×10-2 21% 
15 Cullin-4B 3.77×10-2 -23% 
16 Dihydropyrimidinase-related protein 3 3.99×10-2 -19% 
 
Table 5.3. Proteins (n=16) whose expression was significantly changed in the 
hippocampus of C57BL/6J mice 7 days after administration of vehicle (distilled 
water) followed by PSD95BP, when compared to hippocampi of mice that 
received distilled water alone (n=4 per group). Homogenised hippocampal tissues 
were analysed using liquid chromatography mass spectrometry, and proteins 
identified based on the peptide sequences detected and queried through Mascot. 
Results are ranked in the order of p-value (lowest to highest), with percentage 
change in expression indicated (a negative percentage change represents a down-
regulation). Statistical significance (p<0.05) was determined by one-way Analysis 
of Variance with Bonferroni correction for multiple comparisons.   
 
Rank Protein P-value % change 
1 3'-phosphoadenosine 5'-phosphosulphate synthase 1, isoform 
CRA_b 
5.0×10-3 18% 
2 Protein kinase C and casein kinase substrate in neurons 2, 
isoform CRA_a 
1.0×10-2 12% 
3 Glycine cleavage system H protein, mitochondrial 1.03×10-2 16% 
4 MCG1395 1.27×10-2 -22% 
5 2410002F23Rik protein 1.46×10-2 184% 
6 Dihydropyrimidinase-related protein 3 2.69×10-2 -19% 
7 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial 2.79×10-2 22% 
8 Quinone oxidoreductase-like protein 2 3.34×10-2 115% 
 
Table 5.4. Proteins (n=8) whose expression was significantly changed in the 
hippocampus of C57BL/6J mice 7 days after administration of vehicle (distilled 
water) followed by 1400W, when compared to hippocampi of mice that received 
distilled water alone (n=4 per group). Homogenised hippocampal tissues were 
analysed using liquid chromatography mass spectrometry, and proteins identified 
based on the peptide sequences detected and queried through Mascot. Results are 
ranked in the order of p-value (lowest to highest), with percentage change in 
expression indicated (a negative percentage change represents a down-
regulation). Statistical significance (p<0.05) was determined by one-way Analysis 
of Variance with Bonferroni correction for multiple comparisons.    
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The effect of kainic acid in drug treated mice 
A total of 38 proteins showed significantly altered expression in the hippocampus 
when comparing mice that received KA plus PSD95BP and those that received 
PSD95BP alone. P-values for those proteins ranged from 1.65 × 10-4 to 3.91 × 10-2 
(Table 5.5).  A total of 41 proteins showed significantly altered expression in the 
hippocampus when comparing mice that received KA plus 1400W and those that 
received 1400W alone. P-values for those proteins ranged from 2.33 × 10-5 to 3.86 
× 10-2 (Table 5.6).   
 
The effect of drug interventions in kainic acid treated mice 
A total of 31 proteins showed significantly altered expression in the hippocampus 
when comparing mice that received KA plus PSD95BP and those that received KA 
alone. P-values for those proteins ranged from 1.70 × 10-3 to 3.78 × 10-2 (Table 
5.7).  A total of 36 proteins showed significantly altered expression in the 
hippocampus when comparing mice that received KA plus 1400W and those that 
received KA alone. P-values for those proteins ranged from 1.94 × 10-5 to 3.88 × 10-
2 (Table 5.8).   
 
 
5.3.3. Heatmap visualisation 
Protein quantification using heat map visualisation was based on the detected 
peak areas of the top three unique peptide ratios calculated from the raw MS/MS 
data.  The peak area is illustrated in a spectrum from red to black to green.  
Average peak areas are shown in black, whilst smaller peak areas are shown in 
green and larger peak areas are shown in red.  The gradation of the change in peak 
areas is indicated by the intensity of the green or red colour. 
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Rank Protein P-value % change 
1 Glutathione S-transferase Mu 5 (Fragment) 1.65×10-4 -17% 
2 Glutamine synthetase 9.64×10-4 -16% 
3 Vimentin 9.68×10-4 100% 
4 Angiotensin 1 converting enzyme (Peptidyl-dipeptidase(A) 1 2.02×10-3 62% 
5 Phospholemman 2.42×10-3 31% 
6 Reticulon-4 (RTN4) 2.83×10-3 -25% 
7 Nucleoside diphosphate kinase A 4.52×10-3 14% 
8 DEAH (Asp-Glu-Ala-His) box polypeptide 15, isoform CRA_a 4.68×10-3 28% 
9 Protein Spnb1 (Beta-I spectrin) 5.60×10-3 -15% 
10 Glial fibrillary acidic protein  8.80×10-3 105% 
11 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial 9.72×10-3 27% 
12 Rbp1 protein 1.34×10-2 37% 
13 Heat shock 70kD protein 5 (Glucose-regulated protein) 1.35×10-2 14% 
14 Sodium- and chloride-dependent GABA transporter 1 1.43×10-2 -12% 
15 Gamma-aminobutyric acid receptor subunit beta-1 1.55×10-2 -21% 
16 Keratin, type II cytoskeletal 5 1.76×10-2 -66% 
17 Dehydrogenase/reductase SDR family  member 1 2.41×10-2 43% 
18 Podoplanin 2.47×10-2 77% 
19 Calponin-3 2.50×10-2 53% 
20 Heat shock protein HSP 90-beta 2.54×10-2 14% 
21 Barrier-to-autointegration factor 2.54×10-2 16% 
22 S100 calcium binding protein A13 2.58×10-2 29% 
23 CaM kinase-like vesicle-associated protein 2.61×10-2 -12.43 
24 Eukaryotic translation initiation factor 2, subunit 3, structural 
gene X-linked 
2.74×10-2 10% 
25 Peripheral plasma membrane protein CASK 2.76×10-2 -10% 
26 Ribonuclease inhibitor 2.81×10-2 28% 
27 S100 protein, beta polypeptide, neural, isoform CRA_b 2.83×10-2 36% 
28 Uncharacterised protein (Fragment) F6QH50 2.85×10-2 -20% 
29 Complement C1q subcomponent subunit B 2.86×10-2 38% 
30 Moesin 2.87×10-2 52% 
31 Uncharacterised protein (Fragment) F8WHU8 2.87×10-2 17% 
32 Probable cationic amino acid transporter 3.00×10-2 11% 
33 Hspb1 protein 3.16×10-2 140% 
34 Short coiled-coil protein 3.36×10-2 40% 
35 Small nuclear ribonucleoprotein Sm D3 3.38×10-2 7% 
36 NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 
7 
3.70×10-2 -7% 
37 Clusterin 3.76×10-2 40% 
38 Potassium inwardly-rectifying channel J3 3.91×10-2 -16% 
 
Table 5.5. Proteins (n=38) whose expression was significantly changed in the 
hippocampus of C57BL/6J mice 7 days after administration of kainic acid followed 
by PSD95BP, when compared to hippocampi of mice that received PSD95BP alone 
(n=4 per group). Homogenised hippocampal tissues were analysed using liquid 
chromatography mass spectrometry, and proteins identified based on the peptide 
sequences detected and queried through Mascot. Results are ranked in the order of 
p-value (lowest to highest), with percentage change in expression indicated (a 
negative percentage change represents a down-regulation). Statistical significance 
(p<0.05) was determined by one-way Analysis of Variance with Bonferroni 
correction for multiple comparisons.   
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Rank Protein P-value % change 
1 Cystatin C 2.33×10-5 28% 
2 Moesin 1.82×10-3 91% 
3 Rbp1 protein 1.98×10-3 41% 
4 Glutamine synthetase 2.04×10-3 -15% 
5 BolA-like protein 1 2.13×10-3 -18% 
6 Corticosteroid 11-beta-dehydrogenase isozyme 1 (Fragment) 2.51×10-3 -66% 
7 Glial fibrillary acidic protein 2.70×10-3 116% 
8 Complement C1q subcomponent subunit C 4.68×10-3 46% 
9 Peroxisomal acyl-coenzyme A oxidase 1 4.76×10-3 66% 
10 Complement C1q subcomponent subunit B 5.08×10-3 42% 
11 NADH dehydrogenase [ubiquinone] flavoprotein 1, 
mitochondrial 
5.52×10-3 10% 
12 Cytosolic 10-formyltetrahydrofolate dehydrogenase 6.20×10-3 26% 
13 Alanine aminotransferase 1 6.88×10-3 -32% 
14 Uncharacterised protein putative 8.44×10-3 -16% 
15 Heterogeneous nuclear ribonucleoprotein A1 8.76×10-3 17% 
16 Glycoprotein m6a, isoform CRA_b 9.52×10-3 -13% 
17 Vimentin 1.02×10-2 114% 
18 Peroxisomal multifunctional enzyme type 2 1.06×10-2 20% 
19 Galectin-1 1.16×10-2 77% 
20 Phytanoyl-CoA hydroxylase-interacting protein 1.24×10-2 -17% 
21 CD44 antigen 1.28×10-2 211% 
22 Ras-related protein Rab-8B 1.30×10-2 -15% 
23 Uncharacterised protein E9PWP6 1.50×10-2 -212% 
24 Ribosomal protein 1.56×10-2 6% 
25 Acetyl-CoA acetyltransferase, cytosolic 1.71×10-2 30% 
26 UPF0160 protein MYG1, mitochondrial (Fragment) 1.77×10-2 173% 
27 CaM kinase-like vesicle-associated protein 1.93×10-2 -17% 
28 Calmodulin 1.95×10-2 -9% 
29 Uncharacterised -protein Yjefn3 (Fragment) 2.16×10-2 -51% 
30 Microtubule-associated serine/threonine-protein kinase 3 2.18×10-2 -13% 
31 Catalase 2.24×10-2 24% 
32 Cannabinoid receptor 1 (Brain) 2.30×10-2 -30% 
33 S100 calcium binding protein A13 2.34×10-2 19% 
34 Dgkh protein 2.35×10-2 -32% 
35 Alpha globin 1 2.76×10-2 33% 
36 G protein-regulated inducer of neurite outgrowth 1 3.17×10-2 -11% 
37 Acidic leucine-rich nuclear phosphoprotein 32 family member B 3.51×10-2 47% 
38 RTN4 3.59×10-2 -27% 
39 Tial1 cytotoxic granule-associated RNA binding protein-like 1, 
isoform CRA_c 
3.60×10-2 13% 
40 Neuroligin-2 3.64×10-2 -22% 
41 Kalirin 3.86×10-2 -44% 
 
Table 5.6. Proteins (n=41) whose expression was significantly changed in the 
hippocampus of C57BL/6J mice 7 days after administration of kainic acid followed 
by 1400W, when compared to hippocampi of mice that received 1400W alone (n=4 
per group). Homogenised hippocampal tissues were analysed using liquid 
chromatography mass spectrometry, and proteins identified based on the peptide 
sequences detected and queried through Mascot. Results are ranked in the order of 
p-value (lowest to highest), with percentage change in expression indicated (a 
negative percentage change represents a down-regulation). Statistical significance 
(p<0.05) was determined by one-way Analysis of Variance with Bonferroni 
correction for multiple comparisons.    
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Rank Protein P-value % change 
1 Phosphatidate cytidylyltransferase 1 1.70×10-3 -38% 
2 Gene model 1604B, (NCBI) 2.66×10-3 235% 
3 Basigin 3.73×10-3 -18% 
4 Angiotensin 1 converting enzyme (Peptidyl-dipeptidase(A) 1 4.36×10-3 146% 
5 Putative ATP-dependent Clp protease proteolytic subunit, 
mitochondrial 
4.88×10-3 17% 
6 Glycylpeptide N-tetradecanoyltransferase 7.12×10-3 -15% 
7 Synaptic vesicle membrane protein VAT-1 homolog-like 8.32×10-3 94% 
8 Nitric oxide synthase, brain 8.92×10-3 43% 
9 Potassium inwardly-rectifying channel J3 9.76×10-3 -22% 
10 Mammalian ependymin-related protein 1 1.42×10-2 22% 
11 Proline-rich AKT1 substrate 1 (Fragment) 1.49×10-2 -18% 
12 Sideroflexin-5 1.50×10-2 -12% 
13 CAP-Gly domain-containing linker protein 2 1.56×10-2 -47% 
14 Ataxin-2-like protein 1.64×10-2 -37% 
15 Proprotein convertase subtilisin/kexin type 1 inhibitor 1.64×10-2 44% 
16 Alpha-adducin 1.68×10-2 -24% 
17 Protein kinase C beta type 1.80×10-2 -17% 
18 Calbindin-28K 1.84×10-2 52% 
19 Integral membrane protein 2B 2.07×10-2 -21% 
20 Acyl-CoA thioesterase 11 2.10×10-2 -26% 
21 Small nuclear ribonucleoprotein-associated protein 2.30×10-2 -19% 
22 BTB/POZ domain-containing protein 17 2.62×10-2 -18% 
23 Putative uncharacterised protein 2.63×10-2 -20% 
24 Somatostatin 2.66×10-2 72% 
25 Protein Dos 2.67×10-2 50% 
26 Cytochrome b-c1 complex subunit 10 2.96×10-2 -17% 
27 Neural visinin-like type 1 protein 3.00×10-2 -12% 
28 Long-chain-fatty-acid--CoA ligase 3 3.08×10-2 -13% 
29 Copine-2 3.28×10-2 119% 
30 Plasma membrane calcium-transporting ATPase 2 3.59×10-2 -14% 
31 Nuclear protein localisation protein 4 homolog 3.78×10-2 38% 
 
Table 5.7. Proteins (n=31) whose expression was significantly changed in the 
hippocampus of C57BL/6J mice 7 days after administration of kainic acid followed 
by PSD95BP, when compared to hippocampi of mice that received KA alone (n=4 
per group). Homogenised hippocampal tissues were analysed using liquid 
chromatography mass spectrometry, and proteins identified based on the peptide 
sequences detected and queried through Mascot. Results are ranked in the order 
of p-value (lowest to highest), with percentage change in expression indicated (a 
negative percentage change represents a down-regulation). Statistical significance 
(p<0.05) was determined by one-way Analysis of Variance with Bonferroni 
correction for multiple comparisons.    
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Rank Protein P-value % change 
1 Src substrate cortactin 1.94×10-5 -12% 
2 Sideroflexin-1 2.33×10-3 15% 
3 Acid ceramidase 2.99×10-3 63% 
4 Ataxin-10 5.20×10-3 39% 
5 Basigin 6.32×10-3 -17% 
6 CAP-Gly domain containing linker protein 2 6.60×10-3 -47% 
7 Albumin 1 6.68×10-3 69% 
8 Prosaposin, isoform CRA_e 7.72×10-3 79% 
9 Ferritin heavy chain 9.40×10-3 17% 
10 G protein-regulated inducer of neurite outgrowth 1 1.26×10-2 -14% 
11 Myosin-11 1.35×10-2 85% 
12 Tubulointerstitial nephritis antigen-like 1 1.39×10-2 29% 
13 Quinone oxidoreductase-like protein 2 1.46×10-2 90% 
14 Protein kinase, cAMP dependent regulatory, type II alpha 1.49×10-2 16% 
15 MCG5603 1.72×10-2 -31% 
16 Protein Gm8994 1.72×10-2 33% 
17 Peroxisomal acyl-coenzyme A oxidase 1 1.82×10-2 24% 
18 Uncharacterised protein (putative) 1.96×10-2 -21% 
19 Protein SOGA3 1.98×10-2 -11% 
20 D-dopachrome tautomerase 1.99×10-2 -33% 
21 Signal peptidase complex subunit 2 2.06×10-2 -30% 
22 NADH-ubiquinone oxidoreductase chain 1 2.18×10-2 33% 
23 Acetyl-CoA acetyltransferase, cytosolic 2.33×10-2 29% 
24 Glutamate [NMDA] receptor subunit epsilon-1 2.56×10-2 -23$% 
25 Integral membrane protein 2B 2.59×10-2 -13% 
26 Folh1 protein 2.70×10-2 23% 
27 Echinoderm microtubule-associated protein-like 2 2.81×10-2 36% 
28 MCG5232 3.00×10-2 83% 
29 Immunity-related GTPase family Q protein 3.14×10-2 -27% 
30 Presequence protease, mitochondrial 3.14×10-2 18% 
31 Synaptic vesicle membrane protein VAT-1 homolog-like 3.21×10-2 95% 
32 Metallothionein 3.29×10-2 -16% 
33 Phospholipase D3 3.36×10-2 -18% 
34 Small ubiquitin-related modifier 2 3.44×10-2 -14% 
35 Alpha globin 1 3.72×10-2 63% 
36 Protein Pzp 3.88×10-2 123% 
 
Table 5.8. Proteins (n=36) whose expression was significantly changed in the 
hippocampus of C57BL/6J mice 7 days after administration of kainic acid followed 
by 1400W, when compared to hippocampi of mice that received KA alone (n=4 per 
group). Homogenised hippocampal tissues were analysed using liquid 
chromatography mass spectrometry, and proteins identified based on the peptide 
sequences detected and queried through Mascot. Results are ranked in the order of 
p-value (lowest to highest), with percentage change in expression indicated (a 
negative percentage change represents a down-regulation). Statistical significance 
(p<0.05) was determined by one-way Analysis of Variance with Bonferroni 
correction for multiple comparisons. 
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In the PSD95BP analysis, a total of 20 proteins were shortlisted using heat map 
visualisation. The peak areas of the majority of these proteins were increased 
following KA-induced seizures, whereas those that received vehicle rather than KA 
had peak areas that were typically lower than average (Figure 5.1). Administration 
of PSD95BP led to an increase in peak area for a number of proteins, in comparison 
to controls that received vehicle alone (Figure 5.1). When PSD95BP was given to 
animals that had previously experienced KA-induced seizures, the increase in peak 
areas was compounded and was consistent with an additive effect of the two 
compounds given alone (Figure 5.1). 
 
In the 1400W analysis, a total of 22 proteins were shortlisted using heat map 
visualisation. As in the PSD95BP analysis, KA administration increased peak areas 
of the majority of proteins, while the corresponding vehicle treatment had the 
opposite effect (Figure 5.2). Likewise, treatment with 1400W increased the peak 
areas of several proteins when compared to vehicle-only controls and had an 
additive effective, in terms of numbers of proteins with increased peak area, when 
given to animals that had previously received KA (Figure 5.2).   
 
5.3.4. Protein-protein interactions mapping 
The first 3 proteins with the most significant changes between treatment groups, 
based on the relative quantitative analysis shown in section 5.3.2, were used for 
the protein-protein interactions mapping. 
 
The effect of kainic acid alone 
The three proteins with the lowest p-values in the analysis of hippocampal 
proteomes between KA and corresponding vehicle-treated animals were 
complement C1q subcomponent subunit B, galectin-1 and moesin (Table 5.2). 
Complement component 1 q subcomponent β subunit largely interacts with other 
complement component 1 subcomponents (Figure 5.3A).  Galectin-1 has greatest 
interaction with neuroblastoma ras oncogene compared to the other functional 
partners (Figure 5.3B).  Moesin has the greatest interaction with rho-associated 
coiled-coil containing protein kinase 2 compared to the other functional partners 
(Figure 5.3C).   
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Figure 5.1.  A heat map display comparing the difference in protein quantification between the hippocampi of vehicle and kainic acid (KA)-
treated C57BL/6J mice at 7 days, with or without the subsequent administration of post-synaptic density 95 blocking peptide (PSD95BP) 
(n=4).  Homogenised hippocampal tissues were analysed using liquid chromatography mass spectrometry and protein quantification was 
based on the detected peak areas of the top-3 unique peptide ratios calculated from raw tandem mass spectrometry data.  The horizontal axis 
shows the sample names per treatment group (vehicle samples: M77, M78, M83 and M84; KA samples: M73, M74, M76 and M85; vehicle + 
PSD95BP samples: M1, M2, M3 and M4; KA + PSD95BP samples: M11, M12, M14 and M13).  The vertical axis shows the peaks of the protein 
with unique peptides identified.  The raw data were filtered to a retention time range of 0-270s for each sample and the cut-off value for the 
peptide feature statistical significance was p<0.01.  Average peak areas are shown in black, peak areas lower than the average are shown in 
green and those larger than average are shown in red. 
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Figure 5.2.  A heat map display comparing the difference in protein quantification between the hippocampi of vehicle and kainic acid (KA)-
treated C57BL/6J mice at 7 days, with or without the subsequent administration of 1400W (n=4).  Homogenised hippocampal tissues were 
analysed using liquid chromatography mass spectrometry and protein quantification was based on the detected peak areas of the top-3 
unique peptide ratios calculated from raw tandem mass spectrometry data.  The horizontal axis shows the sample names per treatment 
group (vehicle samples: M77, M78, M83 and M84; KA samples: M73, M74, M76 and M85; vehicle + 1400W samples: M113, M115, M116 and 
M117; KA + 1400W samples: M96, M97, M98 and M99).  The vertical axis shows the peaks of the protein with unique peptides identified.  The 
raw data were filtered to a retention time range of 0-270s for each sample and the cut-off value for the peptide feature statistical significance 
was p<0.01.  Average peak areas are shown in black, peak areas lower than the average are shown in green and those larger than average are 
shown in red. 
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The effect of PSD95BP alone 
The three most significantly changed proteins in the analysis of hippocampal 
proteomes between PSD95BP and corresponding vehicle-treated animals were Ras 
homologous (Rho) guanine nucleotide exchange factor 2, protein 
farnesyltransferase subunit β and DNA topoisomerase 2-β (Table 5.3).  Rho 
guanine nucleotide exchange factor 2 has more evident interactions with RAS-
related C3 botulinum substrate 1, Rho gene family member B and cell division 
cycle 42 homolog compared to the other functional partners (Figure 5.4A).  Protein 
farnestyltransferase subunit B has the greatest interaction with protein 
farnestyltransferase subunit A (Figure 5.4B).  DNA topoisomerase II β and all its 
functional partners, except for DNA topoisomerase II α, interact closely with one 
another (Figure 5.4C).  The functional partners for DNA topoisomerase II β include 
bromodomain adjacent to zinc finger 1B, SWI/SNF related, matrix associated, actin 
dependent regulator of chromatin, subfamily c, member 1; subfamily a, member 2; 
subfamily d, member 3; subfamily a, member 4, AT rich interactive domain 1A; 1B, 
actin-like 6A, PHD finger protein 10 (Figure 5.4C).   
 
The effect of 1400W alone 
The three proteins with the lowest p-values in the analysis of hippocampal 
proteomes between 1400W and corresponding vehicle-treated animals were 3’-
phosphoadenosine 5’-phosphosulphate synthase 1, protein kinase C/casein kinase 
substrate in neurons 2 and glycine cleavage system H protein (Table 5.4). 3’-
phosphoadenosine 5’-phosphosulphate synthase 1 has the greatest interaction 
with 3’-phosphoadenosine 5’-phosphosulphate synthase 2 (Figure 5.5A).  Protein 
kinase C and casein kinase substrate in neurons 2 has the most evident 
interactions with 3’-phosphoadenosine 5’-phosphosulphate synthase 1 and 
dynamin 2 (Figure 5.5B).  Glycine cleavage system protein H interacts mostly with 
glycine decarboxylase, aminomethyltransferase, serine hydroxymethyltransferase 
1, sarcosine dehydrogenase and dimethylglycine dehydrogenase (Figure 5.5C).   
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Figure 5.3. Network representations of the top 3 most significantly affected proteins in the hippocampus of 
C57BL/6J mice following administration of kainic acid or corresponding vehicle, with known or predicted 
protein interactions with other functional partners plotted by Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING).  In this view, the number of different coloured lines represents the number of 
different types of evidence for the association.(A) Complement component 1 q subcomponent, beta subunit 
(C1qb) with functional partners including complement component 1, q subcomponent, α polypeptide (C1qa); 
C chain (C1qc); r subcomponent A (C1ra); s subcomponent (C1s), immunoglobulin heavy chain, γ polypeptide 
(Ighg), serine (or cysteine) peptidase inhibitor, clade G, member 1 (Serping1), lymphocyte antigen 86 (Ly86), 
TYRO protein tyrosine kinase binding protein (Tyrobp); predicted gene 5077 (Gm5077) and Fc receptor, IgG, 
low affinity III (Fcgr3). (B) Galectin-1 (Lgals1) with functional partners including Harvey rat sarcoma virus 
oncogene 1 (Hras1), neuroblastoma ras oncogene (Nras), gem (nuclear organelle) associated protein 4 
(Gemin4), CD7 antigen (Cd7), brain expressed X-linked 2 (Bex2), thymine DNA glycosylase (Tdg), S100 
calcium binding protein A6 (calcyclin) (S100a6), vimentin (Vim), annexin A2 (Anxa2) and POU domain, class 
2, associating factor 1 (Pou2af1). (C) Moesin (Msn) with functional partners including solute carrier 9 
(sodium/hydrogen exchanger), member 3 regulator 1 (Slc9a3r1), Rho-associated coiled-coil containing 
protein kinase 2 (Rock2), CD44 antigen (Cd44), vascular cell adhesion molecule 1 (Vcam1), Rho GDP 
dissociation inhibitor (GDI) alpha (Arhgdia), intercellular adhesion molecule 5 (Icam5), sialophorin (Spn), 
Rho-associated coiled-coil containing protein kinase 1 (Rock1), intercellular adhesion molecule 1 (Icam1) and 
RAS-related C3 botulinum substrate 1 (Rac1).    
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Figure 5.4. Network representations of the top 3 most significantly affected proteins in the hippocampus of 
C57BL/6J mice following the administration of post-synaptic density 95 blocking peptide or corresponding 
vehicle, with known or predicted protein interactions with other functional partners plotted by Search Tool 
for the Retrieval of Interacting Genes/Proteins (STRING).  In this view, the number of different coloured lines 
represents the number of different types of evidence for the association.(A) Rho guanine nucleotide exchange 
factor 2 (Arhgef2) with functional partners: RAS-related C3 botulinum substrate 1 (Rac1); 2 (Rac2); 3 (Rac3), 
ras homolog, member B (Rhob), cell division cycle 42 (Cdc42), Rac GTPase-activating protein 1 (Racgap1), 
glucocorticoid receptor DNA binding factor 1 (Grlf1), Rho-associated coiled-coil containing protein kinase 2 
(Rock2); 1 (Rock1), active BCR-related gene (Abr). (B) Protein farnesyltransferase subunit beta (Fntb) with 
functional partners: protein farnesyltransferase subunit a (Fnta), Rab geranylgeranyl transferase a subunit 
(Rabggta), 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (Hmgcr), nonagouti (a), clathrin (Cltc), protein 
tyrosine phosphatase 4a3 (Ptp4a3), nucleosome assembly protein 1-like 4 (Nap1l4); 1 (Nap1l1). (C) DNA 
topoisomerase II beta (Top2b) with functional partners: bromodomain adjacent to zinc finger 1B (Baz1b), 
topoisomerase (DNA) II alpha (Top2a), SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily c, member 1 (Smarcc1); subfamily a, member 2 (Smarca2); subfamily d, member 3 
(Smarcd3); subfamily a, member 4 (Smarca4), AT rich interactive domain 1A (Arid1a); 1B (Arid1b), actin-like 
6A (Actl6a), PHD finger protein 10 (Phf10).  
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Figure 5.5. Network representations of the top 3 most significantly affected proteins in the hippocampus of C57BL/6J 
mice following the administration of 1400W or corresponding vehicle, with known or predicted protein interactions 
with other functional partners plotted by Search Tool for the Retrieval of Interacting Genes/Proteins (STRING).  In 
this view, the number of different coloured lines represents the number of different types of evidence for the 
association.(A) 3'-phosphoadenosine 5'-phosphosulphate synthase 1 (Papss1) with functional partners: 3'-
phosphoadenosine 5'-phosphosulphate synthase 2 (Papss2), Sulfite oxidase (Suox), carbohydrate sulfotransferase 11 
(Chst11); 13 (Chst13), biphosphate 3’-nucleotidase 1 (Bpnt1), sulfotransferase family 1E member 1 (Sult1e1); 2B 
member 1 (Sult2b1); 1A member 1 (Sult1a1), ectonucleotide pyrophosphatase/phosphodiesterase 1 (Enpp1); 3 
(Enpp3).(B) protein kinase C and casein kinase substrate in neurons 2 (Pacsin2) with functional partners: EH-
domain containing 2 (Ehd2); 3 (Ehd3), protein tyrosine phosphatase non-receptor type 18 (Ptpn18), dynamin 2 
(Dnm2); 3 (Dnm3), protein kinase C and casein kinase substrate in neurons 1 (Pacsin1), Wiskott-Aldrich syndrome-
like (Wasl), patched domain containing 3 (Ptchd3), synaptojanin 1 (Synj1), Fas ligand (TNF family, member 6) 
(Fasl).(C) Glycine cleavage system protein H (Gcsh) with functional partners: aminomethyltransferase (Amt), glycine 
decarboxylase (Gldc), lipoyltransferase 1 (Lipt1), sarcosine dehydrogenase (Sardh), RIKEN cDNA (Pdpr), 
dimethylglycine dehydrogenase (Dmgdh), serine hydroxymethyltransferase 1 (Shmt1), NADH dehydrogenase 1 
alpha/beta subcomplex 1 (Ndufab1), phosphoribosyl-aminoimidazole carboxylase, phosphoribosylaminoribosyl-
aminoimidazole, succinocarboxamide synthetase (Paics), glutathione synthetase (Gss).   
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The effect of kainic acid in PSD95BP-treated mice  
The three most significantly changed proteins in the analysis of hippocampal 
proteomes between PSD95BP-treated animals that had previously received KA or 
its corresponding vehicle were glutathione S-transferase, glutamine synthetase 
and vimentin (Table 5.5).  Glutathione S-transferase mu 5 largely interacts with 
other glutathione S-transferase isoforms (Figure 5.6A).  Glutamine synthetase has 
more interactions with glutaminase and glutaminase 2 than other functional 
partners (Figure 5.6B).  Vimentin has the most evident interactions with caspase 6 
and 8 (Figure 5.6C).   
 
The effect of kainic acid in 1400W-treated mice  
The three proteins with the lowest p-values in the analysis of hippocampal 
proteomes between 1400W-treated animals that had previously received KA or its 
corresponding vehicle were cystatin C, moesin and retinol binding protein 1 (rbp1) 
protein (Table 5.6). Cystatin C interacts closely with all its functional partners and 
each partner interacts with one another (Figure 5.7A).  The functional partners for 
cystatin C include transthyretin, integral membrane protein 2B, amyloid β (A4) 
precursor protein, gelsolin, β-2 microglobulin, apolipoprotein A-I, 
calcitonin/calcitonin-related polypeptide α, milk fat globule-EGF factor 8 protein, 
lactotransferrin, prolactin (Figure 5.7A).  Moesin has the greatest interaction with 
rho-associated coiled-coil containing protein kinase 2 compared to the other 
functional partners (Figure 5.7B).  Rbp1 has more interactions with lecithin-retinol 
acyltransferase, EIA binding protein p300 and retinoic acid receptor α than other 
functional partners (Figure 5.7C).   
 
The effect of PSD95BP in kainic acid treated mice 
The three most significantly changed proteins in the analysis of hippocampal 
proteomes between KA-treated animals that subsequently received PSD95BP or its 
corresponding vehicle were phosphotidate cytidylyltransferase 1, gene model 
1604B, and basigin (Table 5.7). Phosphatidate cytidylyltransferase 1 interacts with 
all its functional partners equally (Figure 5.8A).  Gene model 1604B also interacts 
with all its functional partners equally (Figure 5.8B).  These functional partners 
include gene model 1381, REV1 homolog and secretory carrier membrane protein 
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4 (Figure 5.8B).  Basigin has the most evident interaction with solute carrier family 
16 (Figure 5.8C).   
 
The effect of 1400W in kainic acid treated mice 
The three proteins with the lowest p-values in the analysis of hippocampal 
proteomes between KA-treated animals that subsequently received 1400W or its 
corresponding vehicle were src substrate cortactin, sideroflexin-1 and acid 
ceramidase (Table 5.8). Substrate cortactin has the greatest interactions with 
dynamin 1 compared to the other functional partners (Figure 5.9A).  Sideroflexin 1 
is only functionally interacting with solute carrier family 25 (Figure 5.9B).  Acid 
cerimidase TBC1 domain family member 10c has the greatest interactions with 
DENN/mitogen-activated-protein-kinase activating death domain (MADD) domain 
containing 1C compared to the other functional partners (Figure 5.9C).   
 
5.4. Discussion 
 
A proteomic approach was used to investigate the effects of KA in the hippocampus 
of C57BL/6J mice and the effects of drug interventions, PSD95BP or 1400W, when 
administered after KA-induced seizures.  The results from the overall percentage 
of proteins affected between treatment groups and the heat map visualisation 
showed that the greatest changes in protein expression in the hippocampus 
occurred after KA (Table 5.1, Figures 5.1 and 5.2).  Previous proteomics studies 
using 2D gel quantification have shown that KA-induced seizures significantly 
affect the expression of 19 proteins in the rat brain (Krapfenbauer et al., 2001b).  
PSD95BP or 1400W alone caused changes to only a small number of proteins in 
the hippocampus, although the number of proteins affected was increased when 
the drug interventions were given after mice had KA-induced seizures (Table 5.1).  
The fewer number of proteins significantly affected in vehicle pre-treated mice 
suggest that the drug interventions have lesser impact on protein levels in normal 
hippocampus compared to one that has been challenged with KA.  The proteins 
that were selectively affected by drug treatment in animals that had previously 
been treated with KA might represent those are activated in an effort to protect 
against the brain insult.  
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Figure 5.6. Network representations of the top 3 most significantly affected proteins in the 
hippocampus of post-synaptic density 95 blocking peptide treated C57BL/6J mice treated, 
comparing those that had previously received kainic acid or its corresponding vehicle, with known 
or predicted protein interactions with other functional partners plotted by Search Tool for the 
Retrieval of Interacting Genes/Proteins (STRING).  In this view, the number of different coloured 
lines represents the number of different types of evidence for the association.(A) Glutathione S-
transferase Mu 5 (Gstm5) with functional partners: glutathione S-transferase theta 2 (Gstt2); theta 
1 (Gstt1); Mu 7 (Gstm7); omega 1 (Gsto1); zeta 1 (Gstz1); kappa 1 (Gstk1), microsomal glutathione 
S-transferase 1 (Mgst1); 2 (Mgst2), glutathione synthetase (Gss), cytochrome P450 family 2 
subfamily b polypeptide 19 (Cyp2b19). (B) Glutamine synthetase (Glul) with functional partners: 
carbamoyl-phosphate synthetase 1 (Cps1), solute carrier family 38 member 1 (Slc38a1), glutamic 
acid decarboxylase 1 (Gad1); 2 (Gad2), glutamate dehydrogenase 1 (Glud1), glutaminase (Gls); 2 
(Gls2), histidine ammonia lyase (Hal), asparagine synthetase (Asns), aldehyde dehydrogenase 4 
family member A1 (Aldh4a1).(C) Vimentin (Vim) with functional partners: caspase 6 (Casp6); 8 
(Casp8), plectin 1 (Plec1), thymoma viral proto-oncogene 1 (Akt1), nebulin (Neb), dystrophin 
muscular dystrophy (Dmd), cadherin 2 (Cdh2), tropomodulin 1 (Tmod1), desmin (Des), titin-cap 
(Tcap).    
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Figure 5.7. Network representations of the top 3 most significantly affected proteins in the hippocampus of 1400W 
treated C57BL/6J mice treated, comparing those that had previously received kainic acid or its corresponding 
vehicle, with known or predicted protein interactions with other functional partners plotted by Search Tool for the 
Retrieval of Interacting Genes/Proteins (STRING).  In this view, the number of different coloured lines represents the 
number of different types of evidence for the association.(A) Cystatin C (Cst3) with functional partners: transthyretin 
(Ttr), integral membrane protein 2B (Itm2b), amyloid beta (A4) precursor protein (App), gelsolin (Gsn), beta-2 
microglobulin (B2m), apolipoprotein A-I (Apoa1), calcitonin/calcitonin-related polypeptide, alpha (Calca), milk fat 
globule-EGF factor 8 protein (Mfge8), lactotransferrin (Ltf), prolactin (Prl).(B) Moesin (Msn) with functional 
partners: solute carrier 9 (sodium/hydrogen exchanger), member 3 regulator 1 (Slc9a3r1), Rho-associated coiled-
coil containing protein kinase 2 (Rock2); CD44 antigen (Cd44); vascular cell adhesion molecule 1 (Vcam1); Rho GDP 
dissociation inhibitor (GDI) alpha (Arhgdia); intercellular adhesion molecule 5 (Icam5); sialophorin (Spn); Rho-
associated coiled-coil containing protein kinase 1 (Rock1); intercellular adhesion molecule 1 (Icam1); RAS-related C3 
botulinum substrate 1 (Rac1). (C) Retinol binding protein 1 (Rbp1) with functional partners: arginyl-tRNA 
synthetase (Rars), lecithin-retinol acyltransferase (Lrat), biogenesis of lysosome-related organelles complex-1 
(Rdh5), E1A binding protein p300 (Ep300), thymine DNA glycosylase (Tdg), aldehyde dehydrogenase family 1 
subfamily A2 (Aldh1a2), retinoic acid receptor alpha (Rara), carnitine palmitoyltransferase 1a (Cpt1a), retinaldehyde 
binding protein 1 (Rlbp1), retinol binding protein 4 (Rbp4).  
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Figure 5.8. Network representations of the top 3 most significantly affected proteins in the 
hippocampus of kainic acid treated C57BL/6J mice treated, comparing those that subsequently 
received post-synaptic density 95 blocking peptide or its corresponding vehicle, with known or 
predicted protein interactions with other functional partners plotted by Search Tool for the 
Retrieval of Interacting Genes/Proteins (STRING).  In this view, the number of different coloured 
lines represents the number of different types of evidence for the association.(A) Phosphatidate 
cytidylyltransferase 1 (Cds1) with functional partners: 1-acylglycerol-3-phosphate O-
acyltransferase 1 (Agpat1); 2 (Agpat2); 3 (Agpat3); 5 (Agpat5); 6 (Agpat6), 
phosphatidylglycerophosphate synthase 1 (Pgs1), lysocardiolipin acyltransferase 1 (Lclat1), 
cardiolipin synthase 1 (Crls1), membrane bound O-acyltransferase domain containing 2 (Mboat2), 
CDP-diacylglycerol—inositol 3-phosphatidyltransferase (Cdipt). (B) Gene model 1604B (Gm1604b) 
with functional partners: Gene model 1381 (Gm1381), REV1 homolog (Rev1), secretory carrier 
membrane protein 4 (Scamp4). (C) Basigin (Bsg) with functional partners: solute carrier family 16 
member 1 (Slc16a1); member 3 (Slc16a3); member 8 (Slc16a8), peptidylprlyl isomerase-like 2 
(Ppil2), matrix metallopeptidase 1a (Mmp1a); 1b (Mmp1b), caveolin 1 (Cav1), myelin-associated 
glycoprotein (Mag), sialophorin (Spn), L1 cell adhesion molecule (L1cam).  
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Figure 5.9. Network representations of the top 3 most significantly affected proteins in the 
hippocampus of kainic acid treated C57BL/6J mice treated, comparing those that subsequently 
received 1400W or its corresponding vehicle, with known or predicted protein interactions with 
other functional partners plotted by Search Tool for the Retrieval of Interacting Genes/Proteins 
(STRING).  In this view, the number of different coloured lines represents the number of different 
types of evidence for the association.(A) Substrate cortactin (Cttn) with functional partners: Rous 
sarcoma oncogene (Src), dynamin 1 (Dnm1); 2 (Dnm2); 3 (Dnm3); 1-like (Dnm1l), ARP3 actin-
related protein 3 (Actr3), tight junction protein 1 (Tjp1), predicted gene 4802 (Ubc), potassium 
voltage-gated channel shaker-related subfamily member 2 (Kcna2), Wiskott-Aldrich syndrome-like 
(Wasl). (B) Sideroflexin 1 (Sfxn1) with functional partners: solute carrier family 25 member 1 
(Slc25a1). (C) Acid ceramidase TBC1 domain family member 10c (Tbc1d10c). Functional partners: 
DENN/MADD domain containing 1C (Dennd1c); 2a (Dennd2a), TBC1 domain family member 21 
(Tbc1d21), RAB35 member RAS oncogene (Rab35), protein tyrosine phosphatase receptor type C 
polypeptide-associated protein (Ptprcap), small G protein signalling modulator 1 (Sgsm1), RAB42 
member RAS oncogene (Rab42); RAB43 member RAS oncogene (Rab43), CD79B antigen (Cd79b), 
coiled-coil and C2 domain containing 1A (Cc2d1a).    
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Protein-protein interaction mapping was used to estimate the impact on cellular 
function of changes in protein expression for each of the top 3 proteins in each 
analysis using published functional information.  Following KA administration, 
complement component 1q subunit b (C1qb), galectin-1 and moesin were the top 3 
proteins, all of which were up-regulated (Table 5.2 and Figure 5.3). Complement 
component 1q (C1q) interacts closely with other complement component 1 
subcomponents (Figure 5.3A).  C1q plays a key role in the recognition of immune 
complexes (Kishore and Reid, 2000) and the complement system has a role in the 
pathogenesis of neurological disorders (Griffiths et al., 2009; Amor et al., 2010). 
Up-regulation of C1q and other complement subcomponents have been proposed 
to be associated with synaptic remodelling and neuronal loss after the generation 
of an epileptic focus (Ivens et al., 2007). Galectin-1 and its closest functional 
partner, neuroblastoma ras oncogene (Figure 5.3B) regulate cell adhesion, 
proliferation and survival (Bar-Sagi and Feramisco, 1985; Perillo et al., 1998).  
Moesin is a protein that links actin cytoskeleton to the plasma membrane (Ben-
Aissa et al, 2012), and is closely associated with Rho-associated coiled-coil 
containing protein kinase 2 (Rock2) (Figure 5.3C) that is important for cell-cell 
recognition, signalling and cell movement (Wilgenbus et al., 1994).  Rock2 is one of 
two key regulators of actin organisation that regulates cell migration (Riento and 
Ridley, 2003).  From the interaction mapping, it is hypothesised that KA-induced 
seizures can cause synaptic remodelling, neuronal loss, and may also affect the 
immune/inflammatory pathways, actin organisation and various biological 
processes, such as cell adhesion, proliferation and survival.  
 
Following PSD95BP administration, Rho guanine nucleotide exchange factor 2 and 
protein farnestyltransferase subunit B were significantly down-regulated and DNA 
topoisomerase II β was up-regulated (Table 5.3 and Figure 5.4).  Rho guanine 
nucleotide exchange factor 2 is associated with Ras-related C3 botulinum substrate 
1 (Rac1), rho homolog gene family member B (Rhob) and cell division cycle 42 
homolog (Cdc42) (Figure 5.4A).  Guanine nucleotide exchange factors (GEFs) are 
responsible for the activation of rho-family guanosine triphosphate (GTP) 
hydrolase enzymes, GTPases, to regulate cell proliferation, differentiation and 
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migration (Rossman et al., 2005).  The functional partners Rac1, Rhob and Cdc42 
are groups within the rho family (Rossman et al., 2005). Protein 
farnestyltransferase subunit B has a close interaction with its subunit A (Figure 
5.4B).  The enzymes target members of the Ras superfamily of small GTP-binding 
proteins for cell cycle progression and have roles in signal transduction and 
intracellular trafficking pathways (Casey and Seabra, 1996).  DNA topoisomerase II 
β and its functional partners closely interact with one another, except for its α 
isozyme. Both DNA topoisomerase II isozymes can alter DNA topology by 
introducing transient double strand break (Nitiss, 2009). The α isozyme is 
essential for separating replicated chromosomes for all cells, and the β isozyme is 
required for normal development, but dispensable in some cell types (Nitiss, 
2009).  The β isozyme is also important in transcriptional regulation and has a key 
role in the survival of some neural cells. From the interaction mapping, it is 
hypothesised that PSD95BP administration can affect various biological processes 
such as cell proliferation, differentiation, division and migration. It can also affect 
signal transduction, intracellular trafficking pathways and neural cell survival. 
 
Following 1400W administration, 3’-phosphoadenosine 5-‘phosphosulphate 
synthase 1 (Papss1), protein kinase C and casein kinase substrate in neurons 2, 
glycine cleavage system protein H were significantly up-regulated (Table 5.4 and 
Figure 5.5). Papss1 is associated with Papss2 (Figure 5.5A). 3’-phosphoadenosine 
5’-phosphosulphate (Paps) is a sulphate donor for the catalytic reaction of 
sulphotransferase (Xu et al., 2000). Sulphate conjugation is an important pathway 
in the metabolism of exogenous and endogenous compounds, including drugs and 
xenobiotics (Xu et al., 2000). Protein kinase C and casein kinase substrate in 
neurons 2 (PACSIN2) have close interactions with Papss1 and dynamin 2 (Figure 
5.5B). PACSIN2 is a negative regulator of epidermal growth factor receptor 
activation and signalling (de Kreuk et al., 2012), therefore its up-regulation would 
be expected to suppress these processes.  Dynamin 2 is a GTPase responsible for 
endocytosis in most cell types (Diatloff-Zito et al., 1995; Altschuler et al., 1998). 
Glycine cleavage system protein H and many of its functional partners are 
members of the glycine cleavage system (Figure 5.5C). The glycine cleavage 
system, also called the glycine decarboxylase complex, is a series of enzymes that 
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respond to high concentrations of glycine (Kikuchi, 1973; Kikuchi et al., 2008).  The 
functional partners, aminomethyltransferase and glycine decarboxylase are 
proteins within the system and are involved in glycine decarboxylation (Kikuchi, 
1973; Douce et al., 2001; Kikuchi et al., 2008).  The remaining functional partners 
are involved in glycine production (Porter et al., 1985; Stover and Schirch, 1990).  
From the interaction mapping, it is hypothesised that 1400W may exert its effects 
in the hippocampus by modulating the metabolism of exogenous and endogenous 
compounds, epidermal growth factor activation, endocytosis and regulation of 
glycine. 
. 
When PSD95BP was administered to KA-treated animals, phosphotidate 
cytidylyltransferase 1 (Cds1) and basigin were down-regulated, and gene model 
1604B was significantly up-regulated in comparison to control (Table 5.7 and 
Figure 5.8).  Cds1 interacts with all of its functional partners equally (Figure 5.8A) 
and is involved in the regeneration of the signalling molecule phosphatidylinositol-
4,5-bisphosphate from phosphatidic acid to regulate phosphoinositide-mediated 
signalling cascade (Wu et al., 1995).  Gene model 1604b closely interacts with gene 
model 1381, REV1 homolog and secretory carrier membrane protein 4 (Figure 
5.8B).  The functions of gene models 1604b and 1381 are not reported in the 
literature.  REV1 is a DNA repair protein that recruits DNA polymerases to 
damaged DNA (Lawrence, 2002) and secretory carrier membrane protein 4 is an 
integral membrane protein found in mammals that is implicated in membrane 
trafficking (Hubbard et al., 2000).  Basigin is associated with solute carrier family 
16 (Figure 5.8C) and is a receptor for a parasite ligand that is essential for blood 
stage growth (Crosnier et al., 2011).  Solute carrier family 16 is a family of 
monocarboxylate transporters that carries molecules with one carboxylate group 
across biological membranes (Halestrap and Meredith, 2004).  From the 
interaction mapping, it is hypothesised that PSD95BP affects KA-induced seizures 
by regulating the phosphoinositide-mediated signalling cascade, DNA repair, 
membrane trafficking, blood stage growth and amino acid/acidic drug transport.   
 
When 1400W was administered to KA-treated animals, substrate cortactin was 
down-regulated; sideroflexin 1 and acid cerimidase were up-regulated in 
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comparison to control (Table 5.8 and Figure 5.9).  Substrate cortactin is a cortical 
actin binding protein that promotes cell migration and endocytosis (Cosen-Binker 
and Kapus, 2006; Ammer and Weed, 2008).  Its down-regulation suggests 
suppression in cellular development.  Its functional partner, dynamin 1 is a GTPase 
responsible for endocytosis in neurons and neuroendocrine cells (Altschuler et al., 
1998).  Sideroflexin 1 is associated with solute carrier family 25 (Figure 5.9B) but 
its function is unknown (Li et al., 2010).  Solute carrier family 25 is a large family of 
mitochondrial nuclear-encoded transporters that transport an extensive range of 
solutes (Palmieri, 2013).  Acid cerimidase is associated with DENN/MADD domain 
containing 1C (Figure 5.9C) and is a lipid hydrolase that plays a central role in 
sphingolipid metabolism, particularly in regulating the levels of ceramide and 
sphingosine in cells (Park and Schuchman, 2006).  DENN/MADD domain 
containing 1C functions as a GEF for activating the Rab GTPases to regulate cell 
proliferation, differentiation and migration (Marat et al., 2011).  From the 
interaction mapping, it is hypothesised that 1400W affects KA-induced seizures by 
suppressing cell division, endocytosis of neurons and neuroendocrine cells, 
mitochondrial nuclear-encoded transport and sphingolipid metabolism.   
 
The effect of KA significantly down-regulated glutathione S-transferase and 
glutamine synthetase but up-regulated vimentin in PSD95BP treated mice (Table 
5.5).  Glutathione S-transferases are a family of detoxification enzymes that 
catalyse the conjugation of glutathione to a variety of endogenous and exogenous 
compounds (Hayes and Pulford, 1995; Townsend and Tew, 2003).  These enzymes 
have key roles in the metabolism of leukotrienes/prostaglandins, and regulate 
mitogen-activated protein (MAP) kinase pathway responsible for cellular survival 
and death signals (Townsend and Tew, 2003).  Glutamine synthetase plays an 
essential role in catabolising glutamate into glutamine (Norenberg and Martinez-
Hernandez, 1979) and is closely associated with glutaminase (Figure 5.6B), which 
generates glutamate from glutamine (Yudkoff et al., 1988).  Vimentin is a major 
constituent of the intermediate filament family of proteins and is known to 
maintain cellular integrity and resistance against stress (Satelli and Li, 2011).  
Increased vimentin expression has been reported in various injuries, including the 
brain (Lewis and Fisher, 2003; Bryant et al., 2006; Satelli and Li, 2011).  From the 
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interaction mapping, it is hypothesised that KA affects PSD95BP treated mice by 
decreasing detoxification, glutamate/glutamine regulation and increase resistance 
to stress. 
 
The effect of KA significantly up-regulated cystatin C, moesin and retinol binding 
protein 1 in 1400W treated mice (Table 5.6).  Cystatin C is an endogenous cysteine 
protease inhibitor and has been recently shown to have endogenous 
neuroprotective properties in neuronal cells (Watanabe et al., 2014).  Elevation of 
cystatin C is shown to be associated with neuronal death in Alzheimer’s disease 
(Deng et al., 2001).  Moesin, as previously mentioned, is closely associated with 
Rock2 (Figure 5.3) and are both involved with actin organisation (Wilgenbus et al., 
1994) (Riento and Ridley, 2003; Ben-Aissa et al., 2012).  Retinol binding protein 1 
is involved in vitamin A metabolism (Lepreux et al., 2004) and is present within 
the endothelial cells of the BBB (MacDonald et al., 1990).  Increased levels of 
retinol binding protein have been reported in brains of Alzheimer’s disease 
patients (Maury and Teppo, 1987).  From the interaction mapping, it is 
hypothesised that KA affects 1400W treated mice by increasing neuronal death, 
affect actin organisation and vitamin A metabolism.     
 
Moesin is modulated in more than one analysis described in this chapter, lending 
weight to its involvement in the generation of experimental seizures and its 
attenuation by novel NO pathway targeted agents.  Moesin is up-regulated by the 
effects of KA in vehicle-treated mice and in 1400W-treated mice.  Moesin and its 
closest functional partner, Rock2, regulate actin organisation.  It is therefore 
hypothesised that KA affects actin organisation in mice and the administration of 
1400W does not protect against this.  Interaction mapping is unable to hypothesise 
further on the regulation of functional partners, therefore, the effects of KA on the 
expression of Rock2 in the hippocampus will require further investigation. 
 
Using several methods for analysing proteomics data, theoretical conclusions can 
be drawn from changes in the protein profile between treatment groups and from 
protein-protein interaction mapping.  Using qualitative analysis, basic information 
on protein-protein interactions can be integrated with previously published 
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functional information to build hypotheses on the role of proteins within the 
complex biological mechanisms and pathophysiological processes of a disease.  
With the progression of bioinformatics technology, it may be beneficial to use 
more sophisticated bioinformatics tools and databases to analyse the large amount 
of data generated in this chapter.  The use of large-scale technologies for protein 
analysis can contribute to the volume and complexity of the data (Hondermarck, 
2004).  With only a small sample size used in this study, this introduces greater 
variability to the list of proteins expressed in animals within each treatment group.  
Nevertheless, this experiment was conducted as a pilot study to provide insights 
into the changes in hippocampal proteins after the induction of seizures and when 
potential anti-epileptogenic agents were administered.  A follow-up study will be 
required to investigate potential cellular mechanisms that are associated with the 
effects of PSD95BP or 1400W.    
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Chapter 6 
Effects of nitric oxide signalling 
pathway on albumin-mediated 
transforming growth factor β 
signalling pathways during 
epileptogenesis 
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6.1. Introduction 
 
Albumin is the most abundant protein in the blood, constituting 50% of the total 
human plasma protein content (Peters, 1995; Farrugia, 2010).  It is synthesised 
peripherally by the liver and does not readily diffuse across an intact BBB because 
of its size (Blyth et al., 2009; Farrugia, 2010).  The purpose of the BBB is to limit 
the penetration of a variety of substances from the blood into the brain as a 
defence mechanism (Van Vliet et al., 2007).  In pathological conditions, chemical 
mediators are released that increase BBB permeability and therefore the barrier 
becomes dysfunctional (Ballabh et al., 2004).  BBB dysfunction is a hallmark of 
brain insults and has been found to be associated with several neurological 
disorders, including epilepsy (Roch et al., 2002; Seiffert et al., 2004).  BBB 
dysfunction usually occurs around the lesion (Heinemann et al., 2012) with 
epilepsy patients showing increased BBB permeability localised within the 
presumed epileptic focus (Tomkins et al., 2008; 2011).  Albumin is used as a 
biomarker for BBB damage in several models of neuropathological conditions, 
including epilepsy (Bolwig et al., 1977; Seiffert et al., 2004; Van Vliet et al., 2007).  
Although it has not yet been shown whether the extent of BBB dysfunction can 
predict the development of epilepsy in patients (Seiffert et al., 2004; Heinemann et 
al., 2012), animal studies have shown positive correlation between the extent of 
BBB opening and epileptogenesis (Ivens et al., 2007; Tomkins et al., 2007; Van 
Vliet et al., 2007).  It is still unclear, however, whether the increased BBB 
permeability is a result of the disease process, or is a contributor to the 
pathogenesis of the disease (Seiffert et al., 2004; Friedman, 2011).   
 
Several animal models of acute seizures have shown a transient increase in BBB 
permeability after an initial insult (Nitsch and Klatzo, 1983; Pont et al., 1995; Uva 
et al., 2008; Williams et al., 2009).  A number of blood-borne proteins and 
antibodies can enter the brain through the dysfunctional BBB and affect the 
seizure threshold in animals (Van Vliet et al., 2007; Maggio et al., 2008; Blyth et al., 
2009; Vincent et al., 2010).  Of these, extravasation of albumin into brain has been 
the most extensively investigated (Nadal et al., 1995; Ivens et al., 2007; Cacheaux 
et al., 2009; Farrugia, 2010), with studies showing increased brain albumin level in 
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epileptic patients (Mihály and Bozóky, 1984) and in experimental epilepsy models 
(Lassmann et al., 1984; Sokrab et al., 1989).  This chapter focuses on albumin and 
its role in epileptogenesis. 
 
6.1.1. Albumin-mediated effects in the brain 
Extravasation of albumin into the brain activates the TGFβ signalling cascade and 
alters the function of astrocytes (Ivens et al., 2007; Cacheaux et al., 2009; 
Heinemann et al., 2012).  TGFβ is a pleiotropic cytokine that regulates cellular 
proliferation and differentiation, embryonic development, wound healing, immune 
response and apoptosis in a variety of cells (Blobe et al., 2000; Heinemann et al., 
2012).  Changes in production of TGFβ have been linked to the pathogenesis of 
numerous diseases, as well as the altered expression of its receptors and 
associated intracellular signalling molecules (Blobe et al., 2000).  Elevated TGFβ 
levels have been observed in models associated with BBB dysfunction, such as in 
injured neurons from animals that experienced acute brain insult and in astrocytes 
present in the hippocampus of animals that experienced SE (Aronica et al., 2000; 
Zhu et al., 2000; Dohgu et al., 2005).   
 
The effect of albumin on the brain appears to be receptor-mediated (Nadal et al., 
1995).  In the brains of animals with BBB dysfunction, albumin binds to the TGFβ 
receptor (TGFβR) in order to activate TGFβ signalling (Ivens et al., 2007; Cacheaux 
et al., 2009).  There are two types of TGFβRs, TGFβRI and TGFβRII (Heinemann et 
al., 2012); albumin appears to mediate its effects in the brain via uptake into 
astrocytes by TGFβRI (Ivens et al., 2007) and thereafter by altering potassium 
homeostasis.  During periods of neuronal activity, extracellular potassium 
increases are buffered by astroglial uptake (Binder and Steinhäuser, 2006).  
However, under pathological conditions, potassium regulation fails and high 
extracellular potassium concentrations are able to initiate and propagate seizures 
(Wallraff et al., 2006).  Seizure activity has been shown to increase extracellular 
potassium concentrations in vivo (Hinterkeuser et al., 2000; Binder and 
Steinhäuser, 2006; Jabs et al., 2008).  Impaired potassium buffering has also been 
reported in the hippocampus of people with TLE (Gabriel et al., 1998; Schröder et 
al., 2000) and in epileptic rodents (Wallraff et al., 2006; Xu et al., 2009).   
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Uptake of albumin into astrocytes via TGFβRI results in down-regulation of the 
inward rectifying potassium channel 4.1 (Kir4.1) and impaired potassium buffering 
(Perillan et al., 2002; Ivens et al., 2007; Heinemann et al., 2012).  Kir4.1 has been 
extensively investigated in the brain, where its expression is essentially limited to 
astrocytic membranes (Higashi et al., 2001; Binder and Steinhäuser, 2006).  Down-
regulation of this channel affects potassium homeostasis, leading to depolarisation 
of astrocytes, and enhanced neuronal excitotoxicity that can lead to epileptiform 
discharges (Ivens et al., 2007).    
 
6.1.2. The regulation of TGFβ activity 
TGFβ exists in 5 isoforms, 3 of which, namely TGFβ1, TGFβ2 and TGFβ3, are 
expressed in mammals (Khalil, 1999).  All 3 mammalian isoforms are synthesised 
as precursor proteins (Khalil, 1999).  TGFβ undergoes a number of intracellular 
processing steps prior to its secretion by cells.  One such step is the proteolytic 
digestion of the precursor protein, which has a relative molecular mass of 44kDa 
(Lyons et al., 1990), to yield two products that assemble into a dimer with a 
relative molecular mass of 30kDa (Khalil, 1999).  This dimer form is also referred 
to as the ‘latent form’ (Khalil, 1999; Taylor, 2009).  One of the two products formed 
by proteolytic digestion of the precursor form is termed the latency-associated 
peptide (LAP), and the other is the homodimer, also referred to as ‘mature’ or 
‘active’ TGFβ and which has a relative molecular mass of 25kDa (Lyons et al., 1990; 
Khalil, 1999).  LAP binds TGFβ, which prevents TGFβ binding to TGFβR and 
therefore makes it biologically inactive (Khalil, 1999).  However, LAP can facilitate 
the transport of active TGFβ from the cell by binding to another protein called 
latency binding protein (LTBP)(Khalil, 1999).  TGFβ is secreted in the latent dimer 
form, with LTBP aiding secretion of this form into the extracellular matrix (Khalil, 
1999).  The regulation of TGFβ activity is based on controlling the mechanism that 
converts this important cytokine from its precursor to its biologically active form 
(Khalil, 1999; Taylor, 2009).   
 
Pathways of activation of latent TGFβ1 have been extensively studied, as it is 
believed that this form predominates over the other two TGFβ isoforms and many 
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endogenous substances, including enzymes and proteins, have been shown to be 
able to activate the latent TGFβ1 dimer (Vodovotz, 1997; Khalil, 1999).  ROS can 
activate TGFβ1 by affecting the amino acid residues of LAP that are susceptible to 
oxidation (Khalil, 1999).  The oxidation process results in altered stability of LAP, 
resulting in the loss of its association with active TGFβ1 or a change to its structure 
that exposes the TGFβR binding domain (Khalil, 1999).  Increased ROS production 
can occur from a brain insult and can lead to an increase in TGFβ1 activation 
(Khalil, 1999).  TGFβ1 expression has been shown to be elevated in the brains of 
patients with neurodegenerative diseases (Heinemann et al., 2012).  The role of 
TGFβ1 in neuronal injury is contradictory, with some claims that the production of 
TGFβ1 is protective against cell damage, and other results showing that increased 
production of TGFβ1 exacerbates excitotoxicity (Heinemann et al., 2012).  These 
contrasting findings are believed to be dependent on the cell type and disease state 
(Heinemann et al., 2012).   
 
Recent studies on the regulation of albumin-mediated TGFβ signalling and 
astrocytic transformation during epileptogenesis have aimed to investigate 
whether BBB dysfunction can be used as a potential early biomarker for the 
prediction of the development of epilepsy in the clinic (Heinemann et al., 2012).  At 
present, it is unknown whether albumin mediates its effects on epileptogenesis by 
increasing the level of TGFβ1 or only from binding to TGFβRI (Ivens et al., 2007).  
The angiotensin receptor antagonist, losartan, has recently shown anti-
epileptogenic effects in a model of epilepsy associated with vascular injury by 
blocking albumin-induced TGFβ activation in the brain and thereby preventing the 
development of SRS (Bar-Klein et al, 2014).  This confirms that anti-
epileptogenesis can impact on albumin-mediated TGFβ signalling.  The objective of 
research described in this chapter was therefore to explore the contribution of the 
albumin-mediated TGFβ signalling pathway to epileptogenesis following 
pharmacological modulation of nitric oxide pathway in the aftermath of an acute 
brain insult.  The abundance of albumin, TGFβ1, TGFβRI and Kir4.1 in the 
hippocampus of C57BL/6J mice following repeated doses of KA to induce acute 
seizures was assessed.  The effect of drug interventions (PSD95BP, 1400W and 
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PSD95BP plus 1400W combined) on expression of these proteins was also 
investigated.  
 
6.2. Materials and methods 
 
6.2.1. Animals  
All experimental procedures were completed in accordance with the Animal 
(Scientific Procedures) Act, 1986 (UK).  The methodological details regarding the 
source of the animals, their housing conditions, KA-induced seizures are described 
in section 2.1.  The preparation and dosing regimens of PSD95BP and 1400W are 
described in section 4.2.2.  For western blot, animals were euthanised 7 or 14 days 
after KA-induced seizures as described in section 2.1.4.  A separate cohort of 
animals was used for IHC; these animals were anaesthetised and their brains 
perfused 7 or 14 days after KA-induced seizures as described in section 2.7.2.  
These timepoints were chosen based on the results from the EEG chapter (chapter 
4) that showed a difference in the EEG algorithms used between control and drug-
intervention groups.  The divergence on day 7 may be indicative of the start of 
spontaneous seizures in the control animals and day 14 might be when the control 
animals have developed epilepsy.  All control animals in this chapter refers to KA-
treated animals without drug-interventions to compare to drug-intervention 
effects after KA-induced seizures. 
 
6.2.2. Sample collection for western blot 
Terminal blood samples were collected by cardiac puncture and stored in lithium 
heparin tubes that were placed on ice prior to centrifugation.  The heparin blood 
tubes were then centrifuged at 2,000 × g for 20 minutes at 4oC and the plasma was 
isolated.  Plasma samples were aliquoted into microcentrifuge tubes and stored at 
-20oC.  Hippocampi were dissected from whole brains and placed in cryovials 
before being snap frozen in liquid nitrogen.  Hippocampal samples were stored at -
80oC until required.   
 
 140 
 
6.2.3. Sample preparation for western blot 
Plasma samples were diluted to 1:100 with 25mM ammonium bicarbonate and 1µl 
of the diluted plasma was used for western blot.  Hippocampal tissues were 
prepared as described in section 2.5.2.  Bradford protein assay was performed to 
determine the protein concentration of all resulting supernatants and to establish 
the volume required for each assay.  The total amount of protein per assay was as 
follows: albumin 10µg, TGFβ1 20µg, TGFβRI 30µg and Kir4.1 30µg.  Supernatant 
samples were reduced and denatured prior to loading onto the gel, as described in 
section 2.5.3. 
 
6.2.4. Western blot 
Anti-albumin mouse polyclonal antibody (Abcam, UK) was diluted to 1:1000 and 
anti-mouse secondary antibody conjugated with HRP (Abcam, UK) was diluted to 
1:5000 with 5% skim milk in TBST.  The formulation of TBST is described in 
section 2.5.1.  Anti-TGFβ1 rabbit polyclonal antibody (Abcam, UK) was diluted to 
1:200 and anti-rabbit secondary antibody conjugated with HRP (Santa Cruz 
Biotechnology Inc., UK) was diluted to 1:1000 with 5% skim milk in TBST.  Anti-
TGFβRI rabbit polyclonal antibody (Abcam, UK) was diluted to 1:50 and anti-rabbit 
secondary antibody conjugated with HRP was diluted to 1:1000 with 5% skim milk 
in TBST.  Anti-Kir4.1 rabbit polyclonal antibody (Millipore, UK) was diluted to 1:40 
and anti-rabbit polyclonal antibody was diluted to 1:1000 with 5% skim milk in 
TBST.   
 
6.2.5. Densitometric analysis 
The relative intensity of the bands was measured as described in section 2.5.4.  The 
optical density ratio between the bands of each protein and their corresponding 
GAPDH bands was normalised and expressed using arbitrary units. 
 
6.2.6. Immunohistochemistry 
All brains for IHC were prepared as described in section 2.7.2.  Immunostaining 
was carried out as described in section 2.7.3.  In order to determine the optimum 
concentration for each antibody, serial dilutions were carried out for each 
antibody on spare brain sections and the antibody concentrations that produced 
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the best visualisation using a fluorescence microscope was chosen.  The anti-
albumin mouse polyclonal (Abcam, UK) primary antibody was tested at 1:1000, 
1:500 and 1:200 dilutions, and the anti-mouse secondary antibody conjugated with 
CY3 fluorophore was tested at 1:500, 1:250 and 1:150 dilutions.  The anti-TGFβ 
rabbit polyclonal (Abcam, UK) primary antibody was tested at 1:20, 1:10 and 1:5 
dilutions, and the anti-rabbit secondary antibody conjugated with CY3 fluorophore 
was tested at 1:300 and 1:150 dilutions.  The anti-TGFβRI rabbit polyclonal 
(Abcam, UK) primary antibody was tested at 1:20, 1:10 and 1:5 dilutions, and the 
anti-rabbit secondary antibody conjugated with CY3 fluorophore was tested at 
1:300 and 1:150 dilutions.  The anti-Kir4.1 guinea pig polyclonal (Alomone Labs, 
Israel) primary antibody was tested at 1:300 and 1:150 dilutions, and the anti-
guinea pig secondary antibody conjugated with CY3 fluorophore (Abcam, UK) was 
tested at 1:300 and 1:150 dilutions.  All antibodies were diluted in antibody 
diluting fluid, as described in section 2.7.1.  All brain slices were counterstained 
with DAPI (as described in section 2.7.3.).  DAPI is a DNA-specific stain that forms a 
fluorescent complex by binding to the adenine-thymine rich sequences of DNA 
(Kapuscinski, 1995).  Therefore, this stain can be used to identify the presence of 
living cells in the tissue. 
 
6.2.7. Cell area measurement and cell counting in the hippocampal 
formation 
IHC analyses were carried out by measuring the area of stained cells and by 
determining the percentage of stained cells against counterstained DAPI-stained 
cells, as described in section 2.7.5.  The hippocampal structure was separated into 
specific anatomical sub-fields, comprising DG, CA3, CA2, CA1 and subiculum (Sb) 
(Figure 6.1).  IHC analyses were carried out within each sub-field separately, and 
as a mean of all the sub-fields in the hippocampal formation.  No comparisons were 
made between the sub-fields in the hippocampal formation. 
 
6.2.8. Statistical analysis 
Statistical analysis to compare the abundance of proteins between vehicle control 
and KA-treated animals at 7 and 14 days after KA-induced seizures, and between 
control animals and those that received drug interventions, again at 7 and 14 days 
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after KA-induced seizures, were performed by one way ANOVA with Tukey 
correction using SPSS version 21.   
 
6.3. Results 
6.3.1. Albumin  
 
Changes in albumin levels induced by KA administration 
When KA was administered to mice, there were no significant differences in the 
abundance of albumin in the hippocampus or in the plasma at either 7 or 14 days 
after KA-induced seizures, when compared to vehicle-treated mice that received 
distilled water alone (Figure 6.2 and 6.3).   
 
Images and figures resulting from western blot are included for representative 
purposes, even where negative.  For all subsequent results, only those showing 
statistically significant data are included in the interests of space.  
 
 
Figure 6.1.  Diagram illustrating the anatomical regions of the hippocampal 
formation used in IHC analysis.  Paraformaldehyde-fixed gelatin-embedded mouse 
hippocampus tissue was sectioned coronally.  Tissue was stained with 4’,6-
diamidino-2-phenylindole (DAPI) to show the cellular structure of the 
hippocampal formation.  For the purposes of analysis, the following regions were 
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used - dentate gyrus (DG), Cornu Ammonis 3 (CA3), Cornu Ammonis 2 (CA2), Cornu 
Ammonis 1 (CA1) and subiculum (Sb).  Magnification, 2.5X.   
 
Changes in albumin levels induced by 1400W administration 
When 1400W was administered following KA-induced seizures, there were no 
changes in the abundance of plasma albumin at either 7 or 14 days thereafter 
(Figure 6.4).  A significant increase in hippocampal albumin, measured by western 
blot, and in the overall percentage of albumin stained cells within the entire 
hippocampal formation, measured by DAPI-adjusted IHC, was however observed 
at day 7 (Figures 6.4 and 6.5).  The mean normalised albumin to GAPDH ratio 
increased from 1.2 ± 0.29 arbitrary units in control mice to 5.63 (± 1.55) arbitrary 
units in 1400W-treated mice (p<0.05) (Figure 6.4).  In addition, the percentage of 
albumin to DAPI-stained cells in the hippocampal formation as a whole increased 
from 2.37% (± 0.12) in control mice to 6.10% (± 0.09) in 1400W-treated mice 
(p<0.01) (Figure 6.5).  There were no other changes in the abundance of albumin 
in relation to area, GAPDH or DAPI staining in the hippocampal subfields or in the 
hippocampal formation as a whole (data not shown). 
 
 
Figure 6.2.  Representative western blots for albumin and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) in (A) hippocampal homogenates and (B) 
plasma for vehicle-treated animals 7 days post-administration and for kainic acid 
(KA)-treated animals 7 and 14 days after KA-induced seizures in C57BL/6J mice.  
An equal amount of protein was used for all homogenates and all plasma samples 
were diluted to 1:100.  All samples were analysed by western blot using polyclonal 
antibodies directed against albumin at 1:1000 and GAPDH at 1:5000 dilutions. 
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Changes in albumin levels induced by PSD95BP administration 
When PSD95BP was administered 1 hour after KA-induced seizures, there were no 
significant changes in hippocampal albumin levels compared to vehicle-treated 
controls (Figures 6.6 and 6.7; data for IHC not shown).  There was however a 
significant decrease in plasma albumin levels at day 14, from 3.32 (± 0.59) 
arbitrary units in the vehicle-treated control mice to 1.28 (± 0.34) arbitrary units 
in PSD95BP treated mice (p<0.05) (Figure 6.7).   
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Figure 6.3.  The effect of kainic acid (KA) on abundance of albumin in the hippocampus 
and plasma at 7 and 14 days after KA-induced seizures in C57BL/6J mice.  Vehicle-treated 
control animals received distilled water alone, with plasma and hippocampal samples 
harvested 7 days thereafter. (A) Densitometric analysis of western blots for albumin in 
hippocampal homogenates and plasma of vehicle-treated (n=4) and KA-exposed mice 
(n=4-5) mice.  Data are expressed as mean (± SEM) normalised albumin to glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) ratio in arbitrary units. (B) Immunohistochemical 
analysis of albumin stained cells in the dentate gyrus (DG), Cornu Ammonis 3 (CA3), Cornu 
Ammonis 2 (CA2), Cornu Ammonis 1 (CA1) and subiculum (Sb) sub-fields of the 
hippocampus and the hippocampal formation as a whole in vehicle-treated and KA-
exposed mice (n=2 per group), with pixel intensity adjusted to a set threshold in order to 
standardise gray level for all images.  Data are expressed as mean (± SEM) area of gray 
levels. (C) Immunohistochemical analysis of albumin stained cells in relation to 4’,6-
diamidino-2-phenylindole (DAPI) stained cells in the DG, CA3, CA2, CA1 and Sb regions of 
the hippocampus and the hippocampal formation as a whole in vehicle-treated and KA-
exposed mice (n=2 per group).  Data are expressed as mean (± SEM) percentage of 
albumin to DAPI-stained cells.   
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Figure 6.4.  Representative western blots for albumin and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) in (A) hippocampal homogenates and (B) 
plasma for control and 1400W-treated animals 7 and 14 days after kainic acid-
induced seizures in C57BL/6J mice.  An equal amount of protein was used for all 
homogenates and all plasma samples were diluted to 1:100.  All samples were 
analysed by western blot using polyclonal antibodies directed against albumin at 
1:1000 and GAPDH at 1:5000 dilutions. (C) Densitometric analysis of western blots 
for albumin in hippocampal homogenates and plasma of control and 1400W-
treated mice (n=4-5 for all groups).  Data are expressed as mean (± SEM) 
normalised albumin to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ratio 
in arbitrary units and was compared statistically using a one way Analysis of 
Variance with Tukey correction (*p<0.05).   
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Figure 6.5. The effect of 1400W treatment on the abundance of albumin in the 
hippocampus at 7 and 14 days after kainic acid (KA)-induced seizures in C57BL/6J 
mice using immunohistochemical analysis of albumin stained cells in relation to 
4’,6-diamidino-2-phenylindole (DAPI) stained cells in the hippocampal formation 
as a whole (n=2 per group).  Data are expressed as mean (± SEM) percentage of 
albumin to DAPI-stained cells and was compared statistically using a one way 
Analysis of Variance with Tukey correction (*p<0.01). 
 
 
Changes in albumin levels induced by combined administration of PSD95BP and 
1400W 
When PSD95BP plus 1400W were co-administered after KA-induced seizures, no 
changes were observed in plasma or hippocampal albumin levels using western 
blot or IHC at either day 7 or day 14 (data not shown).      
 
 
6.3.2. Transforming growth factor β1 
 
Changes in TGFβ1 levels induced by KA administration 
There was an increase in TGFβ1 precursor form in hippocampus after KA-induced 
seizures (Figure 6.8 and 6.9).  The TGFβ1 precursor form increased from 0.25 (± 
0.09) arbitrary units in vehicle-treated control mice to 0.82 (± 0.47) arbitrary units 
at 7 days after KA exposure and 2.49 (± 0.76) arbitrary units at 14 days after KA 
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(Figure 6.8 and 6.9), although this was only statistically significant (p<0.05) at 14 
days.  For the dimer form of TGFβ1, there were no differences between vehicle-
treated control mice and those that received KA, but there was a significant 
reduction in hippocampal expression between 7 and 14 days after KA, dropping 
from 1.54 (± 0.37) arbitrary units at day 7 to 0.18 (± 0.05) arbitrary units at day 14 
(p<0.05).  The active form of TGFβ1 showed a marginal increase in hippocampal 
expression after KA administration increasing from 0.05 (± 0.03) arbitrary units in 
vehicle-treated control mice to 0.18 (± 0.05) arbitrary units at 7 days after KA and 
0.23 (± 0.04) arbitrary units at 14 days (Figure 6.8 and 6.9).  This effect was 
statistically significant (p<0.05) at 14 days alone.   
 
 
 
 
 
Figure 6.6.  Representative western blots for albumin and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) in (A) hippocampal homogenates and (B) 
plasma for control and post-synaptic density 95 blocking peptide (PSD95BP) 
treated animals at 7 and 14 days after kainic acid-induced seizures.  An equal 
amount of protein was used for all homogenates and all plasma samples were 
diluted to 1:100.  All samples were analysed by western blot using polyclonal 
antibodies directed against albumin at 1:1000 and GAPDH at 1:5000 dilutions.  
  
 149 
 
 
 
Figure 6.7.  The effect of post-synaptic density 95 blocking peptide (PSD95BP) 
treatment on albumin levels at 7 and 14 days following kainic acid-induced 
seizures in C57BL/6J mice.  Densitometric analysis of western blot for albumin in 
hippocampal homogenates and plasma of the control and PSD95BP-treated mice 
(n=5 per group).  Data are expressed as mean (± SEM) normalised albumin to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) ratio in arbitrary units and 
was compared statistically using one way Analysis of Variance with Tukey 
correction (*p<0.05). 
 
 
 
In IHC analysis, no difference in the area of TGFβ1-stained cells was observed (data 
not shown).  The percentage of TGFβ1 to DAPI-stained cells in the DG increased 
from 1.82% ± 0.38 in vehicle-treated control mice to 6.93% (± 0.95) in KA-exposed 
mice at 7 days (p<0.05) but then decreased to 2.58% (± 0.23) on day 14 (p<0.05; 
compared to 7 days) (Figure 6.9).  There were no significant changes in other 
hippocampal sub-fields.  The percentage of TGFβ1 to DAPI-stained cells in the 
entire hippocampal formation also showed no difference following KA-induced 
seizures (data not shown).   
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Figure 6.8.  Representative western blots for transforming growth factor β1 
(TGFβ1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in 
hippocampal homogenates from C57BL/6J mice at 7 days after treatment with 
vehicle (distilled water) and at 7 and 14 days after kainic acid (KA)-induced 
seizures.  An equal amount of protein was used for all homogenates and all 
samples were analysed by western blot using polyclonal antibodies directed 
against TGFβ1 at 1:200 and GAPDH at 1:5000 dilutions. 
 
 
Changes in TGFβ1 levels induced by 1400W administration 
When 1400W was administered from 1 hour up to 3 days after KA-induced 
seizures, a significant decrease in the precursor form of TGFβ1 was observed at 
day 14, from 2.49 (± 0.76) arbitrary units in the control group that also 
experienced KA-induced seizures, to 0.08 (± 0.01) arbitrary units in the 1400W-
treated group (*p<0.05) (Figures 6.11 and 6.12).  There was also a significant 
decrease in the dimer form of TGFβ1 at day 7, from 1.54 (± 0.37) arbitrary units in 
the control group to 0.35 (± 0.01) arbitrary units in the 1400W-treated group 
(p<0.05) (Figures 6.11 and 6.12).  In contrast, at 14 days after 1400W treatment 
there was a significant increase in the expression of the dimer form of TGFβ1 in the 
hippocampus, from 0.18 ± 0.05 arbitrary units in the control group to 0.56 (± 0.03) 
arbitrary units in the 1400W-treated group (p<0.001) (Figures 6.11 and 6.12).  
Finally, 1400W treatment reduced the hippocampal expression of the active form 
of TGFβ1, from 0.18 (± 0.05) arbitrary units (day 7 control) and 0.23 (± 0.04) 
arbitrary units (day 14 control) to below detectable limits in both cases (both 
p<0.01) (Figure 6.12).    
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Figure 6.9.  The effect of kainic acid (KA) on the abundance of transforming growth 
factor β1 (TGFβ1) in the hippocampus at 7 and 14 days after KA-induced seizures 
in C57BL/6J mice.  Vehicle-treated control mice received distilled water alone, 
with hippocampal samples harvested 7 days thereafter. (A) Densitometric analysis 
was performed on the western blots for the precursor, dimer and active forms of 
TGFβ1 (n=4-5 per group), and normalised to corresponding glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) bands.  Data are expressed as the mean (± 
SEM) TGFβ1 to GAPDH ratio in arbitrary units and was compared statistically 
using one way Analysis of Variance (ANOVA) with Tukey correction (*p<0.05). (B) 
Immunohistochemical analysis of TGFβ1 stained cells in relation to 4’,6-diamidino-
2-phenylindole (DAPI) stained cells in the dentate gyrus (DG), Cornu Ammonis 3 
(CA3), Cornu Ammonis 2 (CA2), Cornu Ammonis 1 (CA1) and subiculum (Sb) sub-
fields of the hippocampus in mice (n=2 per group).  Data are expressed as mean (± 
SEM) percentage of TGFβ1 to DAPI-stained cells and was compared statistically 
using one way ANOVA with Tukey correction (*p<0.05).  
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Figure 6.10. The effect of kainic acid on the number of transforming growth factor 
β1 (TGFβ1) stained cells in the hippocampus at 7 or 14 days after treatment in 
C57BL/6J mice. Paraformaldehyde-fixed gelatin-embedded mouse hippocampus 
tissue was cut coronally and the dentate gyrus region of two vehicle-treated 
control mice (A+B) and two KA-treated mice 7 days (C+D) and 14 days (E+F) after 
treatment was stained with TGFβ1 antibody conjugated with cyanine fluorescent 
dye (red).  Tissue was counterstained with 4’,6-diamidino-2-phenylindole (blue).  
Magnification, 20X.  Scale bar, 100μm. 
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For IHC analyses, there were no changes in the area of TGFβ1 stained cells after 
1400W treatment (data not shown).  There was a significant decrease in the 
percentage of TGFβ1 to DAPI-stained cells in the DG on day 7, from 6.93% (± 0.95) 
in the control mice to 0.42% (± 0.02) in the 1400W-treated mice (p<0.05) (Figure 
6.12), but no changes in other hippocampal sub-fields or at day 14 (Figure 6.12).  
Similarly, there was no effect of 1400W treatment on the percentage of TGFβ1 to 
DAPI-stained cells across the hippocampal formation as a whole (data not shown). 
 
Changes in TGFβ1 levels induced by PSD95BP administration 
Administration of PSD95BP 1 hour after KA-induced seizures resulted in a 
reduction in the hippocampal expression of TGFβ1 precursor and dimer forms, 
from 0.82 (± 0.47) arbitrary units (precursor) and 1.54 (± 0.37) arbitrary units 
(dimer) to below detectable limits at 7 days thereafter (precursor, not significant; 
dimer p<0.01) (Figures 6.13 and 6.14).  A similar effect was observed at 14 days, 
with reductions from 2.49 (± 0.76) arbitrary units (precursor) and 0.18 (± 0.05) 
arbitrary units (dimer), to below detectable limits of the assay (precursor, p<0.05; 
dimer p<0.01) (Figures 6.13 and 6.14).  In contrast, hippocampal expression of the 
active form of TGFβ1 increased significantly from 0.18 (± 0.05) arbitrary units in 
the control group to 0.49 (± 0.06) arbitrary units in the PSD95BP-treated group on 
day 7 (p<0.01) (Figure 6.14) and again from 0.23 (± 0.04) arbitrary units in the 
control group to 1.13 (± 0.18) arbitrary units in the PSD95BP-treated group on day 
14 (p<0.01) (Figure 6.14).  No changes were observed in albumin levels using IHC 
at either day 7 or day 14 (data not shown). 
 
Changes in TGFβ1 induced by combined administration of PSD95BP and 1400W  
When PSD95BP and 1400W were administered together after KA-induced 
seizures, a significant increase in the dimer form of TGFβ1 on day 14 was 
observed, rising from 0.18 ± 0.05 arbitrary units in the hippocampus of control 
mice to 1.89 ± 0.24 arbitrary units in that of drug-treated animals (p<0.001) 
(Figures 6.15 and 6.16).  There were no treatment-related differences in the 
expression of the different isoforms of TGFβ1 in the hippocampus at 7 days and no 
change in the abundance of the precursor and active forms at day 14 (Figure 6.16). 
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Figure 6.11.  Representative western blots for transforming growth factor β1 
(TGFβ1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in 
hippocampal homogenates from 1400W-treated C57BL/6J mice at 7 and 14 days 
after kainic acid (KA)-induced seizures.  An equal amount of protein was used for 
all homogenates and all samples were analysed by western blot using polyclonal 
antibodies directed against TGFβ1 at 1:200 and GAPDH at 1:5000 dilutions. 
 
 
In IHC analysis, there was an increase in the area of TGFβ1 stained cells in the Sb 
on day 7, rising from 9.06µm2 ± 1.97 in control animals to 21.36µm2 ± 0.31 in mice 
treated with a combination of PSD95BP and 1400W (p<0.05) (Figure 6.16 and 
6.17), but this did not influence the total area of TGFβ1 stained cells in the 
hippocampal formation as a whole (data not shown).  Likewise, there were no 
significant differences in the percentage of TGFβ1 to DAPI-stained cells in any of 
the hippocampal sub-fields, or in the hippocampal formation as a whole, following 
the combined treatments (data not shown). 
 
6.3.3. Transforming growth factor β receptor 1 
 
The antibodies used for TGFβRI were not detectable using western blot despite 
increasing the hippocampal supernatant volume to the maximum capacity for each 
loading well (equivalent to 30g of protein), and increasing the primary antibody 
dilution to 1:50.  As a result, only IHC was used to quantify TGFβRI expression. 
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Figure 6.12.  The effect of 1400W treatment on the abundance of transforming 
growth factor β1 (TGFβ1) in the hippocampus at 7 and 14 days after kainic acid-
induced seizures in C57BL/6J mice. (A) Densitometric analysis was performed on 
the western blots for the precursor, dimer and active forms of TGFβ1 (n=4-5 per 
group), and normalised to their corresponding glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) bands.  Data are expressed as mean (± SEM) TGFβ1 to 
GAPDH ratio in arbitrary units and was compared statistically using a one way 
Analysis of Variance (ANOVA) with Tukey correction (*p<0.05; **p<0.01; 
***p<0.001). (B) Immunohistochemical analysis of TGFβ1 stained cells in relation 
to 4’,6-diamidino-2-phenylindole (DAPI) stained cells in the dentate gyrus (DG), 
Cornu Ammonis 3 (CA3), Cornu Ammonis 2 (CA2), Cornu Ammonis 1 (CA1) and 
subiculum (Sb) sub-fields of the hippocampus in mice (n=2 per group).  Data are 
expressed as mean (± SEM) percentage of TGFβ1 to DAPI-stained cells and was 
compared statistically using one way ANOVA with Tukey correction (*p<0.05).  
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Figure 6.13.  Representative western blots for transforming growth factor β1 
(TGFβ1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in 
hippocampal homogenates from post-synaptic density 95 blocking peptide 
(PSD95BP) treated animals at 7 and 14 days after kainic acid (KA)-induced 
seizures in C57BL/6J mice.  An equal amount of protein was used for all 
homogenates by western blot using polyclonal antibodies directed against TGFβ1 
at 1:200 and GAPDH at 1:5000 dilutions. 
 
 
Changes in TGFβRI levels induced by KA administration 
Following administration of KA to mice, there were no changes in the area of 
TGFβRI stained cells in the hippocampus or the percentage of TGFβRI to DAPI-
stained cells in the hippocampus at either 7 or 14 days after KA-exposure (data not 
shown).  This lack of effect applied equally to all hippocampal sub-fields and the 
hippocampal formation as a whole. 
 
Changes in TGFβRI levels induced by 1400W administration 
Following the administration of 1400W to mice after KA-induced seizures there 
were no changes in the area of TGFβRI stained cells in the hippocampus on days 7 
and 14 (data not shown).  The percentage of TGFβRI to DAPI-stained cells in the 
various hippocampal sub-fields was unchanged following treatment with 1400W 
(data not shown), but there was a significant reduction in the percentage of 
TGFβRI to DAPI-stained cells in the hippocampal formation as a whole at day 7, 
decreasing from 3.50% ± 0.13 in control animals to 1.95% ± 0.16 in the 1400W-
treated mice (p<0.05) (Figure 6.18).  
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Figure 6.14.  The effect of post-synaptic density 95 blocking peptide (PSD95BP) on 
the abundance of transforming growth factor β1 (TGFβ1) in the hippocampus at 7 
and 14 days after kainic acid-induced seizures in C57BL/6J mice.  Densitometric 
analysis was performed on the western blots for the precursor, dimer and active 
forms of TGFβ1 (n=5 per group) and normalised to the corresponding 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) bands.  Data are expressed 
as the mean (± SEM) TGFβ1 to GAPDH ratio in arbitrary units and was compared 
statistically using one way Analysis of Variance with Tukey correction (*p<0.05; 
**p<0.01).  
 
 
Changes in TGFβRI levels induced by PSD95BP administration 
Following the administration of PSD95BP administration to mice after KA-induced 
seizures, there were no changes in the area of TGFβRI stained cells in the 
hippocampus or the percentage of TGFβRI to DAPI-stained cells in the 
hippocampus at either 7 or 14 days after KA exposure (data not shown). 
 
Changes in TGFβRI levels induced by combined administration of PSD95BP and 
1400W 
Combined treatment with PSD95BP and 1400W in C57BL/6J mice following KA-
induced seizures had no significant effect on the expression of TGFβRI in any 
hippocampal sub-field or in the hippocampal formation as a whole when measured 
by either TGFβRI staining area or as a percentage of DAPI-stained cells and at 
either 7 or 14 days after KA-exposure (data not shown).  
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Figure 6.15.  Representative western blots for transforming growth factor β1 
(TGFβ1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in 
hippocampal homogenates from C57BL/6J mice treated with a combination of 
post-synaptic density 95 blocking peptide (PSD95BP) and 1400W at 7 and 14 days 
after kainic acid (KA)-induced seizures.  An equal amount of protein for all 
homogenates were analysed by western blotting using polyclonal antibodies 
directed against TGFβ1 at 1:200 and GAPDH at 1:5000 dilutions. 
 
 
6.3.4. Inwardly-rectifying potassium channel 4.1 
 
Changes in Kir4.1 levels induced by KA administration 
Following KA administration to mice, there were no significant changes in Kir4.1 
expression, as determined by western blot and by the area of Kir4.1 stained cells in 
hippocampal sub-fields and in the hippocampal formation as a whole (data not 
shown).  However, a significant reduction in the percentage of Kir4.1 to DAPI-
stained cells was observed in the CA3 region at day 7, decreasing from 11.5% (± 
2.53) in vehicle-treated control animals to 1.71% (± 0.03) in mice that experienced 
KA-induced seizures (p<0.05) (Figure 6.19).  This effect was mirrored by a 
significant decrease in the percentage of Kir4.1 to DAPI-stained cells, from 5.14% 
(± 0.29) in the vehicle-treated mice to 2.07% (± 0.58) in the KA-treated mice, in the 
hippocampal formation as a whole (p<0.05) (Figure 6.19).  There were no 
significant changes in the percentage of Kir4.1 to DAPI-stained cells in hippocampal 
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sub-fields other than CA3 at 7 days (Figure 6.19) and no changes in any measure of 
Kir4.1 expression at 14 days after KA-exposure (data not shown). 
 
 
 
 
Figure 6.16.  The effect of combined treatment with post-synaptic density 95 blocking 
peptide (PSD95BP) and 1400W on the abundance of transforming growth factor β1 
(TGFβ1) in the hippocampus at 7 and 14 days after kainic acid-induced seizures in 
C57BL/6J mice. (A) Densitometric analysis was performed on the western blots for the 
precursor, dimer and active forms of TGFβ1 (n=5 per group) and normalised to the 
corresponding glyceraldehyde 3-phosphate dehydrogenase (GAPDH) bands.  Data are 
expressed as the mean (± SEM) TGFβ1 to GAPDH ratio in arbitrary units and was 
compared statistically using a one way Analysis of Variance (ANOVA) with Tukey 
correction (***p<0.001). (B) Immunohistochemical analysis of TGFβ1-stained area in the 
dentate gyrus (DG), Cornu Ammonis 3 (CA3), Cornu Ammonis 2 (CA2), Cornu Ammonis 1 
(CA1) and subiculum (Sb) sub-fields of the hippocampus (n=2 per group), with pixel 
intensity adjusted to a set threshold, in order to standardise gray level for all images.  Data 
are expressed as the mean (± SEM) area of gray levels and was compared statistically 
using a one way ANOVA with Tukey correction (*p<0.05).  
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Figure 6.17. The effect of post-synaptic density 95 blocking peptide and 1400W 
administered together on the area of transforming growth factor β1 (TGFβ1) 
stained cells in the hippocampus at 7 days after kainic acid (KA)-induced seizures 
in C57BL/6J mice. Paraformaldehyde-fixed gelatin-embedded mouse hippocampus 
tissues were cut coronally and the subiculum region of two control mice (A+B) and 
two drug-treated mice (C+D) were stained with TGFβ1 antibody conjugated with 
cyanine fluorescent dye (red).  Tissue was counterstained with 4’,6-diamidino-2-
phenylindole (blue).  Magnification, 20X.  Scale bar, 100μm. 
 
 
Changes in Kir4.1 levels induced by 1400W administration 
Administration of 1400W following KA-induced seizures had no effect on the 
expression of Kir4.1 levels in the hippocampus or in hippocampal sub-fields, when 
measured by western blot or when expressed as a percentage of DAPI-stained cells 
following IHC (data not shown).  However, there was an isolated increase in the 
area of Kir4.1 stained cells in the CA2 sub-field of the hippocampus at day 7, rising 
from 10.19 (± 0.47) µm2 in control animals to 14.85 (± 0.51) µm2 in 1400W-treated 
mice (p<0.05) (Figure 6.20).  There were no changes in the area of Kir4.1 staining 
in other hippocampal sub-fields at day 7, no changes in any sub-fields or in the 
whole hippocampus on day 14, and the localised increase in Kir4.1 staining in CA2 
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on day 7 did not impact the area of staining in the hippocampal formation as a 
whole (data not shown).  
 
 
 
 
Figure 6.18. The effect of 1400W on the abundance of transforming growth factor 
β receptor 1 (TGFβRI) in the hippocampus at 7 and 14 days following kainic acid-
induced seizures in C57BL/6J mice using immunohistochemical analysis of 
TGFβRI-stained cells in relation to 4’,6-diamidino-2-phenylindole (DAPI)-stained 
cells in the DG, CA3, CA2, CA1 and Sb sub-fields of the hippocampus (n=2 per 
group).  Data are expressed as the mean (± SEM) percentage of TGFβRI to DAPI-
stained cells and was compared statistically using a one way Analysis of Variance 
with Tukey correction (*p<0.05). 
 
 
 
Changes in Kir4.1 levels induced by PSD95BP administration 
PSD95BP administration 1 hour after KA-induced seizures was associated with an 
increase in hippocampal Kir4.1 expression, measured by western blot on day 14, 
rising from 0.23 (± 0.05) arbitrary units in control animals to 0.65 (± 0.13) 
arbitrary units in PSD95BP-treated mice (p<0.05) (Figures 6.21 and 6.22).  No 
changes in Kir4.1 abundance were noted in any of the IHC analyses (data not 
shown). 
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Figure 6.19. The effect of kainic acid (KA) on the abundance of the inwardly-
rectifying potassium channel (Kir4.1) in the hippocampus at 7 and 14 days after 
KA-induced seizures in C57BL/6J mice (n=2 per group).  Vehicle-treated control 
animals received distilled water alone, with hippocampal samples harvested 7 
days thereafter.  Immunohistochemical analysis for Kir4.1 in relation to 4’,6-
diamidino-2-phenylindole (DAPI) stained cells in the dentate gyrus (DG), Cornu 
Ammonis 3 (CA3), Cornu Ammonis 2 (CA2), Cornu Ammonis 1 (CA1) and subiculum 
(Sb) sub-fields of the hippocampus, and the hippocampal formation as a whole.  
Data are expressed as the mean (± SEM) percentage of Kir4.1 to DAPI-stained cells 
and was compared statistically using one way Analysis of Variance with Tukey 
correction (*p<0.05).  
 
 
 
Figure 6.20. The effect of 1400W on the abundance of the inwardly-rectifying 
potassium channel (Kir4.1) stained cells in the hippocampus at 7 and 14 days 
following kainic acid-induced seizures in C57BL/6J mice (n=2 per group).  
Immunohistochemical analysis of the Kir4.1-stained area was undertaken in the 
dentate gyrus (DG), Cornu Ammonis 3 (CA3), Cornu Ammonis 2 (CA2), Cornu 
Ammonis 1 (CA1) and subiculum (Sb) sub-fields of the hippocampus, with pixel 
intensity adjusted to a set threshold in order to standardise gray levels for all 
images.  Data are expressed as the mean (± SEM) area of gray levels and was 
compared statistically using a one way Analysis of Variance with Tukey correction 
(*p<0.05).  
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Figure 6.21.  Representative western blots for inwardly-rectifying potassium 
channel (Kir4.1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in 
hippocampal homogenates from vehicle-treated control and post-synaptic density 
95 blocking peptide (PSD95BP) treated animals at 7 and 14 days after kainic acid-
induced seizures in C57BL/6J mice (n=4-5 per group).  An equal amount of protein 
for all homogenates were analysed by western blotting using polyclonal antibodies 
directed against Kir4.1 at 1:400 and GAPDH at 1:5000 dilutions. 
 
 
 
Figure 6.22.  The effect of post-synaptic density 95 blocking peptide (PSD95BP) 
treatment on the abundance of the inwardly-rectifying potassium channel (Kir4.1) 
in the hippocampus at 7 and 14 days after kainic acid-induced seizures in 
C57BL/6J mice.  Densitometric analysis of the western blot for Kir4.1 in 
hippocampal homogenates from vehicle-treated control and PSD95BP-treated 
mice (n=4-5 per group) were normalised to glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) bands.  Data are expressed as mean (± SEM) Kir4.1 to 
GAPDH ratio, using arbitrary units, and was compared statistically using a one way 
Analysis of Variance with Tukey correction (*p<0.05). 
 
 
Changes in Kir4.1 levels induced by combined administration of PSD95BP and 1400W  
Combined administration of PSD95BP and 1400W after KA-induced seizures led to 
a significant elevation in Kir4.1 expression, as measured by western blot, in the 
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hippocampus on day 14, rising from 0.23 (± 0.05) arbitrary units in control 
animals  to 0.42 (± 0.03) arbitrary units in the drug-treated mice (p<0.05) (Figures 
6.23 and 6.24).  IHC data revealed a significant increase in the area of Kir4.1 stained 
cells in the CA2 region of the hippocampus on day 7, rising from 10.19 (± 0.47) µm2 
in control mice to 13.01 (± 0.4) µm2 in drug-treated animals (p<0.05) (Figure 
6.24).  There were no changes in the area of Kir4.1 staining in other hippocampal 
sub-fields on day 7 (Figure 6.24) or in the hippocampal formation as a whole (data 
not shown).  This method similarly failed to find any significant effect of drug-
treatment on day 14 (Figure 6.24). 
 
The combined administration of PSD95BP and 1400W after KA-induced seizures 
resulted in a significant increase in the percentage of Kir4.1 to DAPI-stained cells in 
the CA2, CA1 and Sb sub-fields of the hippocampus on day 7 (Figure 6.24).  In CA2, 
the percentage of Kir4.1 to DAPI-stained cells increased from 0.66% (± 0.18) to 
16.20% (± 2.05), CA1 increased from 2.32% (± 1.21) to 14.64% (± 2.1), and in the 
Sb it increased from 3.48% (± 2.17) to 18.41% (± 1.32) (all p<0.05) (Figure 6.24).  
These increases impacted on the overall percentage of Kir4.1 to DAPI-stained cells 
in the hippocampus on day 7, which increased from 2.07% (± 0.58) in control 
animals to 13.56% (± 2.11) in the drug-treated animals (p<0.05) (Figure 6.24).   
 
Further changes were observed at 14 days, at which point the combined treatment 
was associated with a significant decrease in the percentage of Kir4.1 to DAPI-
stained cells in the Sb, dropping from 6.48% ± 0.24 in control animals to 1.48% ± 
1.29 in drug-treated animals (p<0.05) (Figure 6.24).  There were no changes in 
other hippocampal sub-fields on day 14 (Figure 6.24) or in the hippocampal 
formation as a whole (Figure 6.24).   
 
6.4. Discussion 
 
The purpose of this study was to investigate the effects of KA-induced seizures 
with or without targeting NO pathway by pharmacological intervention, on 
albumin-mediated pathways in the brain.  Quantification of the expression of 
albumin, TGFβ1, TGFβRI and Kir4.1 in the hippocampus of C57BL/6J mice was 
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performed using western blot and also IHC, which allowed for more specific 
regional assessments within the hippocampal formation.   
 
 
Figure 6.23.  Representative western blot for inwardly-rectifying potassium 
channel (Kir4.1) and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) in 
hippocampal homogenates from control and combined drug treatment (post-
synaptic density 95 blocking peptide (PSD95BP) and 1400W) groups at 7 and 14 
days after KA-induced seizures in C57BL/6J mice (n=4-5 per group).  An equal 
amount of protein for all homogenates were analysed by western blotting using 
polyclonal antibodies directed against Kir4.1 at 1:400 and GAPDH at 1:5000 
dilutions. 
 
 
6.4.1. Albumin 
No significant changes in albumin were observed in the hippocampus at either 7 or 
14 days after KA-induced acute insult (Figure 6.3).  Given that increased BBB 
permeability only occurs transiently after the initial insult, it is possible that 
extravasation of albumin may have occurred before day 7.   
 
When 1400W was administered to mice following KA-induced seizures, the 
resulting increase in albumin levels in the hippocampus indicates that 1400W has 
either disrupted BBB permeability or that initial BBB dysfunction after the acute 
insult was prolonged.  There were no changes in plasma albumin levels after 
1400W administration, therefore the observed increase in hippocampal albumin is 
unlikely to be influenced by the peripheral blood.  A previous study revealed that 
NO production is involved in the preservation of BBB function by triggering the 
release of interleukin-6 (IL-6) (Krizanac-Bengez et al., 2003).   
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Figure 6.24.  The effect of combined treatment with post-synaptic density 95 blocking peptide 
(PSD95BP) and 1400W on the abundance of the inwardly-rectifying potassium channel (Kir4.1) in 
the hippocampus at 7 and 14 days after kainic acid-induced seizures in C57BL/6J mice. (A) 
Densitometric analysis of western blots for Kir4.1 in hippocampal homogenates of control and drug-
treated animals (n=4-5 per group).  Data are expressed as mean (± SEM) Kir4.1 to glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) ratio in arbitrary units and was compared statistically using a 
one way Analysis of Variance (ANOVA) with Tukey correction (*p<0.05). (B) Immunohistochemical 
analysis of the Kir4.1-stained area in the dentate gyrus (DG), Cornu Ammonis 3 (CA3), Cornu 
Ammonis 2 (CA2), Cornu Ammonis 1 (CA1) and subiculum (Sb) sub-fields of the hippocampus (n=2 
per group), with pixel intensity adjusted to a set threshold in order to standardise the gray level for 
all images.  Data are expressed as mean (± SEM) area of gray levels and compared statistically using 
a one way ANOVA with Tukey correction (*p<0.05). C) Immunohistochemical analysis of the Kir4.1-
stained cells in relation to 4’,6-diamidino-2-phenylindole (DAPI) stained cells in the DG, CA3, CA2, 
CA1 and Sb sub-fields of the hippocampus, and the hippocampal formation as a whole (n=2 per 
group).  Data are expressed as the mean (± SEM) percentage of Kir4.1 to DAPI-stained cells and was 
compared statistically using a one way ANOVA with Tukey correction (*p<0.05; **p<0.01).  
 167 
 
NO production in astrocytes occurs specifically by iNOS activation through 
cytokine up-regulation, and blood-borne cytokines such as IL-6 diffuse into the 
CNS by binding to the BBB endothelial cells (Krizanac-Bengez et al., 2003).  Many 
studies have demonstrated that IL-6 acts as a neuroprotective agent by preserving 
BBB endothelial cells as part of the ROS defense system (Matsuda et al., 1996; 
Hayashi et al., 1997; Loddick et al., 1998; Ali et al., 2000; Yamashita et al., 2005; 
Suzuki et al., 2008; Jung et al., 2011).  Inhibition of NOS has been shown to 
decrease IL-6 production and increase permeability across the endothelial 
monolayer (Krizanac-Bengez et al., 2003).  This may explain, at least partly, the 
mechanism of 1400W disruption of BBB permeability, leading to an increase in 
albumin levels in the hippocampus.    
 
When PSD95BP was administered after the KA-induced seizures, no changes in 
hippocampal albumin levels were observed either 7 or 14 days after treatment.  
The decrease in plasma albumin levels observed on day 14 is unlikely to have had 
any impact on epileptogenesis, unless this resulted from extravasation of 
peripheral albumin into other brain regions that were not measured in this study.   
PSD95BP and 1400W administered together had no effect in hippocampal albumin 
levels either 7 or 14 days after treatment.   
 
6.4.2. Transforming growth factor β1 
The expression of the precursor and active forms of TGFβ1 showed an upward 
trend over time following KA exposure.  This would suggest that TGFβ1 synthesis 
and activation increased with time following acute seizures.  This result is 
consistent with reports that showed TGFβ1 up-regulation in the hippocampus of 
rats that experienced SE (Aronica et al., 2000), and an increase in TGFβ1 activation 
following a brain insult (Khalil, 1999).  The decrease in the dimer form of TGFβ1 
from day 7 to day 14 after KA may have been due to the increased demand of 
TGFβ1 secretion from cells to compensate for the increase in activation at day 14.  
Using IHC, an increase in TGFβ1 expression in the DG of KA-treated animals was 
observed at day 7 but was decreased again by day 14.  Since the 3 forms of TGFβ1 
were not distinguished in the IHC staining, it is not possible to draw any 
conclusions with regards to the regulation of TGFβ1 activity from this observation.  
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However, the increase in staining at day 7 was seen only in the DG, which has a 
role in spatial learning and memory (Amaral et al., 2007; Jonas and Lisman, 2014), 
and is known to support the neurogenesis of granule cells (Cameron and McKay, 
2001; Kempermann, 2002).  Seizure-induced neurogenesis has been shown in 
animal models of epilepsy and was suggested to have a pro-epileptogenic role in 
the epileptic hippocampus (Parent and Lowenstein, 2002).  It is possible that 
seizure-induced neurogenesis might occur through TGFβ1 since this cytokine can 
regulate the proliferation and differentiation of cells.  Nevertheless, further 
investigation is required to confirm this hypothesis.   
 
When 1400W was administered after KA-induced seizures, the decrease in the 
precursor form of TGFβ1 and the failure to detect the active form suggested that 
1400W had prevented the increase in TGFβ1 synthesis and activation that were 
induced by KA exposure.  A decrease in the dimer form occurred at day 7, with a 
rebound increase at day 14 (Figure 6.12).  The increase in dimer form at day 14 
may have been the result of the reduced activation of TGFβ1 by 1400W, causing a 
reduced demand for cellular secretion and leading to an accumulation of the dimer 
form.  1400W also appeared to reverse the increase in TGFβ1 in the DG 7 days 
after the acute insult (Figure 6.12).   
 
Following administration of PSD95BP, the precursor and dimer forms of TGFβ1 
were below detectable limits of the western blot (Figure 6.14).  In contrast, an 
increase in the active form of TGFβ1 occurred with PSD95BP, suggesting that it 
may have induced the activation of TGFβ1 but not its synthesis.   
 
When PSD95BP and 1400W were co-administered, there was an increase in the 
dimer form observed at day 14 (Figure 6.16).  There were no changes in 
expression of the precursor and active form of TGFβ1 after the combined 
treatments, suggesting that increased synthesis and activation caused by KA was 
not altered by the combined treatment.  The increased expression of the dimer 
form observed after combined treatments may have been related to increased 
cellular secretion to compensate for TGFβ1 activation.  Using IHC, an increase in 
the area of TGFβ1 staining was observed at day 7 in the Sb sub-field of the 
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hippocampus (Figure 6.16).  The Sb is also responsible for memory retrieval and 
spatial encoding and plays an important role in the initiation and maintenance of 
epileptic discharges in TLE (Stafstrom, 2013).  Acute overproduction of TGFβ1 in 
the brain is thought to organise the repair processes and protect neurons from 
degeneration, whereas chronic overproduction resulted in degeneration (Wyss-
Coray et al., 2001).  The increase in TGFβ1 in the Sb only occurred at day 7 with no 
difference in TGFβ1 levels on day 14 compared to vehicle.  This transient increase 
suggests that there is a possibility that the combined treatments contributed to the 
promotion of repair and protection from TGFβ1 in response to the acute insult in 
the hippocampal region.  
 
Overall, TGFβ1 synthesis and activation were up-regulated after KA-induced 
seizures.  PSD95BP and 1400W inhibited the increase in TGFβ1 synthesis.  1400W 
also inhibited the increase in TGFβ1 activation seen following seizures, whereas 
PSD95BP increased its activation and the combined treatment was without effect.  
Some hypotheses can be drawn from the regional expressions of TGFβ1 in the 
hippocampus regarding its contribution towards epileptogenesis. However, 
because TGFβ1 has multiple functions with complex interactions between different 
cell types in the brain, further investigation is required to further characterise the 
mechanism of TGFβ1 regulation in epileptogenesis and the impact of PSD95BP and 
1400W, both independently and in combination.  
 
6.4.3. Transforming growth factor β receptor I 
Albumin effects in the brain derive from binding to TGFβRI to activate TGFβ 
signalling (Ivens et al., 2007; Cacheaux et al., 2009).  There were no changes in 
TGFβRI expression after KA-induced seizures.  When 1400W was administered, 
there was an overall decrease in the percentage of TGFβRI stained cells in the 
hippocampal formation as a whole.  When PSD95BP alone or in combination with 
1400W were administered after KA-induced seizures, there were no effects on 
TGFβRI level.   
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6.4.4. Inwardly-rectifying potassium channel 4.1 
The uptake of albumin into astrocytes can result in down-regulation of Kir4.1, with 
evidence of Kir currents being down-regulated in the CA1 region of the sclerotic 
hippocampus from epilepsy patients (Hinterkeuser et al., 2000).  In the current 
study, the expression of Kir4.1 was decreased in the hippocampus 7 days after KA-
induced seizures, and most prominently in the CA3 region.  This is consistent with 
reported literature showing that Kir4.1 is down-regulated in response to brain 
insult (Seifert et al., 2006; Wetherington et al., 2008; Heinemann et al., 2012).  The 
CA3 pyramidal cells are the most susceptible hippocampal cell type to the 
epileptogenic effects of KA (as discussed in chapter 3) and the selective reduction 
in the expression of Kir4.1 in CA3 may be a marker of KA-induced pyramidal cell 
loss in this area.   
 
When 1400W was administered following KA exposure, there was an increase in 
Kir4.1 expression in the CA2 region of the hippocampus at 7 days.  The CA2 region 
is essential for social memory and is known to be damaged in patients with TLE 
(Helmstaedter et al., 2003; Hitti and Siegelbaum, 2014).  The effects of PSD95BP 
administration were less discrete with an increase in Kir4.1 levels throughout the 
hippocampus 14 days after KA-induced seizures.  When PSD95BP and 1400W 
were administered together, there was a widespread increase in Kir4.1 abundance 
throughout the hippocampus and which was most pronounced on day 7.  There 
was sufficient overlap to suggest that day 7 results with combination treatment 
were largely mediated by 1400W (i.e. effects on CA2) and day 14 results mediated 
by PSD95BP.  However, the combination therapy also led to an increase in Kir4.1 
expression in the CA1 and Sb sub-fields of the hippocampus, which are regions that 
are also affected in epilepsy patients (Lehmann et al., 2000; Stafstrom, 2013).  
 
In summary, it is well-documented that down-regulation of Kir4.1 occurs following 
BBB dysfunction and that when the brain is exposed to albumin, it triggers the 
uptake of albumin into astrocytes by TGFβRI, activating TGFβ1 signalling, thereby 
affecting potassium buffering that can, in turn, affect neuronal excitability leading 
to epileptiform activity (Perillan et al., 2002; Ivens et al., 2007; Cacheaux et al., 
2009; David et al., 2009).  From the results reported in this chapter, it would 
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appear that KA-induced seizures do not affect hippocampal albumin levels, 
possibly because this is a transient effect that has subsided by 7 days.  The seizure-
induced reduction in Kir4.1 expression levels may reflect the selective vulnerability 
of CA3 pyramidal cells to KA neurotoxicity.  For the most part, PSD95BP and 
1400W reduced or reversed the effects of the seizures.  It is important to note that 
all treatments were given after KA-induced seizures, meaning that their effects are 
not mediated simply by modulation of the initial insult.  Other notable effects were 
observed including (1) an increase in hippocampal albumin following 1400W 
treatment that may be explained by iNOS inhibition leading to reduced IL-6 release 
and preservation of BBB endothelial cells, (2) an enhanced activation of TGFβ1 
mediated by PSD95BP but inhibition of its synthesis and secretion, and (3) a 
possible synergistic effect of PSD95BP and 1400W on Kir4.1, which was 
characterised by widespread increase in Kir4.1 abundance in the hippocampus that 
was more extensive than the effects of either drug given alone. 
 
It remains unclear whether albumin mediates its effects in the brain by increasing 
the level of TGFβ1 since there was no increase in albumin observed after acute 
seizures in this study.  However, KA did up-regulate TGFβ1 synthesis and 
increased the level of the active form of TGFβ1 that binds to TGFβRI.  Further 
investigations are required to confirm whether these effects may have been the 
aftermath of a transient increase in albumin that was missed by waiting until 7 
days before taking brain specimens.  Nevertheless, the therapeutic approach used 
here, i.e. target NO pathway, has for the first time been shown to moderate and in 
some cases reverse the cellular effects of KA-induced seizures on TGFβ signalling 
pathways that are believed to contribute to the development of epilepsy.  This 
represents a positive signal for anti-epileptogenesis.   
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Chapter 7 
The influence of intracranial 
surgical implantation of 
electrodes in a kainic acid model 
of epileptogenesis 
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7.1. Introduction 
 
The incidence of seizures following intracranial surgery in the clinic is estimated to 
be 15-20% (Pulman et al., 1996; Manaka et al., 2003).   Post-operative seizures are 
most likely to occur in patients within the first month of surgery and in acute 
cases, seizures can occur within the first 7 to 10 days (Pulman et al., 1996; Koh et 
al., 2004).  The risk of experiencing a seizure varies greatly depending on the 
severity of the surgically induced brain insult and the patient’s pre-existing 
neurological conditions (Pulman et al., 1996; Manaka et al., 2003).  Seizures after 
intracranial surgery typically occur as a result of haemorrhage or when the brain 
tissue becomes ischemic or hypoxic (Manaka et al., 2003).  These post-operative 
seizures may develop into epilepsy (Pulman et al., 1996).   
 
7.1.1. Intracranial surgery in animal models of epilepsy 
In some animal models of epilepsy, intracranial surgery is used to implant 
electrodes for EEG recordings (Galanopoulou et al., 2013) or for electrical kindling 
(Löscher et al., 1993; 1995; Niespodziany et al., 1999).  Surgery can also be used to 
implant cannulae for intracerebral administration of chemoconvulsants to induce 
seizures (Ben-Ari et al., 1980; Schwob et al., 1980; Cavalheiro et al., 1982; Rattka et 
al., 2013).  Post-operative seizures in animal models do not commonly occur.  
However, several studies have reported an alteration in seizure threshold and 
severity in epilepsy models in which intracranial surgery took place prior to the 
initial insult (Boast et al., 1976; Löscher et al., 1993; 1995; Ebert and Koch, 1996; 
Niespodziany et al., 1999).  These models typically employed the kindling process 
to induce seizures.  Kindling refers to a phenomenon where daily application of an 
initially sub-convulsive, behaviourally inert stimulus leads to a progressive 
increase in seizure sensitivity that manifests initially as focal seizures, then 
generalised seizures and results in the occurrence of spontaneous seizures 
(Löscher et al., 1993; Löscher and Brandt, 2010).  Implantation of the kindling 
electrodes causes focal neuronal damage that has been proposed to resemble a 
penetrating brain injury in humans (Löscher et al., 1993; 1995; Niespodziany et al., 
1999; Löscher, 2002) and is thought to play a role in the kindling process (Löscher 
and Brandt, 2010).   
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In a study where electrodes had previously been implanted into the amygdala of 
rats, enhanced susceptibility to electrical kindling was demonstrated by the 
modified epileptiform pattern of the field potential in ex vivo hippocampal slices 
(Niespodziany et al., 1999).  It was also demonstrated in another study that 
prolonged intra-amygdala electrode implantation induced changes in amino acid 
levels in several brain regions (Löscher et al., 1993).  Depth electrode implantation 
alone without electrical stimulation results in functionally significant 
haemorrhagic vascular damage and the consequent extravasation of blood into the 
brain tissue causing iron deposits (Boast et al., 1976).  Brain exposure to iron has 
been shown to induce chronic focal epileptic discharges (Boast et al., 1976; 
Willmore et al., 1978).  These studies therefore suggest that depth electrode 
implantation itself may contribute to the development of chronic epilepsy 
(Willmore et al., 1978).  Long-term depth electrode implantation in the limbic 
system has also been reported to lower the seizure threshold and the rate of 
kindling of the implanted region (Löscher et al., 1993; 1995).  Intracranial surgery 
has also been shown to reduce the seizure threshold and increase the convulsive 
response to pentylenetetrazole in rats where intra-hippocampal electrodes were 
implanted prior to chemical kindling (Löscher et al., 1995), although this 
observation has not been substantiated to date.   
 
7.1.2. Intracranial surgery on neuroinflammation 
The implantation of depth or extra-dural electrodes in the brains of patients and 
rodents has been shown to lead to widespread chronic neuroinflammation that 
results from the surgical trauma and the prolonged presence of electrodes in the 
brain (Yuen et al., 1987; Wolf et al., 1993; Hirshler et al., 2010).  This can increase 
cytokine production, which is also associated with the development of epilepsy 
(Vezzani et al., 2002; Vezzani, 2004; Matsumoto et al., 2005; Vezzani and Granata, 
2005; Choi and Koh, 2008; Vezzani et al., 2008).  Cytokines are regulators of 
responses to infection, inflammation, trauma and immune-system challenge 
(Matsumoto et al., 2005).  They are expressed at very low levels under 
physiological conditions, however overexpression of cytokines or their expression 
in regions not associated with inflammation can have adverse effects on overall 
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immune function (Matsumoto et al., 2005).  Pro-inflammatory cytokines promote 
systemic inflammation, whilst anti-inflammatory cytokines reduce inflammation 
(Dinarello, 2000; Cavaillon, 2001).  In the CNS, increased production of cytokines 
can occur following several pathological processes (Vezzani et al., 2002; Lehtimäki 
et al., 2003a; 2007; Vezzani et al., 2013).  Increased production of cytokines and 
their secretion into the cerebrospinal fluid and plasma has been reported after 
epileptic seizures in humans (Peltola et al., 2000; Lehtimäki et al., 2003b; Sinha et 
al., 2008).   
 
The involvement of inflammation in disease pathogenesis and prognosis varies 
depending on the individual cytokine (Deverman and Patterson, 2009).  Cytokines 
are recognised to play important roles in the physiology of the CNS and have 
implications in the pathogenesis of epilepsy (Probert et al., 1995; Peltola et al., 
2000; Vezzani, 2004; Rao et al., 2009).  Evidence has shown that pro-inflammatory 
cytokines interact with glutamatergic neurotransmission and therefore have an 
impact on neuronal excitability during seizures (Vezzani, 2004).  Epileptic seizures 
can also induce the production of cytokines, which in turn can influence the 
pathogenesis of the disorder (Li et al., 2011).  The roles of pro-inflammatory 
cytokines, such as IL-1β, IL-6 and tumour necrosis factor alpha (TNF-α), and anti-
inflammatory cytokines such as IL-10 have been extensively studied in 
experimental models and clinical epilepsy (Vezzani et al., 1999; Peltola et al., 2000; 
Vezzani et al., 2002; Vezzani, 2004; Rao et al., 2009). 
 
Protein expression profiles of inflammatory mediators from surgically resected 
hippocampi of patients with temporal lobe epilepsy and from serum samples of 
epilepsy patients have previously been investigated using multiplex 
immunoassays (Sinha et al., 2008; Kan et al., 2012).  The measurement of 
inflammatory cytokines using a multiplex platform is the most convenient and 
efficient way of measuring the levels of several cytokines in a single experiment 
and using only small amounts of biological samples.  In this chapter, the MSD 
electro-chemiluminescence V-PLEX assay was used to explore cytokine levels in 
plasma and homogenates of cerebral cortex from vehicle and KA-treated mice, 
with or without prior intracranial surgery.  The V-PLEX platform quantifies the 
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levels of 10 inflammatory cytokines - interferon-γ (IFN-γ), IL-10, bioactive IL-
12p70 heterodimer, IL-1β, IL-2, IL-4, IL-5, IL-6, keratinocyte-derived 
cytokine/growth-related oncogene (KC/GRO) and TNF-α - in a customised 96-well 
plate with 10-spot multi-array configurations (MSD, USA).    
 
Intracranial surgery is commonplace in animal models of epileptogenesis but it 
risks causing changes to brain biochemistry and to epileptogenicity that might 
render the respective model pathologically different from those models that do not 
incorporate surgery and may therefore model a different ‘type’ of epileptogenesis, 
i.e. one that follows a penetrating injury to the brain (Löscher and Brandt, 2010).  
There is evidence that implantation of intra-cerebral electrodes, which penetrate 
the dura mater, leads to a change in seizure threshold (Boast et al., 1976; Löscher 
et al., 1993; 1995; Ebert and Koch, 1996; Niespodziany et al., 1999) but it remains 
unknown if extra-dural electrodes have a similar effect on the threshold to 
seizures induced by subsequent application of electrical or chemical stimuli.  
Therefore, the aim of the work described in this chapter was to investigate changes 
in the threshold to KA-induced seizures, when implantation of extra-dural 
electrodes had occurred one week prior to seizure induction.  Analyses of 
hippocampal proteins using protein expression modifications and 2D heat map 
visualisation (as previously described in chapter 5), as well as inflammatory 
cytokine profiling of the cortex and plasma by multiplex technology were 
additionally performed.   
 
7.2. Material and methods 
 
7.2.1. Animals 
All experimental procedures were completed in accordance with the Animal 
(Scientific Procedures) Act, 1986 (UK).  All methodological details regarding the 
source of animals, housing conditions, surgical implantation of telemetry 
electrodes and KA-induced seizures are provided in sections 2.1 and 2.2.  
Determination of the effects of electrode implantation on seizure threshold was 
undertaken in all mice described in this thesis, comparing KA sensitivity between 
implanted and non-implanted animals.  In addition, a total of 16 mice were used 
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exclusively in this chapter for proteomics and MSD multiplex assay.  Eight of those 
animals were surgically implanted with telemetry electrodes, while the remaining 
eight were surgically naïve (non-implanted).  Seven days thereafter, four 
implanted and four non-implanted mice were subject to KA-induced seizures, with 
the remainder (4 implanted, 4 non-implanted) receiving treatment with distilled 
water only as vehicle control.  After a further seven days, all mice were euthanised 
as described in section 2.1.4.  Terminal blood samples were collected by cardiac 
puncture into lithium heparin coated tubes, centrifuged at 2,000 × g for 20 minutes 
at 4oC for the isolation of plasma, and stored at -20oC.  Brains were removed and 
the hippocampi and cortices were dissected and stored in cryovials prior to being 
snap-frozen in liquid nitrogen.  Brain samples were stored in -80oC until required. 
 
7.2.2. Proteomics protocol 
All methodological details regarding tissue homogenisation, digestion and LC-MS 
are described in section 2.4.  Tryptic digests of hippocampus homogenates were 
analysed by nanoflow reversed-phase LC-MS on the Orbitrap Velos™ (Thermo 
Fisher, UK) at 2h LC gradients with an Orbitrap analyser.  Each MS cycle had a full 
range scan at high resolution followed by sequential fragmentation of the 20 most 
abundant peptide ions.  The fragments were then measured at high mass 
resolution in the Orbitrap.   
 
7.2.3. Data collection and statistical analysis for proteomics 
Raw data files were searched against the Universal Protein Resource (UniProt) 
mouse database, as previously described in section 5.2.3.  Label-free LC-MS 
analysis with protein identifications from the Mascot search engine based on the 
UniProt mouse database returned 1,747 protein hits.  Statistical analysis of the 
proteomics data was performed by one-way ANOVA using a built-in tool within the 
Progenesis software, and with subsequent application of the Bonferroni 
correction, as described in section 5.2.4.  Identified proteins were short-listed on 
the basis of p≤0.05.   
 
 178 
 
7.2.4. Protein quantification and interaction mapping 
The absolute number of proteins (plus % of total) that were down-regulated, up-
regulated and the total that had significantly changed between treatment groups 
were compared.  A heat map was generated using PEAKS Studio 7.0 
(Bioinformatics Solutions Inc., Canada).  The raw tandem MS data were filtered to a 
retention time range of 0-270s for each sample and the cut-off value for the 
peptide feature statistical significance was p<0.01. 
 
7.2.5. Linearity of dilution for the Meso Scale Discovery V-PLEX kit 
The linearity of dilution was performed on 16 wells of the customised 96-well 
plate using two cortex supernatant samples.  One sample was from a mouse in the 
non-implanted, non-KA group, while the other sample was from a mouse that had 
been implanted and treated with KA.  These samples were predicted to have the 
least and the greatest amount of inflammatory changes due to the extent of insult 
applied to the brain.  The preparation of the cortical supernatants for the kit is 
described in section 2.6.2.  Supernatant samples were serially diluted to 1:2, 1:4, 
1:8 and 1:16 using Diluent 41 (MSD).  The observed values were assessed relative 
to the assay standard curve produced by the standards solution for all 10 
inflammatory cytokines. The results were calculated based on the standard curve 
and the observed concentration was multiplied by the dilution factor.  The criteria 
for acceptable dilutional linearity was for the corrected observed concentrations to 
vary no more than 80% to 120% of the theoretical concentration between each 
serial dilution for each analyte (Ray et al., 2005).    
 
7.2.6. Meso Scale Discovery V-PLEX assay 
MSD reagent preparation, experimental protocol and procedure for reading the 
MSD assay plate are described in section 2.6.  Frozen plasma samples were thawed 
on ice, centrifuged at 10,000 × g for 10 minutes and diluted 1:2 using Diluent 41 
before being added to the wells of the customised 96-well plate, in accordance 
with the manufacturer’s instructions (MSD kit reference K15048D-1).  The cortex 
supernatants were diluted using Diluent 41 (MSD) before being added to the 
remaining wells of the plate.  The inflammatory cytokine levels were expressed in 
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pg/ml for plasma and pg/mg of protein detected in 100 mg/ml cortex tissue, 
determined using the Bradford protein assay. 
 
7.2.7. Statistical analysis  
Statistical analysis of the dose of KA required to induce generalised seizures in 
naïve, non-implanted mice compared to those that underwent intracranial surgery 
for electrode implantation was performed by two-sample t-test using SPSS version 
21 (IBM).  Statistical analysis of the proteomics data is described in section 7.2.3.  
Statistical analysis of the MSD assay data was performed by one-way ANOVA with 
Tukey’s post hoc test using SPSS.  The changes in cytokine levels from the MSD 
assay were only considered based on statistical significance of p<0.005, which 
incorporates a Bonferroni correction to account for multiple comparisons (n=10).  
For the purposes of this analysis, cytokine concentrations were assumed to be 
independent variables. 
 
7.3. Results 
 
7.3.1. KA sensitivity between surgical implanted and non-implanted mice 
The effects of surgical implantation of telemetry electrodes on sensitivity to KA-
induced seizures was assessed in all animals employed in this thesis.  The effect on 
KA sensitivity was compared in this chapter using the implanted mice from 
chapter 4 and non-implanted mice from chapters 3, 5 and 6.  Therefore, the n 
numbers of the implanted and non-implanted mice were not balanced because the 
experiments were not designed for this comparison.  The mean total KA dose 
required to induce acute seizures in 187 non-implanted mice was compared to the 
dose required to produce the same effect in 15 implanted mice.  Implanted mice 
required significantly lower total KA doses (15.78 (± 1.47) mg/kg) than non-
implanted mice (27.98 (± 0.6) mg/kg), to induce the onset of generalised seizures 
(p<0.01) (Figure 7.1).  The range of total KA doses for implanted mice was 5 - 30 
mg/kg and for non-implanted mice, the range was 15 - 55 mg/kg (Figure 7.2).  
After a single dose of 5 mg/kg KA, 20% of implanted mice experienced generalised 
seizures, whereas none of the non-implanted mice did (Figures 7.2 and 7.3).  At a 
total dose of 30 mg/kg KA, all implanted mice had experienced generalised 
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seizures, compared to just 74.4% of non-implanted mice (Figure 7.3).  The ED50 for 
the emergence of generalised seizures was 13.1 mg/kg for implanted mice and 
24.8 mg/kg for non-implanted mice (Figure 7.3). 
 
Figure 7.1. The mean kainic acid (KA) dose required to induce generalised 
convulsive seizures in C57BL/6J mice that were either implanted (n=15) or not 
implanted (n=187) with extra-dural electrodes one week previously.  Data are 
expressed as the mean (± SEM) KA dose (mg/kg) and compared statistically using 
two-sample t-test (* p<0.01). 
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Figure 7.2. Total kainic acid (KA) dose required to induce generalised convulsive 
seizures in C57BL/6J mice that were either implanted (n=15) or not implanted 
(n=187) with extra-dural electrodes one week previously.  Data are expressed as a 
percentage of the total number of animals in each group that reached Stage 5 
seizures at each dose increment. 
 
 
Figure 7.3. Relationship between total kainic acid (KA) dose and emergence of 
Stage 5 generalised convulsive seizures in C57BL/6J mice that were either 
implanted (n=15) or not implanted (n=187) with extra-dural electrodes one week 
previously.  Data are expressed as a cumulative percentage of the total number of 
animals in each group. 
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7.3.2. Protein expression between non-implanted and implanted mice 
Comparisons between treatment groups in terms of proteomic profile were 
represented as the number of proteins that were significantly down-regulated, the 
number that was significantly up-regulated, and number that was significantly 
changed overall as a percentage of the 1,747 proteins identified.  The effects of 
surgical implantation of electrodes and/or KA exposure on hippocampal protein 
expression are shown in Table 7.1.  The impact of surgery was greater than that of 
KA-induced seizures in terms of the number of proteins with altered expression.  
KA had a greater effect in non-implanted animals (144 proteins altered; 8% of 
total) than it had in implanted animals (77 proteins altered; 4% of total) (Table 
7.1).  Likewise, surgical implantation of electrodes had more impact on 
hippocampal protein expression in animals that did not subsequently receive KA 
(474 proteins altered; 27% of total) than in those that did receive KA (354 proteins 
altered; 20% of total) (Table 7.1).   
 
Treatment group 
comparisons 
Down-regulated (n) Up-regulated (n) % significant of all 
proteins identified 
NS+V vs. S+V 266 208 27% 
NS+V vs. NS+KA 45 99 8% 
S+V vs. S+KA 39 38 4% 
NS+KA vs. S+KA 172 182 20% 
 
Table 7.1. Comparison of the change in hippocampal protein expression between 
treatment groups, reported as absolute numbers and percentage of total identified 
proteins.  Treatment groups (n=4) comprised animals that had undergone surgery 
(S) for electrode implantation or no surgery (NS) and that subsequently received 
kainic acid (KA) to induce seizures or vehicle (V) as a control.  Data reports 
proteins with significantly (one-way Analysis of Variance with Bonferroni 
correction, p<0.05) altered expression only, either as an absolute number (n) or as 
a percentage of all identified proteins (n=1,747). 
 
 
7.3.3. Heatmap expression 
Protein quantification using heat map visualisation was based on the detected 
peak areas of the top-3 unique peptide ratios calculated from the raw MS/MS data, 
as described in section 5.3.3.  The hippocampi of implanted mice showed increased 
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peak areas of the majority of proteins in the heat map visualisation compared to 
non-implanted mice, irrespective of whether animals subsequently received KA or 
vehicle (Figure 7.4).  In contrast, there was much less difference in the effect of KA 
compared to vehicle in either implanted or non-implanted animals (Figure 7.4). 
 
7.3.4. Meso Scale Discovery V-Plex analysis 
 
Linearity of dilution assessment 
According to the manufacturer’s instructions, the MSD assay had been validated on 
mouse serum, plasma and urine samples, but not on mouse brain samples.  
Therefore, a pre-study validation assessing serial dilutions of mouse cortex 
supernatant was conducted to determine the extent of the sample dilution 
required in order that the MSD assay remained in the linear range for each 
cytokine.   
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Figure 7.4. Heat map display illustrating the difference in hippocampal protein quantification in 
groups of animals that had undergone surgery for electrode implantation or no surgery and that 
subsequently (7 days thereafter) received kainic acid (KA) to induce seizures or vehicle as a 
control.  Protein quantification was based on the detected peak areas of the top-3 unique peptide 
ratios calculated from raw tandem mass spectrometry data.  Each animal in each treatment group is 
represented by a single column of peak areas, as detailed in the top horizontal bar and 
corresponding colour key.  The vertical axis shows protein peaks with unique peptides identified.  
Raw data was filtered to a retention time range of 0-270s for each sample and the cut-off value for 
the peptide feature significance was p<0.01.  Average peak areas are shown in black, peaks areas 
smaller than average are shown in green and those larger than average are shown in red. 
 
 
Two cortical supernatants were used; one from a non-implanted, non-KA mouse 
that was expected to have the lowest cytokine concentrations and one from an 
implanted, KA-treated mouse that was expected to have the highest cytokine 
concentrations.  Based on the linearity of dilution results (data not shown), neither 
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of the serial dilutions showed acceptable dilutional linearity for all 10 analytes, 
therefore the least diluted sample of 1:2 was considered to be the optimum 
dilution for the quantification of inflammatory cytokines using the MSD kit. 
 
The detection ranges of all inflammatory cytokines 
For the next step, it was necessary to determine whether the cytokine levels in a 
1:2 dilution of cortex supernatants lie within the detectable range of the MSD 
assay.   
 
For IFN-γ, the homogenate samples from the non-implanted mouse (NS+V) and the 
implanted, KA-treated mouse (S+KA) showed concentrations of 321 and 346 
pg/ml, respectively, which lie within the proposed dynamic range (0.0471 to 815 
pg/ml) of the MSD kit.  For IL-10, supernatants from NS+V and S+KA animals had 
concentrations of 1016 and 1590 pg/ml, respectively, which lie within the 
proposed dynamic range (0.742 to 2540 pg/ml) of the MSD kit.  For IL-12p70, the 
NS+V and S+KA animals had concentrations of 429 and 422 pg/ml, respectively, 
which lie within the proposed dynamic range (7.98 and 22900 pg/ml) of the MSD 
kit.  For IL-1β, the NS+V and S+KA animals had concentrations of 617 and 2367 
pg/ml, respectively, and the lower of which lies within the proposed dynamic 
range (0.123 to 1470 pg/ml) of the MSD kit.  For IL-2, the NS+V and S+KA animals 
had concentrations of 441 and 581 pg/ml, respectively, which lie within the 
proposed dynamic range (0.259 to 2110 pg/ml) of the MSD kit.  For IL-4, the NS+V 
and S+KA animals had concentrations of 753 and 886 pg/ml, respectively, which 
lie within the proposed dynamic range (0.120 to 1320 pg/ml) of the MSD kit.  For 
IL-5, the NS+V and S+KA animals had concentrations of 123 and 131 pg/ml, 
respectively, which lie within the proposed dynamic range (0.0667 to 821 pg/ml) 
of the MSD kit.  For IL-6, the NS+V and S+KA animals had concentrations of 846 
and 3838 pg/ml, respectively, the lower of which lies within the detection range of 
0.830 to 3490 pg/ml.  For KC/GRO, the NS+V and S+KA animals had 
concentrations of 3032 and 18048 pg/ml, respectively, neither of which lies within 
the proposed dynamic range (0.208 and 1540 pg/ml).  For TNF-α, the NS+V and 
S+KA animals had concentrations of 866 and 1124 pg/ml, respectively, neither of 
which lies within the proposed dynamic range (0.127 to 507 pg/ml).  For IL-1β and 
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IL-6, the supernatant from the S+KA mouse, which was expected to have high 
cytokine concentrations, was above the dynamic range of the assay.  For KC/GRO 
and TNF-α, supernatants from the S+KA mouse and the NS+V mouse, which was 
expected to have low cytokine concentrations, showed concentrations that were 
above the dynamic range of the respective assays.  This raises a concern that 
results of these 4 analytes may be unreliable as a result of concentrations being 
higher than can be accurately measured by the MSD kit at a 1:2 dilution of cortex 
supernatant.  Nevertheless, it was accepted that in an assay with 10 analytes 
quantified in a single well, some of those analytes would be more reliable than 
others.  Rather than risk diluting the samples further, it was concluded that a 1:2 
dilution was preferred and would allow analysis of baseline and moderately 
elevated concentrations of 8 cytokines from the panel of 10.   
 
Inflammatory cytokine levels in cortex 
There were no effects on IFN-γ levels, following surgical implantation of EEG 
electrodes, irrespective of whether animals receive vehicle or KA, and KA-induced 
seizures irrespective of whether animals had previously been implanted or not 
(Figure 7.5A). 
 
There were no effects on IL-10 levels following surgical implantation, irrespective 
of whether animals subsequently received vehicle or KA, and following KA-induced 
seizuresirrespective of whether animals had previously been implanted or not 
(Figure 7.5B).   
 
Surgical implantation of EEG electrodes caused concentrations of IL-12p70 to 
increase from below detectable limits to 25.87 ( 3.69) pg/mg protein in cerebral 
cortices of mice that subsequently received vehicle-treatment (NS+V vs. S+V; 
p<0.005).  An increase was also seen in implanted versus non-implanted animals 
that later received KA, with IL-12p70 levels increasing from 8.24 (± 3.21) pg/mg 
protein to 24.82 (± 1.62) pg/mg protein (NS+KA vs. S+KA, p<0.005).  There were 
no effects of KA on IL-12p70 levels, irrespective of whether animals had previously 
been implanted or not (Figure 7.5C). 
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There were no effectson IL-1β levels following surgical implantation of EEG 
electrodes, irrespective of whether animals subsequently received vehicle or KA, 
and following KA-induced seizures, irrespective of whether animals had previously 
been implanted or not (Figure 7.5D). 
 
Concentrations of IL-2 in the cerebral cortex were unaffected by surgical 
implantation of EEG electrodes, irrespective of whether animals subsequently 
received vehicle or KA, and were also unaffected by KA exposure, irrespective of 
whether animals had previously undergone surgery (Figure 7.5E). 
 
Concentrations of  IL-4 were unaffected by surgical implantation of EEG electrodes, 
irrespective of whether animals subsequently received vehicle or KA, and were 
also unaffected by KA exposure, irrespective of whether animals had previously 
undergone surgery (Figure 7.5F). 
 
Concentrations of IL-5 were unaffected by surgical implantation of EEG electrodes, 
irrespective of whether animals subsequently received vehicle or KA, and were 
also unaffected by KA exposure, irrespective of whether animals had previously 
undergone surgery (Figure 7.5G).   
 
Surgical implantation of EEG electrodes caused concentrations of IL-6 to increase 
from 16.87 (± 0.53) pg/mg protein to 322.16 (± 80.42) pg/mg protein in cerebral 
cortices of mice subsequently received vehicle-treatment (NS+V vs. S+V; p<0.005).  
There were no effects of surgery on IL-6 levels in animals that subsequently 
received KA.  Likewise, there was no effect of KA in animals that had not previously 
been implanted.  However, KA exposure did cause a significant decrease in IL-6 
levels, from 322.16 (± 80.42) pg/mg protein to 64.01 (± 11.57) pg/mg protein in 
cerebral cortex of animals that had previously undergone surgery (S+V vs. S+KA; 
p<0.005) (Figure 7.5H). 
 
Concentrations of KC/GRO were unaffected by surgical implantation of EEG 
electrodes, irrespective of whether animals subsequently received vehicle or KA, 
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and were also unaffected by KA exposure, irrespective of whether animals had 
previously undergone surgery (Figure 7.5I). 
 
Surgical implantation of EEG electrodes caused concentrations of TNF-α to 
increase from 2.08 ( 0.14) pg/mg protein to 5.82 ( 0.4) pg/mg protein in 
cerebral cortices of mice that subsequently received vehicle-treatment (NS+V vs. 
S+V; p<0.005).  An increase was also seen in implanted versus non-implanted 
animals that later received KA, with TNF-α levels increasing from 2.42 (± 0.12) 
pg/mg protein to 4.78 (± 0.26) pg/mg protein (NS+KA vs. S+KA; p<0.005).  There 
were no effects of KA on TNF-α levels, irrespective of whether animals had 
previously been implanted or not (Figure 7.5J).  
 
In summary, IL-12p70, IL-6 and TNF-α were significantly increased in cerebral 
cortex following the surgical implantation of EEG electrodes when animals 
subsequently received vehicle.  IL-12p70 and TNF-α were also significantly 
increased in cerebral cortex following the surgical implantation of EEG electrodes 
in those that subsequently received KA. Interestingly, KA treatment had relatively 
modest effects on the cytokine profile, with no difference from vehicle-treatment 
in animals that had not previously been implanted, and a decrease in IL-6 and 
KC/GRO in animals that had previously undergone surgery.   
 
Inflammatory cytokine levels in plasma 
The effect of surgical implantation of EEG electrodes and/or KA-induced seizures 
on the cytokine profile was also explored in plasma samples.  There were no 
significant effects of either surgery or KA exposure on plasma concentrations for 
all the cytokines (Figure 7.6).   
 
In summary, there were no significant effects of electrode implantation and/or KA-
induced seizures on the plasma cytokine profile.   
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Figure 7.5. The effect of surgical implantation of EEG electrodes and/or kainic acid (KA)-induced seizures on inflammatory cytokine 
levels in the cerebral cortex of C57BL/6J mice.  KA or corresponding vehicle (distilled water) was given 7 days after surgical 
intervention (where appropriate), with brains samples (n=4) collected 7 days thereafter.  The following inflammatory cytokines were 
measured:(A) interferon-γ (IFN-γ),(B) interleukin-10 (IL-10),(C) interleukin-12p70 (IL-12p70),(D) interleukin-1β (IL-1β),(E) 
interleukin-2 (IL-2),(F) interleukin-4 (IL-4),(G) interleukin-5 (IL-5),(H) interleukin-6 (IL-6),(I) keratinocyte-derived cytokine/growth-
related oncogene (KC-GRO),(J) tumour necrosis factor-α (TNF-α).  Data are expressed as the mean (± SEM) cytokine concentration in 
pg/mg protein was compared statistically using one-way Analysis of Variance with Tukey correction (* p<0.05; ** p<0.01; ***p<0.005).
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Figure 7.6. The effect of surgical implantation of EEG electrodes and/or kainic acid (KA)-induced seizures on inflammatory cytokine 
levels in the plasma of C57BL/6J mice.  KA or corresponding vehicle (distilled water) was given 7 days after surgical intervention 
(where appropriate), with plasma samples (n=4) collected a further 7 days thereafter.  The following inflammatory cytokines were 
measured(A) interferon-γ (IFN-γ),(B) interleukin-10 (IL-10),(C) interleukin-12p70 (IL-12p70),(D) interleukin-1β (IL-1β),(E) 
interleukin-2 (IL-2),(F) interleukin-4 (IL-4),(G) interleukin-5 (IL-5),(H) interleukin-6 (IL-6),(I) keratinocyte-derived cytokine/growth 
related oncogene (KC-GRO),(J) tumour necrosis factor-α (TNF-α).  Data are expressed as the mean (± SEM) cytokine concentration in 
pg/ml of plasma and was compared statistically using one-way Analysis of Variance with Tukey correction (*p<0.05). 
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7.4. Discussion 
 
The purpose of the work described in this chapter was to assess the impact of 
intracranial surgery on protein and cytokine profiles in a mouse KA model of 
epileptogenesis.  Extra-dural electrode implantation was performed by drilling 
burr holes bilaterally and placing the electrode terminals on the surface of the dura 
mater.  It was observed from two previous cohorts of mice described in chapter 3 
(mice without receiving any surgical procedures) and chapter 4 (mice implanted 
with EEG transmitters) that the surgical procedure significantly lowered the 
threshold to generalised seizures induced by KA (Figures 7.1-7.3).  This effect may 
be explained by a localised disruption of the BBB as a result of the surgical 
procedure, allowing more KA to enter the brain after systemic administration.  It is 
also possible that the surgery causing mechanical or thermal damage to the brain, 
lowering its tolerance to the neurotoxic effects of KA and rendering the brain more 
prone to develop acute seizures.  Further studies will be required to confirm these 
hypotheses.  The research described in this chapter explored the molecular events 
occurring in the brain (and plasma) following implantation of EEG electrodes 
and/or KA-induced seizures using proteomics and cytokine screening in an effort 
to understand pathways that may have led to altered KA sensitivity. 
 
7.4.1. Proteomics profile and heat map visualisation 
A large scale study of proteins was used to compare the neurobiological effects of 
surgical implantation and/or KA-induced seizures.  Comparing the percentage of 
proteins affected between treatment groups and also the heat map visualisation 
suggested that the most significant changes in protein expression in the 
hippocampus occurred as a result of intracranial surgery, irrespective of whether 
it was followed by administration of vehicle or KA (Table 7.1, Figure 7.4).  Overall 
seizures had a lesser effect on protein expression than surgery and interestingly a 
more pronounced impact in animals than did not have EEG electrodes implanted 
than in those that did.  This is difficult to understand but may be the result of 
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adaptive changes in the brain in response to surgical implantation of electrodes 
that subsequently dampened the proteomic if not epileptogenic effects of KA.  
 
7.4.2. Inflammatory cytokine levels 
The results from the multiplex cytokine assay showed that intracranial surgery 
caused the induction of inflammatory cytokines and that this predominantly 
occurred centrally rather than peripherally as the majority of cytokines were up-
regulated in the brain supernatants and not in the plasma.  IL-12p70, IL-6 and 
TNF-α  were up-regulated in the cerebral cortex as a result of the surgical 
procedure, except for IL-6 in animals that subsequently received KA.  All the 
cytokines investigated here are pro-inflammatory cytokines except for IL-10, that 
is known to be anti-inflammatory; and IL-5, whose role in inflammation is still 
unclear (see below).  Chronic inflammation has been observed upon histological 
examination of subdurally implanted brain regions of animals (Yuen et al., 1987; 
Wolf et al., 1993; Waziri et al., 2009) and extensive neuroinflammation has also 
been observed using peripheral benzodiazepine receptor labelling in rat brains 
that were chronically implanted with a transmitter but without any stimulation 
(Hirshler et al., 2010).  However, there are no reported studies showing any effects 
on individual inflammatory cytokines following extra-dural electrode 
implantation.  The increased expression of 3 pro-inflammatory cytokines in the 
brain reported in this chapter is consistent with previous findings of intracranial 
surgery and subdural electrode implantation causing inflammation in the brain. 
 
The roles of the cytokines on inflammation 
IFN-γ is a pro-inflammatory cytokine that is produced in inflammatory diseases or 
by infections and its production is controlled by IL-12 and IL-18, which are also 
pro-inflammatory (Schroder et al., 2004).  Significantly increased levels of IFN-γ 
have been observed in serum samples from epilepsy patients collected within 24 h 
of a seizure (Sinha et al., 2008).  IL-10 is an anti-inflammatory cytokine that is 
produced by activated T cells, B cells, keratinocytes and monocytes (Zdanov et al., 
1995) and which relays negative feedback signals that dampen the activated 
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immune system after an inflammatory stimulation (Youn et al., 2013).  IL-10 has 
been shown to be significantly elevated in plasma of patients 48-72 hours after 
seizure onset (Youn et al., 2013).  IL-10 inhibits the production of other 
inflammatory mediators, including IFN-γ, TNF-α, IL-1, IL-2, IL-6 and IL-12 (Zdanov 
et al., 1995).  It has been suggested that the increase in IL-10 after seizure onset 
can enhance the inhibition of pro-inflammatory cytokines, therefore IL-10 may 
have a protective role (Youn et al., 2013).  The biological roles of IL-10 and IFN-γ 
are closely related.  These two cytokines have antagonistic effects in several 
biological assays: IL-10 was found to inhibit IFN-γ production in several immune 
cells and IFN-γ was found to inhibit IL-10 production in monocytes (Zdanov et al., 
1995).  IL-10 has also been shown to have anti-convulsant effects against febrile 
seizures (Ishizaki et al., 2009).  An increased production of IL-10 was shown to 
afford resistance to febrile seizures during infectious disease, especially in 
predisposed individuals (Ishizaki et al., 2009).  Bioactive IL-12p70 is a 
heterodimer that consists of two subunits: p35 and p40 (Kalinski et al., 2001).  IL-
12p70 is a pro-inflammatory cytokine produced by dendritic cells, macrophages 
and B cells in response to microbial pathogens and has a key role in the 
development of helper T (Th) cells (Vignali and Kuchroo, 2012).  Surgically 
resected brain tissue from patients with epilepsy has shown a significant increase 
in IL-12p70 expression alongside marked activation of microglia, astrocytes and 
diffuse cell death (Choi et al., 2009). 
 
IL-1β is a pro-inflammatory cytokine that exerts pro-convulsant and neurotoxic 
effects and has been extensively studied in the pathogenesis of epilepsy (Smirnova 
et al., 2002; Lehtimäki et al., 2003b; Zhu et al., 2006; Balosso et al., 2008).  IL-1β 
mediates an increase in glutamate release, induces phosphorylation of the NR2B 
subunit of the NMDAR and prevents glutamate uptake by astrocytes (Hu et al., 
2000; Balosso et al., 2008; Cacheaux et al., 2009).  It has been shown to prolong 
hippocampal seizures induced by KA by enhancing glutamatergic 
neurotransmission (Vezzani et al., 1999).  TNF-α is a pro-inflammatory, pleiotropic 
cytokine that is produced primarily by macrophages in response to pathogens 
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(MacEwan, 2002a; 2002b).  TNF-α has been shown to have a direct role in seizure 
sensitivity (Beattie et al., 2002; Cacheaux et al., 2009; Weinberg et al., 2013).  Over-
expression of TNF-α causes seizures by promoting the recruitment of AMPA 
receptors containing the GluR2 subunit to the neuronal membrane, leading to 
increased calcium influx and enhanced endocytosis of GABAA receptors (Beattie et 
al., 2002; Cacheaux et al., 2009).  In addition, over-expression of TNF-α increases 
its pro-inflammatory effects, including leukocyte activation, adherence of 
neutrophils and monocytes to the endothelium, migration of inflammatory cells 
into the intercellular matrix, fibroblast proliferation and a locally enhanced 
production of other pro-inflammatory cytokines (Tracey and Cerami, 1992; Tracey 
et al., 1994; Probert et al., 1995; Smirnova et al., 2002).  Increased levels of TNF-α 
and IL-1β have been reported to occur after experimental seizures (Lehtimäki et 
al., 2003b).  Significantly increased levels of TNF-α and IL-1β have also been 
observed in serum samples from epilepsy patients, compared to samples from 
healthy control individuals when collected within 24 h of a seizure (Sinha et al., 
2008).   
 
IL-2, also known as T-cell growth factor, is a pro-inflammatory cytokine that 
stimulates T-cell proliferation and is essential for the generation and regulation of 
the immune response (Cantrell and Smith, 1984; Smith, 1988).  IL-4 is also a pro-
inflammatory cytokine, which induces proliferation and differentiation of T-cells 
into type 2 Th cells (Choi and Reiser, 1998; Van Kampen et al., 2005).  Significantly 
increased levels of IL-2 and IL-4 have been observed in serum samples from 
epilepsy patients collected within 24 h of a seizure (Sinha et al., 2008).  IL-5 is 
another cytokine with a major role in the pathogenesis of asthma and other allergic 
diseases (Leckie et al., 2000).  It is unknown whether IL-5 is a pro- or anti-
inflammatory cytokine as its role in inflammation is unclear (Takatsu, 2004).  
Increased serum levels of IL-5 have been observed in epilepsy patients after 
treatment with AEDs, including carbamazepine, valproic acid and phenytoin 
(Andrzejczak, 2011), but there are no reports linking IL-5 levels to the 
pathogenesis of epilepsy. 
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IL-6 plays a central role in host defence with pleiotropic activities including 
immunoglobulin secretion by B cells, maturation of B cells, osteoclast activation 
and induction of monocyte differentiation into macrophages (Barton, 1996; 
Smirnova et al., 2002).  The biological effects of IL-6 are largely mediated by other 
cytokines (Peltola et al., 2000), especially IL-1β, which is a potent stimulator of IL-
6 production in astrocytes and microglial cells (Erta et al., 2012).  IL-6 has a role in 
adult neurogenesis (Bauer et al., 2007; Deverman and Patterson, 2009) and its 
levels are transiently increased in response to neuronal injury (Erta et al., 2012).  
IL-6 concentrations are significantly increased in the cerebrospinal fluid and 
serum of epilepsy patients within 24 h of a seizure and correlate with seizure 
severity (Peltola et al., 2000; Lehtimäki et al., 2007; Sinha et al., 2008).  This 
increase in IL-6 is likely to be a consequence of neuronal activity associated with 
seizures and IL-6 may act as an activation signal for other cytokines in the brain 
(Peltola et al., 2000).  IL-6 has both pro-inflammatory and anti-inflammatory 
properties, depending on the clinical condition (Jones et al., 2001).  Anti-
inflammatory IL-6 is capable of limiting neutrophil recruitment and suppresses the 
activities of pro-inflammatory mediators, such as TNF-α, IFN-γ and IL-8 (Jones et 
al., 2001).  Pro-inflammatory IL-6 binds to IL-6 receptor and forms a complex that 
has been shown to enhance chemokine and adhesion molecule expression in an in 
vivo model of arthritis (Jones et al., 2001).  IL-6 can also afford neuroprotection 
after an acute seizure insult by preventing the spread of excitation in the rat brain 
via inhibition of glutamate release (D'arcangelo et al., 2000; Penkowa et al., 2001).   
 
KC/GRO, also known as chemokine C-X-C motif ligand 1 is the IL-8 related protein 
in rodents (Shiratori et al., 1994).  It is a chemoattractant for neutrophils (Shiratori 
et al., 1994) that directs neutrophils to injured tissues and propagates the 
inflammatory response by inducing the synthesis of pro-inflammatory cytokines, 
such as IL-1, IL-6 and TNF-α (Wolpe et al., 1988; Shaftel et al., 2007; Johnson et al., 
2011).  Chemokines are a family of small proteins involved in the modulation of 
numerous biological functions, including leukocyte migration and activation, and T 
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cell activation via G-protein coupled receptors (Cao et al., 2014).  Neutrophil 
infiltration through the BBB is an important step in the development of 
neuropathology following a seizure insult (Ravizza et al., 2008; Johnson et al., 
2011).  Significantly increased levels of CXCL-1 in the rat brain have been shown 
up to 72 hours following SE (Johnson et al., 2011).   
 
Surprisingly, KA failed to have any effects on cytokine expression in animals that 
had not previously undergone surgery.  This contradicts some observations in the 
literature, including increased expression of IL-1β, IL-6 and TNF-α in rat brains 
within 24h following KA injection (Lehtimäki et al., 2003b).  However, in the 
current study the hippocampus was dissected 7 days after KA-induced seizures at 
which point these cytokines may have returned to baseline levels.  Looking instead 
at implanted mice, KA caused a significant decrease in the expressions of IL-6 in 
the cerebral cortex at 7 days.  Reduced expression seems a little strange, especially 
following electrode implantation and KA-induced seizures, both of which might be 
expected to elevate cytokine levels, but this may reflect adaptive changes in the 
brain in the period between surgery and KA exposure.   
  
The effects of intracranial surgery were more pronounced than those of KA.  This 
was particularly evident in animals that subsequently received vehicle treatment 
to control for the effect of KA exposure.  In animals that later received KA, IL-6 
levels were unaffected by the impact of surgery Why animals that experienced 
both surgery and seizures should have lower cytokine levels, or at least a less 
severe cytokine profile, is unclear but may be the result of the activation of 
protective mechanisms in the brain following surgery that render it less 
susceptible to pro-inflammatory insults thereafter.   
 
The role of inflammatory pathways in epileptogenesis is not completely 
understood (Vezzani et al., 2013), but it is well-documented that some pro-
inflammatory cytokines are up-regulated within hours of an acute seizure insult 
(Vezzani et al., 1999; 2002; Rizzi et al., 2003; Vezzani, 2004; Somera-Molina et al., 
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2009).  This has led to the hypothesis that inflammation may play a role in seizure-
induced brain damage (Rizzi et al., 2003).  Three inflammatory cytokines 
measured in this study showed increased expression in the cortex following 
surgery but no significant changes after KA exposure in non-implanted animals.  
This would suggest that intracranial surgery is associated with a greater degree of 
neuroinflammation in the brain than KA-induced seizures or that 
neuroinflammation observed following surgery is longer-lasting than that 
resulting from seizure activity.  An additional confounder is the fact that some pro-
inflammatory cytokines, such as TNF-α, can have pro-convulsant effects, whereas 
others, including IL-6 have anti-convulsant effects.  A greater increase in anti-
convulsant cytokines than in pro-convulsant cytokines following surgery may have 
moderated the subsequent effects of KA and the consequences of KA-induced 
seizures.  
 
In conclusion, animals that have undergone surgical implantation of EEG 
electrodes are more prone to the development of acute seizures following KA-
administration than non-implanted animals, even when the electrodes are placed 
extra-durally and without obvious damage to either the dura mater or the cortical 
surface.  The work in this chapter highlights an important issue regarding surgical 
implantation of electrodes in models of epilepsy, especially when investigating the 
role of neuroinflammation in epileptogenesis.  This is not so important in carefully-
controlled studies where all animals receive some form of surgery, with sham-
operated animals rather than untreated animals employed as controls.  Even then, 
however, it is possible to over-state or misinterpret the involvement of 
neuroinflammation.  In studies such as this one, where unoperated animals serve 
as controls, perhaps due to limited resources or limited availability of dummy 
electrodes and transmitters, a satellite group of implanted animals might be run 
alongside the main study group, to give an indication of EEG changes in the main 
group without necessarily recording from all animals.  This is not uncommon but it 
runs the risk of providing false or misleading data regarding the biological changes 
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that are occurring in the brain and the mechanisms that may be responsible for 
epileptogenesis.   
 
In this chapter, the total dose of KA required to induce seizures was significantly 
lower in implanted animals than in those that were not implanted.  This is an 
interesting observation but relatively few animals were implanted and the purpose 
of the project, as a whole, was not to explore variability per se but rather to try to 
standardise the KA model and use it to investigate the effects of drugs.  EEG 
electrodes were implanted to facilitate that and to look for changes between 
treatment groups in terms of brain excitability that were not manifest 
behaviourally.  It is important to remember that in the large n number of animals 
that received KA without previously having undergone surgery, there was still 
large variability in the dose required to elicit generalised seizures.  Likewise, the 
difference in proteomics and cytokine profiles were observed a small number of 
animals, and in the case of proteomics, were expressed in relative terms without 
any real sense of whether the changes were biologically significant. 
 
Nevertheless, the data reported in this chapter suggest that careful considerations 
are required when comparing results from epilepsy models within and between 
laboratories, especially where the use of intracranial surgery and/or implantation 
of electrodes are involved.  An epilepsy model with implanted electrodes may not 
be comparable to the clinical condition as enduring neuroinflammation is not an 
inevitable characteristic of epilepsy.  By optimising surgical techniques, the impact 
of surgery on the brain might be minimised, however, it is unlikely to be 
completely eliminated.  Opening the skull is always likely to have consequences.  
The effects of intracranial surgery and depth electrode implantation in epilepsy 
studies have been explored previously (Boast et al., 1976; Löscher et al., 1993; 
1995; Ebert and Koch, 1996; Niespodziany et al., 1999) but the impact may have 
been underestimated.  The findings from this chapter should be considered when 
choosing an epilepsy model to study and when interpreting data generated from 
models in which intracranial surgery has been performed.  
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Chapter 8 
General discussion 
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The overall objective of the work reported in this thesis was to determine whether 
the effects of PSD95BP and 1400W in a mouse model of epileptogenesis, might 
represent novel therapeutic strategies for the treatment of TLE.  TLE is often 
resistant to AED therapy and the current alternative approach for drug-resistant 
TLE is surgical resection to remove specific structural lesions in the hippocampus 
of patients (Samuel, 2000; Schmidt and Löscher, 2003; Buckmaster, 2004). Several 
experimental methodologies were employed to explore the effects of potential 
novel therapeutic drugs in epilepsy.   
 
One of these methodologies involved using an animal model of epileptogenesis to 
understand the cellular and molecular mechanisms of TLE, and to test potential 
novel therapies (Herman, 2002; Löscher, 2002; Buckmaster, 2004; Friedman et al., 
2009; Bauer and Norwood, 2013).  In chapter 3, a KA model of epileptogenesis that 
employed a repeated dose regimen to administer KA via i.p. injection to C57BL/6J 
mice was characterised. The hippocampus is susceptible to the epileptogenic 
effects of KA, which has been shown to elicit patterns of SE-induced neuronal cell 
loss and astrogliosis in experimental animals that are similar to the 
neuropathology observed in human TLE.  Repeated low dosing of KA was chosen 
for this model in an attempt to titrate the KA dose according to the animals’ 
behaviour and to ensure that all mice consistently experienced generalised 
seizures and to limit mortality.  Nevertheless, this method introduces variability in 
the total KA dose that each animal is exposed to.  Considerable inter-animal 
variation in KA sensitivity, acute seizure severity and mortality rate caused by KA-
induced seizures was observed.  KA has been widely used to induce acute seizures 
and the variation observed in these experiments was consistent with literature 
confirming inter-animal variability in response to KA that is difficult to avoid 
despite refinement of protocols (Lothman et al., 1990; Simonian et al., 1996; 
Hellier et al., 1998; Kürschner et al., 1998; Hellier and Dudek, 1999; Ben-Ari and 
Cossart, 2000; Wenzel et al., 2000; Araki et al., 2002; Benkovic et al., 2004; 
Buckmaster, 2004; Williams et al., 2009; Bauer and Norwood, 2013; Lévesque and 
Avoli, 2013; Rattka et al., 2013; Carta et al., 2014).  Variability might be reduced by 
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increasing the number of animals used or alternatively by breeding a homogenous 
colony of mice in-house to reduce batch effects observed in animals from 
commercial suppliers.  However, developing an entirely reproducible model is 
unrealistic and not representative of the clinical condition. 
 
All mice were single-housed from the start of KA-induced seizures until the end of 
the experiment when they were then sacrificed.  Single-housing animals is thought 
to induce stress and there is no literature to date that suggests single-housing 
animals would affect epileptogenesis.  However, it has been reported that repeated 
experimental stress from restraint for 30 minutes accelerated the development of 
epileptogenesis in a kindling model (Jones et al, 2013).  Nevertheless, all animals 
used in this thesis were single-housed so the effects of the environmental factors 
would not have affected the epileptogenesis model.  In addition to the drugs being 
explored for their antiepileptogenic potential, animals were exposed to diazepam 
and pentobarbitone during the course of the various studies. Such drugs have the 
potential to interfere with the progression of epileptogenesis and to impact results 
(Aroniadou-Anderjaska et al., 2008; Löscher and Brandt, 2010).  However, the 
administration of GABA agonists after an acute insult has been shown not to 
prevent epileptogenesis (Halonen et al., 2001; Herman, 2002; Aroniadou-
Anderjaska et al., 2008).  The use of hypnotic doses of pentobarbitone also did not 
affect the epileptiform discharges induced by repetitive electrical stimulation of 
isolated brain tissue (Vazquez et al., 1975).  It is therefore unlikely that the 
administration of diazepam two hours after the onset of KA-induced generalised 
seizures to standardise the duration of SE, or the overdose of sodium 
pentobarbitone for euthanasia would have had significant effects on 
epileptogenesis in this model or on the results reported from this work.   
 
Another method used in this thesis was EEG monitoring of freely-moving mice that 
allowed an objective and quantitative measure of brain activity in experimental 
animals to support the subjective behavioural observations that could vary 
between experimenters.  In chapter 4, two EEG algorithms, involving analysis of 
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spike frequency and EEG coastline, were used to quantify epileptiform activity 
from extra-dural electrodes. Spike frequency analysis measured the number of 
electrographic spikes with amplitudes above a pre-specified threshold determined 
from baseline EEG recordings (prior to acute seizures induced by KA), whereas 
coastline analysis involved calculating the sum of distances between consecutive 
data points on the EEG trace over a specified time interval. Both algorithms had 
previously been shown to have low sensitivity to detect non-convulsive seizures 
(White et al., 2006).  In this chapter, both algorithms were correlated against 
behavioural seizure severity, which was calculated using modified Racine scores 
recorded during each 5-minute epoch throughout the 2-hour period of SE. Both 
algorithms showed changes from baseline after KA-induced seizures. Comparing 
the two algorithms, spike frequency was shown to correlate better with 
behavioural seizure severity than coastline analysis. However, neither algorithm 
could accurately predict the occurrence of spontaneous seizures.  
 
Video monitoring was used concurrently with EEG to confirm the presence of 
spontaneous seizures following the initial insult.  Video monitoring on days 7 and 
14 after KA-induced SE showed the occurrence of a spontaneous seizure in 3 mice 
from the control group, with one mouse experiencing a convulsive seizure on day 7 
and the other two experiencing a convulsive seizure each on day 14.  No evident 
seizure behaviour was observed on days 7 or 14 after KA-induced SE in the drug 
intervention groups that received either PSD95BP plus 1400W combined or 
1400W alone.  Diazepam administration was used to terminate SE in all mice, with 
no seizure observed in any animal in the 24 hour period thereafter.  This suggests 
that the seizure behaviour observed in control mice on days 7 and 14 was most 
likely to be spontaneous seizures arising as a result of an epileptogenic process. 
Spike frequency and the number of 5-minute epochs with extended EEG coastline 
per day showed significant differences between the control group and the drug 
intervention groups.  Lower spike frequency and fewer extended coastlines per 
day in the drug intervention groups is suggestive of potential antiepileptogenic 
effects by targeting NO pathways using either PSD95BP or 1400W.  However, these 
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EEG effects would require further, extensive review of the video monitoring to 
confirm the onset of epilepsy and seizure frequency in each animal, which was not 
possible within the timeframe of this project due to the associated demands on 
time.   
 
In chapter 5, a large-scale proteomic analysis was used to explore the protein 
expression profile of the brain and to study alterations in expression that may be 
linked to seizures and epileptogenesis and that might indicate a potential novel 
therapeutic target. Tandem MS and label-free quantification was used to measure 
and compare the relative amount of proteins in hippocampal samples. Another 
method of quantification was performed using PEAKS to calculate the peptide 
ratios based on peak areas to visualise the results in a 2D heat map. Protein 
quantification analyses showed significant changes in the protein profile of the 
hippocampus following KA-induced seizures.  This finding is consistent with a 
previous study that used 2D gel proteomics quantification and also showed 
changes in protein expression in the hippocampus following KA-induced seizures 
(Krapfenbauer et al., 2001b).  
 
Treatment with either PSD95BP or 1400W resulted in fewer affected proteins in 
control animals than in those previously exposed to KA, suggesting that the effects 
of drug interventions on protein expression may be selective for brain that has 
previously undergone a neurological insult. The protein moesin was commonly up-
regulated by the effects of KA in vehicle and 1400W-treated mice.  This finding 
suggests that moesin and/or its associated proteins may be direct or indirect 
targets in KA-induced seizures.   
 
Functional analysis based on protein expression comparisons between treatment 
groups can be used to map protein-protein interaction networks (Kumar and 
Mann, 2009).  This then allows hypotheses to be made about the role of those 
proteins within the complex mechanisms underpinning the biological effect using 
publically available databases (Banks et al., 2000).  Follow up studies are obviously 
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required to confirm these hypotheses.  The results from this chapter are novel 
since there are currently no published reports of proteomics being used to identify 
the mechanism of potential antiepileptogenic drugs or on interventions targeting 
NO signalling pathways.  A similar approach has however been used to identify 
proteins that were modified by nitration in the brains of patients with Alzheimer’s 
disease, to provide new insight into potential mechanisms of onset and 
progression of the disorder (Calabrese et al., 2007).  
 
In order to test the efficacy of the drug interventions on epileptogenesis following 
an acute brain insult, signalling pathways activated by brain insults and known to 
contribute to epileptogenesis were investigated. It is commonly known that BBB 
dysfunction is a hallmark of neurological insults and that albumin can enter the 
brain via a dysfunctional BBB (Sokrab et al., 1989; Roch et al., 2002; Ballabh et al., 
2004; Seiffert et al., 2004; Blyth et al., 2009).  The uptake of albumin into 
astrocytes has been shown to occur via TGFβRI and results in activation of TGFβ1 
signalling (Ivens et al., 2007; Cacheaux et al., 2009; Heinemann et al., 2012).  This 
activation can affect potassium buffering via Kir4.1 which can, in turn, cause 
neuronal excitability leading to epileptiform activity (Ivens et al., 2007; Cacheaux 
et al., 2009; Heinemann et al., 2012). In chapter 6, the effects of PSD95BP and 
1400W on the expression of albumin, TGFβ1, TGFβRI and Kir4.1 were investigated 
using western blot and IHC. KA-induced seizures increased TGFβ1 activity and 
reduced Kir4.1 expression in the hippocampus at 7 days, which is consistent with 
previous reports in the literature (Perillan et al., 2002; Ivens et al., 2007; Cacheaux 
et al., 2009; David et al., 2009).  
 
Albumin levels increased in the hippocampus when 1400W was administered 
following KA-induced seizures, indicating that either 1400W caused subsequent 
damage to the BBB or that 1400W prolonged the increase in BBB permeability 
induced by the initial insult. This effect is not previously reported in the literature 
although the induction of iNOS following a brain insult is thought to serve as a 
defense mechanism by releasing cytokines, such as IL-6, to preserve the BBB 
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endothelial cells and this mechanism may be crucial to maintaining the integrity of 
the BBB (Hayashi et al., 1997; Loddick et al., 1998; Krizanac-Bengez et al., 2003; 
Jung et al., 2011). It has been shown that the release of IL-6 by glia is NO 
dependent (Krizanac-Bengez et al., 2003). Thus, inhibiting excess NO production 
that causes neurotoxicity should, in theory, protect the brain against further 
damage.  However, directly inhibiting iNOS activity may also abolish the defense 
mechanism required to maintain BBB integrity and as a result, may augment the 
increase in BBB permeability seen after an insult.  Since BBB dysfunction has been 
shown to contribute to epileptogenesis (Ivens et al., 2007; Tomkins et al., 2007; 
Van Vliet et al., 2007; Tomkins et al., 2008; 2011), direct inhibition of iNOS may not 
be ideal as a potential antiepileptogenic treatment. 
 
Selective inhibition of the production of NO via iNOS without affecting the release 
of IL-6 or any other cytokines that may contribute to the defense mechanism in 
response to the initial insult may be beneficial. 1400W inhibited the increase in 
TGFβ1 activity following KA and increased Kir4.1 expression after the insult.  In 
contrast, PSD95BP increased TGFβ1 activation but decreased its synthesis and 
secretion. PSD95BP also increased Kir4.1 expression when administered after KA-
induced seizures. Co-administration of PSD95BP and 1400W showed a 
combination of effects that were consistent with data from experiments in which 
both drugs were given alone. However, the increase in Kir4.1 expression seen with 
the combination was more extensive than expected of a simple additive effect, 
suggesting a possible synergistic effect of the two drug interventions on Kir4.1.   
 
Overall, the drug interventions tended to reverse the effects of KA on TGFβ1 and 
Kir4.1 expressions in the hippocampus, which may suggest possible restorative 
effects following KA-induced neurotoxicity. Losaratan, an angiotensin II receptor 
antagonist approved for the treatment of cardiovascular disorders, has shown 
antiepileptogenic effects in an experimental model of epilepsy associated with 
vascular injury by blocking albumin-induced TGFβ activation in the brain and, in 
turn, the subsequent development of SRS (Bar-Klein et al., 2014).  This gives 
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strength to the suggestion that PSD95BP and/or 1400W can be potential 
antiepileptogenic agents. 
 
Two distinct groups of mice were used in the research described in this thesis; one 
group underwent intracranial surgery and the implantation of extra-dural 
electrodes, while the other group was treatment-naive at the time of KA-induced 
seizures. To assess the impact of intracranial surgery on epileptogenesis, a 
comparison between these two groups of mice was undertaken using proteomics 
and a multiplex cytokine assay (chapter 7). Intracranial surgery lowered the total 
KA dose required to induce generalised seizures and also caused changes to the 
neurobiology of the hippocampus and a gross neuroinflammation of the cortex in 
otherwise naive animals that was more prominent than the effects of KA-induced 
SE. These findings suggest that the effect of surgery on the brain can potentially 
compound the initial insult produced by KA.   
 
It is surprising that a surgical technique to implant EEG electrodes in which the 
dura mater remained intact resulted in such a significant change in KA sensitivity. 
It has previously been reported that intracranial surgery and depth electrode 
implantation can affect the kindling process used to induce seizures in rodents 
(Boast et al., 1976; Willmore et al., 1978; Löscher et al., 1993; 1995; Ebert and 
Koch, 1996; Niespodziany et al., 1999).  Depth or subdural electrode implantation 
has also been shown to lead to widespread chronic neuroinflammation (Yuen et al., 
1987; Wolf et al., 1993; Hirshler et al., 2010). The design of epileptogenesis studies 
comparing naive animals with those that have undergone intracranial surgery 
requires careful consideration to ensure that the effect of electrode implantation is 
adequately controlled. Ideally, all animals in any given experiment should either 
receive EEG electrodes or not; at the very least, a sham-operated control group is 
required to draw valid conclusions. Fortunately in the work described in this 
thesis, the effects of the drug interventions were always compared between a 
control group (that only received KA) and the drug intervention groups (that 
received drug interventions following KA), except in the analysis of EEG signatures, 
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where all animals were additionally implanted with EEG electrodes. Thus, all mice 
in this study had an adequate and corresponding control, meaning that the impact 
of surgery on epileptogenesis was nullified. 
 
8.1. Review of the current status of glutamate/nitric oxide 
pathway in epilepsy research 
 
Despite glutamate being one of the more popular targets in the search for new 
AEDs, only a few glutamate receptor agents have been successful in epilepsy trials.  
NMDA receptor antagonists have been unsuccessful in clinical trials due to 
unacceptable adverse effects (Lipton, 2004; Rogawski, 2011).  More recently, the 
focus has been on AMPA receptor as an AED target (Rogawski, 2011).  Perampanel 
is a highly selective non-competitive AMPA receptor antagonist that was recently 
marketed for the treatment of epilepsy (Hanada et al., 2011; Rogawski, 2011; 
Ceolin et al., 2012; Löscher and Schmidt, 2012; Krauss et al., 2013).  Currently, 
researchers are exploring KA-type ionotropic glutamate receptors, and specifically 
the sodium binding site within the channel complex, with the aim of designing an 
anticonvulsant agent that can prevent sodium flux through the kainate receptor 
(Dawe et al., 2013). The recent success of PSD95BP in preclinical stroke studies 
and in phase 2 clinical trials in patients with iatrogenic stroke shows that there 
may be scope to target NO pathway in the treatment of neurological insults, 
including epilepsy (Cook et al., 2012; Hill et al., 2012; Savitz and Schäbitz, 2012). 
1400W has also been shown to decrease glutamate release and to improve 
outcome in a rat model of experimental cerebral ischemia (Pérez-Asensio et al., 
2005), but there are no reported clinical studies as yet. At this time, there are no 
other known drug interventions that target the NO signalling pathway and that 
have shown promise for the treatment of epilepsy.   
 
The influence of NO in epilepsy is still a matter of debate, with studies showing 
both pro-convulsant and anticonvulsant effects when NO production is inhibited 
(Del-Bel et al., 1997; Banach et al., 2011). It is likely that the extent to which NO 
 208 
 
 
 
 
precipitates seizures is dependent on its brain concentration (Mülsch et al., 1994; 
Bashkatova et al., 2000; 2003; Gupta and Dettbarn, 2003; Kato et al., 2005; 
Sumanont et al., 2006), since the balance between neuroprotection and 
neurotoxicity is dependent on its level of production (Benarroch, 2011).  The 
ability to selectively inhibit the various isoforms of NO synthase is also crucial for a 
clearer understanding of the physiological and pathological roles of this important 
signalling molecule. 
 
8.2. Future research 
 
Several further investigations are required to investigate fully whether PSD95BP 
or 1400W have antiepileptogenic properties and whether these drug interventions 
might be useful clinically. Although the mouse model used here identified potential 
antiepileptogenic effects of targeting NO pathway, it is unclear whether this would 
be translated to humans. If PSD95BP or 1400W can be shown to be at least safe for 
human use, then it may be possible to test them for their ability to prevent the 
development of epilepsy following a neurological insult, assuming they can be 
administered sufficient quickly. Even then, however, this may be unrealistic given 
the need to treat all individuals with a potentially epileptogenic insult in order to 
prevent epilepsy in just a few and also given the likely duration of follow-up 
required. A more realistic approach might be to explore the effects of PSD95BP 
and/or 1400W in an animal model where drug interventions are not administered 
until after the onset of SRS. Given that epileptogenesis can continue beyond the 
first onset of SRS (Williams et al., 2007; 2009), the prevention of the further 
development of epilepsy by initiating potential antiepileptogenic therapy as soon 
as an epilepsy diagnosis is made would be a feasible and a potentially beneficial 
approach. If successful, it would then be useful to investigate how long beyond the 
insult or first spontaneous seizure the drug interventions remained effective.  This 
would provide information towards the time-window for effective 
antiepileptogenic therapy in the clinic. 
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Appendix 
 
For loop script for splitting raw Spike2 data files into individual channels in 
text file using Python 
 
for i in range(file_number, 0, -1): 
channel_raw = header_raw[-i]   
#looks for channel according to header 
channel = re.sub(re.compile('[A-Z a-z\"]'), '', channel_raw)  
#removes KA and leaves only the channel number 
file = open('{0}/channel{1}.txt'.format(file_directory, channel), 
'w') 
#create new text file i.e. channel1.txt 
                file.close() 
  #finish 
                 
 file_dict[count] = '{0}/channel{1}.txt'.format(file_directory, 
channel) 
#put name of text file into temporary storage structure 
 count += 1 
#move on to next channel number 
         
     
for x in file_dict: 
                print('file = {0}'.format(file_dict[x])) 
               #tells user which file accessing 
                file = open('{0}'.format(file_dict[x]), 'a') 
               #opens the accessed file 
for i in read[1:]: 
#reads data except header 
j = i.split('\t') 
#recognises each tab as a separate channel 
j[-1] = j[-1].replace('\n', '') 
#removes new line character 
                        line = '{0}\n'.format(j[x]) 
   #reads the relevant data entry point 
                        file.write(line) 
   #writes the relevant data entry point into correct file 
                file.close() 
  #finish 
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For loop script for data filtering on EEGLAB toolbox using MATLAB 
for days = start: final, 
     
    hours_directory = sprintf('Day %d', days); 
 #look for folder by day 
 
    disp(hours_directory); 
 #tells users which hour being analysed 
 
    cd(hours_directory); 
 #change directory to go into folder 
 
    hours_folders = dir('*'); 
 #list all files in the folder 
 
    disp(length(hours_folders)) 
 #tells user how many files there are in the folder 
 
    for hours = 3: length(hours_folders), 
 #only look in hours folder 
 
         
        disp(hours_folders(hours).name); 
  #tells user which hour folder is being analysed 
  
        cd(hours_folders(hours).name) 
  #change directory to folder being analysed 
 
        j = dir('channel*.txt'); 
  #look for files called channel*.txt 
 
  
        for i = 1: length(j), 
  #go through each channel files 
 
            disp(j(i).name); 
  #tells user which channel/file is being analysed 
 
            channel = strcat(j(i).name(1:2), j(i).name(8)); 
  #recognise channel in eeglab by ch* 
 
            EEG = 
pop_importdata('dataformat','ascii','nbchan',0,'data',j(i).name,'srate',100,'pnts',
0,'xmin',0); 
            EEG.setname = channel; 
            EEG = eeg_checkset( EEG ); 
            EEG = pop_eegfilt( EEG, 1, 0, [], [0]); 
            EEG = eeg_checkset( EEG ); 
#internal command for eeglab data filtering 
  
            filename = strcat(j(i).name(1:8), 'rejected.txt'); 
  #gives name as rejected.txt 
 
            pop_export(EEG,filename,'erp','on','transpose','on'); 
  #saves rejected.txt file into folder 
 
        end 
        cd('../') 
    end 
    cd('../') 
end 
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For loop script for counting local maxima using findpeaks toolbox in MATLAB 
for days = start: finish, 
     
    hours_directory = sprintf('Day %d', days); 
 #look for the folder by day 
 
    disp(hours_directory); 
 #tells users which hour being analysed 
 
    cd(hours_directory); 
 #change directory to go into folder 
 
    hours_folders = dir('*'); 
 #list all files in the folder 
 
    for hours = 3: length(hours_folders); 
 #only look in hours folder 
         
        disp(hours_folders(hours).name) 
  #tells user which hour folder is being analysed 
 
        cd(hours_folders(hours).name) 
  #change directory to folder being analysed 
 
        j = dir('channel*rejected.txt'); 
  #look for files called channel*rejected.txt 
 
         
        for i = 1:length(j), 
  #go through each channel files 
 
            disp(sprintf('Channel %s', j(i).name(8))); 
  #display channel number on command window i.e. Channel 1 
 
            channelselect = str2num(j(i).name(8)); 
  #find the channel number  
 
            channel = strcat(j(i).name(1:2), j(i).name(8)); 
  #recognise as ch* i.e. ch1 
 
            A = importdata(j(i).name); 
  #import data 
 
            chYpos=A(:,2); 
  #create a new variable for second column called chYpos 
  
            chYneg=chYpos*-1; 
  #create a new variable called chYneg which flips chYpos upside down 
            spk=findpeaks(chYpos,'minpeakheight',thresholds(channelselect)); 
  #calculate the number of local maxima above threshold in chYpos 
 
            posspk=sum(spk>thresholds(channelselect)); 
  #count the number of local maxima above the threshold in chYpos 
 
            spk=findpeaks(chYneg,'minpeakheight',thresholds(channelselect)); 
  #calculate the number of local maxima above the threshold in chYneg 
 
            negspk=sum(spk>thresholds(channelselect)); 
  #count the number of local maxima above the threshold in chYneg 
 
            disp(sprintf('posspk = %d', posspk)); 
  #display the number of local maxima in chYpos on command window 
 
            disp(sprintf('negspk = %d', negspk)); 
  #display the number of local maxima in chYneg on command window 
 
            manual_copy = input('press enter to continue'); 
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  #display next result by pressing enter 
 
        end 
        cd('../') 
    end 
    cd('../') 
end 
cd('../') 
  
 
Script for calculating coastline analysis using JAVA 
 Clean file 
writer = new BufferedWriter( new OutputStreamWriter( 
                    new FileOutputStream(filename+"_cleanfile.txt"), "utf-8"));  
             
            int evenCheck = 0;  
            s.next(); 
            s.next(); 
            int test = 0;  
            while(s.hasNext()) { 
                 
                if(evenCheck%2==0) { 
                   String line = s.next(); 
                   if(line.equals("nan")) {  
                      
                       line = "0.000";  
                   } 
               writer.write(line+"\n"); 
 
 Creating a 30-sec epoch of 3000 data points 
int numOfWindows = (int) Math.ceil(numberOfLines / 3000.0); 
                System.out.println("Num windows: "+numOfWindows);  
                 
                int i = 0;  
               double sumCoastLine = 0; //Make a sum of the coastLine results from 
each window 
                
               int windowSize = 3000;  
                while(i<numOfWindows) { 
                   double progress = (double) i/numOfWindows*100; 
           
                   publish(progress*2); 
           //update the size of the window 
           if (i == numOfWindows-1) { 
              
               windowSize = numberOfLines; 
               System.out.println("Window size is: "+windowSize); 
           } 
           //Make window     
           double[] window = wc.setWindow(i*3000, Seizure_Liverpool.filename + 
"_cleanfile.txt", windowSize); 
           double coastResult = cl.coast(window); 
           
           sumCoastLine+=coastResult; 
           output.add(Double.toString(coastResult)); 
 
 
Coastline analysis 
double d = 0;  
        for (int i = 1; i < data.length; i++) { 
             d += (Math.abs(data[i]-data[i-1])); 
             
        } 
        return d;  
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Script for automatically listing all coastline data using Python 
 Fill up data in 120-datapoint window 
def read_file(root_directory, day, hours, coastline_files_list): 
  
 clean = {} 
  
 for channels in coastline_files_list: 
  file = open('{0}/{1}/{2}/{3}'.format(root_directory, day, hours, 
channels)) 
  #print('{0}/{1}/{2}/{3}'.format(root_directory, day, hours, channels)) 
  read = file.readlines() 
  file.close() 
  raw_data = read[1: -2] 
   
  pre_clean = [''] * 120 
   
   
  for i in range(len(raw_data)): 
   entry = raw_data[i].strip() 
    
   pre_clean[i] = entry 
   
clean[new] = pre_clean 
 
return(clean) 
 
 
 Automatically export data into excel per channel 
 
def export_to_excel(master, date_range): 
 ##Write script to export to an excel file 
  
 multiplyer = date_range[1] - date_range[0] + 1 
 i_range = 24 * multiplyer 
  
 print(multiplyer, i_range) 
  
 wb = openpyxl.Workbook(optimized_write = True) 
 ws = wb.create_sheet(title='coastline by day') 
  
 channel_list = [] 
  
 for channels in master: 
  channel_list.append(channels) 
  
 ordered_channels = sorted(channel_list) 
  
 ws.append(ordered_channels) 
  
 print('exporting') 
 for i in range(i_range): 
  for k in range(120): 
   line = [] 
   for j in ordered_channels: 
       
    line.append(master[j][i][k]) 
   
    
   new_line = [] 
   for individuals in line: 
    try: 
     new_line.append(float(individuals)) 
    except(ValueError): 
     new_line.append(individuals) 
     
   ws.append(new_line) 
    
    
 wb.save('{0}/coastline_by_day.xlsx'.format(root_directory)) 
 print('\nComplete') 
